Infection control and latent tuberculosis infection in health care workers in Indonesia by Apriani, Lika
Infection control and latent tuberculosis 









A thesis submitted for the degree of 
Doctor of Philosophy 








Background: Health care workers (HCWs) and health care students (HCSs), 
especially in low and middle-income countries (LMICs) are particularly vulnerable 
to being infected with Mycobacterium tuberculosis. The extent of latent TB 
infection (LTBI) among HCWs and HCSs in LMICs, and in Indonesia, is currently 
unknown, as is the degree of implementation of infection control measures in 
Indonesian health settings.  
Objective: This thesis aimed to: 1) describe the prevalence and incidence of LTBI 
in HCWs in LMICs and to identify associated risk factors, 2) assess the 
implementation of TB infection control measures in primary health centres (PHCs) 
in Bandung, Indonesia, 3) estimate the prevalence of LTBI measured by tuberculin 
skin test (TST) and identify factors associated with LTBI in HCWs in a tertiary 
referral hospital, and 4) estimate the prevalence of LTBI by interferon-gamma 
release assays (IGRA) and TST, the one-year test conversion rates, and identify 
associated risk factors in HCSs.  
Methods and results: In a systematic review of 85 studies published from 2005 to 
2017 the prevalence of LTBI in HCWs using TST ranged from 8-98% (mean 49%), 
and for HCSs from 1-74% (mean 32%). Using IGRA, the prevalence in HCWs 
ranged from 9-86% (mean 39%), and in HCSs from 10-44% (mean 24%). HCWs 
from countries with an annual TB incidence of >300/100,000 had the highest 
prevalence of test positivity. The annual incidence of LTBI ranged from 1-38% 
(mean 17%) in HCWs, and 3-8% (mean 5%) in HCSs, when estimated from serial 
TST, and from 10-30% (mean 18%) and 8% (one study), when estimated with 
IGRA in HCWs and HCSs respectively. Occupational factors associated with LTBI in 
HCWs were those that involved more direct contact with a TB patient or 
prolonged exposure. Only 15 studies reported any TB infection control measures. 
A cross sectional study assessing the implementation of TB infection control 
practices was conducted in 24 selected PHCs in Bandung, Indonesia. The 
evaluation of four key areas showed that TB infection control measures were 
generally not implemented. The median number of TB infection control measures 
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implemented was 21 of 41 assessed. PHCs with laboratory facilities and high TB 
case numbers were more likely to implement TB infection control measures 
compared to other PHCs. 
A cross-sectional study examining the prevalence of LTBI measured by TST was 
conducted in 395 HCWs working in one public tertiary referral hospital in 
Bandung. The prevalence of positive TST was 75.1% (95% confidence interval 
69.4-80.0%). The risk of TST positivity increased with increasing work years and 
was high across the hospital, suggesting that hospital wide measures are needed 
to counter the risk. 
A cohort study was conducted in HCSs entering their clinical training programme. 
At baseline, the prevalence of a positive IGRA was 18.5% (n=379), and of a 
positive TST was 32.7% (n=272). At one-year follow up, the risk of M. tuberculosis 
infection according to IGRA conversion was 8.9% (n=293) and according to TST 
was 35.4% (n=180). Discordance between the tests increased from baseline to 
follow-up. Neither the difference in conversion rates or the increasing discordance 
were fully explained by boosting of the TST. In the multivariate analysis, medical 
students (adjusted relative risk (ARR) 5.15, P=0.002), and participation in sputum 
collection or bronchoscopy procedures (ARR 2.74, P=0.008) were positively 
associated with IGRA conversion. For one-year TST conversion, increasing age was 
the only significant factor (ARR 1.22, P=0.017). 
Conclusion: The prevalence and incidence of LTBI in HCWs in LMICs continues to 
be high, especially in high TB incidence countries. In Bandung, TB infection control 
measures in PHCs were generally not well implemented and the prevalence and 
incidence of LTBI in HCWs and HCSs was high and predominantly associated with 
occupational exposures. Exposure to M. tuberculosis appears to be high across the 
tertiary hospital. Our study highlights the importance of strengthening effective 
TB infection control measures to reduce TB transmission in health care facilities. 
HCWs and HCSs with LTBI might benefit from receiving LTBI treatment. Bacille 
Calmette-Guerin re-vaccination or a novel vaccine might confer additional 
protection for M. tuberculosis uninfected HCWs and HCSs. Together with improved 
infection control measures, this strategy is worthy of further investigation.  
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In 2017, the World Health Organisation (WHO) estimated there were 10 million 
new cases of tuberculosis (TB) and 1.3 million who died from the disease globally 
[1]. About one-fourth of the world’s population or 1.7 billion individuals have 
latent TB infection (LTBI) [2], harbouring Mycobacterium tuberculosis 
asymptomatically. Although individuals with LTBI do not manifest overt 
symptoms and are not infectious, they are at increased risk for developing TB 
disease. Approximately 5-15% of these individuals will progress to TB disease 
during their lifetime [3]. 
Health care workers (HCWs), especially in high TB incidence countries and low 
and middle-income countries (LMICs) are particularly vulnerable to being infected 
with M. tuberculosis which is likely due to their increased exposure to TB cases 
managed at health care facilities and inadequate implementation of TB infection 
control measures [4, 5]. Health care students (HCSs), including medical and 
nursing students involved in clinical training in health care facilities, are likely to 
be exposed to similar occupational risks as HCWs. The 2009 WHO guidelines for 
TB infection control in health care settings recommended various infection control 
measures for HCWs in relation to TB [6, 7]. It is, however, unclear as to what 
extent these measures have been implemented.  
Several systematic reviews on LTBI and TB disease among HCWs have been 
conducted previously [4, 5, 8-10]. One study by Joshi et al, (2006) that included 51 
studies from LMICs published from 1999-2005 showed the prevalence of LTBI as 
measured by tuberculin skin test (TST) was, on average, 54% (range 33% to 79%). 
A history of contact with TB patients, participation in procedures such as sputum 
collection and autopsy, and working in medical wards were independent 
occupational risk factors for LTBI. The annual incidence of LTBI ranged from 0.5% 
to 14.3% and of TB disease ranged from 25 to 5,631 per 100,000 person years. A 
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higher level of clinical training, nursing occupation, and recent exposure to TB 
were reported as independent risk factors for TST conversion [5].   
The difficulty in the diagnosis of LTBI is that there is no gold standard diagnostic 
test. The intra-dermal TST has known limitations in accuracy and reliability 
(described in Chapter two) [11, 12]. Interferon-gamma release assays (IGRA) have 
been developed as an alternative to TST for the diagnosis of LTBI [13, 14]. They 
are in vitro blood-based tests, if used for a repeated screening of LTBI, they can be 
repeated any number of times, are not subject to sensitisation or boosting and 
they require only one visit to a health care facility [15]. There are, however, also 
some problems with IGRA tests, such as higher rates of test reversion than seen 
with the TST [15, 16] and have unresolved issues around defining test conversions 
in the presence of imperfect tests.  
There is a need for an updated review to understand the current knowledge of 
LTBI in HCWs in LMICs including studies that used TST and/or IGRA. Existing 
reviews are either out-dated (up to 2005) [5], only included studies that used TST, 
did not include information on risk factors associated with LTBI [8], included only 
studies with a comparison group of non-HCWs, or were not focused on studies 
conducted in LMICs [10]. 
Indonesia has the third highest number of incident TB cases in the world (TB 
incidence rate of approximately 320/100,000/year in a country of around 264 
million people) [1], yet there is no information on the burden of LTBI in HCWs. 
The National TB Programme of Indonesia focuses largely on case detection and 
treatment using the Directly Observed Treatment Short Course (DOTS) strategy 
recommended by the WHO. In high TB incidence settings, there is a 
recommendation to screen and treat for TB disease in TB household contacts. The 
WHO guidelines on the management of LTBI in 2015 recommended to give TB 
preventive treatment in; a) children aged less than 5 years who are household 
contacts of people with bacteriologically confirmed pulmonary TB and, b) patients 
with human immunodeficiency virus (HIV) who do not to have active TB [17], but 
these guidelines are rarely followed. For example, the coverage of TB preventive 
treatment in children (aged less than 5 years) who are household contacts of 
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bacteriologically-confirmed TB cases and among people newly enrolled in HIV 
care in Indonesia was only 8.5% and 16%, respectively [1]. In 2014, using 
mathematical modelling, it was estimated that around 120 million people (46%) 
in Indonesia latently infected with M. tuberculosis. With this estimate, Indonesia 
has the third highest LTBI burden in the world after China and India [2].  
There is an Indonesian National TB Infection Control policy adapted from WHO 
guidelines, but there are no data on implementation of these guidelines, including 
screening for LTBI and TB among HCWs [18]. Knowledge of standard precautions 
for infection control in health care facilities is important for preventing 
transmission of infection not only to the HCWs but also to the general population 
[19, 20]. Previous research has shown variable knowledge of TB infection control 
among HCWs [21-23]. Educating HCWs is one of the WHO recommendations for 
effective TB infection control programmes [6].  
TB can be a stigmatising condition [24], fed by a combination of fear and denial, 
which can aggravate delays in diagnosis and treatment [25]. Research on TB-
related stigma has mainly focused on TB patients and the general population, with 
much less attention on HCWs.  
To date, no studies have reported on the prevalence of LTBI, factors associated 
with LTBI, level of knowledge of TB infection control, TB and LTBI, and TB and 
LTBI attitudes, care-seeking behaviour and stigma among HCWs in Indonesia.   
1.2 Objectives 
The overall goal of this research was to systematically review the current situation 
of LTBI in HCWs in LMICs, to study LTBI in HCWs and HCSs in Bandung, Indonesia 
and to assess the implementation of TB infection control measures in health care 
facilities. The following are the specific objectives:  
- Describe the prevalence and incidence of LTBI in HCWs in LMICs, including 
studies that used TST and/or IGRA and to identify associated risk factors 
(Chapter three); 
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- In primary health centres (PHCs), assess TB infection control practices, TB 
and LTBI knowledge, attitudes, care-seeking behaviour, and stigma in 
HCWs (Chapter four); 
- In a tertiary referral hospital, estimate the prevalence of LTBI measured by 
TST and identify factors that are associated with LTBI in HCWs, including 
their knowledge of TB infection control, TB, and LTBI, attitudes, care-
seeking behaviour, and stigma (Chapter five); 
- In nursing and medical students entering their clinical training, estimate 
the prevalence of LTBI by IGRA and TST, the one-year test conversion rates 
and identify associated risk factors (Chapter six). 
1.3 Study setting 
1.3.1 Indonesia  
Geographically, Indonesia is located in Southeast Asia, between the Indian and 
Pacific oceans. It has more than seventeen thousand islands [26]. With a total 
population of 261,115,000 in 2016, and a gross national income per capita of 
$9,260, it is listed as one of the low and middle-income countries [27].   
According to data from the Ministry of Health of Indonesia, in 2017 there were 
2,776 hospitals throughout the country, with a total of 305,242 beds, around 1.2 
beds per 1,000 people. Most hospitals are in the urban areas. In addition, there are 
9,825 government-financed PHCs that provide comprehensive individual and 
public health care in the sub-district level. Individual health care consists of 
outpatient and inpatient services [28].  
In 2017 there was a total of 1,143,494 HCWs working in all types of health care 
facilities in Indonesia, of whom 836,466 (73%) delivered health services and 
307,028 (27%) were support workers or engaged in health management rather 
than direct provision of health services [28].   
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Source: https://asiapacific.anu.edu.au/mapsonline/base-maps/indonesia 
Figure 1.1 Map of Indonesia 
1.3.2 Bandung City 
The studies were conducted in Bandung, Indonesia. Bandung is the capital of West 
Java Province and the third largest city in Indonesia (Figure 1.1). Bandung city has 
an estimated 2.5 million people and a population density of approximately 14,736 
km2 [29]. In 2017, 5204 pulmonary TB cases (2025 smear positive, 2586 smear 
negative and chest x-ray positive, and 593 retreated cases) were notified to the 
Bandung Municipal Health Office (unpublished data). 
 
Source: Google Map, 2018 
Figure 1.2 Map of West Java Province and Bandung City, Indonesia 
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1.3.3 Primary Health Centres 
Seventy-three PHCs in Bandung City provide general health services, including TB 
diagnosis and treatment (Figure 1.2). Five of these have inpatient facilities and 30 
have laboratory facilities.  
 
 
Figure 1.3 Map of 73 Primary Health Centres in Bandung City 
People with symptoms of TB can choose whether to seek diagnosis and treatment 
from a PHC or from a private medical practitioner, a private hospital, or a public 
hospital. If a patient first seeks treatment in a PHC without sputum smear 
examination facilities, they will be referred to a PHC that has a laboratory. No 
PHCs have the facilities to undertake chest x-rays and are required to refer 
patients to a private radiology facility, district hospital, or specific TB clinic. 
All PHCs have the facilities to carry out case treatment using DOTS – which is 
undertaken by HCWs trained in the communicable disease programme – usually a 
doctor, nurse or laboratory personnel. Of 5204 pulmonary TB cases who were 
notified to the Bandung Municipal Health Office in 2017, 37% were diagnosed 
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through a PHC. There are approximately 20 HCWs employed in each PHC (Box 
1.1).  
Box 1.1: Example of a PHC structure in Bandung City 
 
 
1.3.4 Hasan Sadikin General Hospital 
Hasan Sadikin Hospital is a large referral teaching hospital in West Java Province, 
with approximately 3,000 HCWs, excluding trainee medical and nursing students. 
Hasan Sadikin Hospital has, since 2007, the facilities to carry out TB case 
detection, screening, diagnosis, and treatment using DOTS. In 2011, it was 
designated as one of 13 referral hospitals for multidrug-resistance TB (MDR-TB) 
patients in Indonesia and the only one located in West Java Province. In 2017, 258 
pulmonary TB cases (113 smear positive new cases, 45 smear negative/chest x-
ray positive cases, and 100 retreated cases) were diagnosed at the Hospital, which 
was approximately 5% of the total number of pulmonary TB cases notified to the 
Bandung Municipal Health Office (unpublished data).  
Example of one PHC (Pasir Kaliki) in Bandung 
 
Total population: 103,100 – divided into 6 administrative sub-municipals: 
1. Pasir Kaliki – approx. 13,275 population 
2. Pamoyanan – approx. 13,275 population 
3. Pajajaran – approx. 25,000 population  
4. Arjuna – approx. 13,275 population 
5. Husen – approx. 13,275 population 
6. Sukaraja – approx. 25,000 population  
 
HCWs in a PHC: 
• 1 Doctor in charge 
• 2 General practitioners (Doctors) 
• 4 Nurses 
• 7 Midwives 
• 2 Dentists 
• 1 Laboratory personnel 
• 1 Pharmacist 
• 2 Nutritionists 
• 1 Environmental health officer 
• 1 Public health officer 
• Administrative staff 
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1.3.5 Universitas Padjadjaran Bandung, Indonesia 
Universitas Padjadjaran (UNPAD) is a public university located in Bandung, and is 
one of the top five universities in Indonesia. Every year approximately 450 
medical and nursing students from the Faculties of Medicine and of Nursing 
graduate with a bachelor degree after finishing their pre-clinical programme. 








Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. It 
commonly affects the lungs (called pulmonary TB) prompting severe and long-
term coughing, fever, chest pain, and shortness of breath, yet can also affect 
different organs (called extra pulmonary TB). The disease is spread when 
individuals with pulmonary TB release aerosolised M. tuberculosis, for instance by 
coughing [1, 30, 31].  
2.1.2 Global epidemiology of tuberculosis  
In 2017, TB remained a major global health concern. It is one of the top 10 leading 
causes of death worldwide and since 2011 it has been the leading cause from a 
single infectious agent, ranking above human immunodeficiency virus infection 
and acquired immune deficiency syndrome (HIV/AIDS). There were an estimated 
1.3 million TB deaths among HIV-negative people and an additional 300,000 
deaths among HIV-positive people in 2017 [1].  
According to the WHO, in 2017, there were an estimated 10 million new cases of 
TB, equivalent to 133 cases per 100,000 population. Two-thirds of the total global 
cases were in India (27%), China (9%), Indonesia (8%), the Philippines (6%), 
Pakistan (5%), Nigeria (4%), Bangladesh (4%), and South Africa (3%) [1]. The 
annual TB incidence varies widely between countries, as shown in Figure 2.1. 
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Figure 2.1 Estimated TB incidence rates, by country, in 2017 from The WHO global 
TB report 2018 [1] 
2.1.3 Tuberculosis in Indonesia  
Although Indonesia has made remarkable progress developmentally over the last 
decade, TB remains one of the top four causes of death in the country. In 
Indonesia, in 2017, a total of 446,732 TB cases were notified, 90% of which were 
pulmonary TB. The treatment success rate among new smear-positive (defined as 
the presence of acid fast bacilli in at least one sputum sample) was 86% for the 
cohort of patients registered in 2016. The mortality rate in HIV-negative people 
was 40 per 100,000 population and an additional 3.6 per 100,000 population in 
HIV-positive people. Based on the 2017 national TB inventory study, TB under-
reporting in Indonesia was high (41%) [1]. This poses a significant challenge to 
the national programme. 
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2.2 Latent tuberculosis infection 
2.2.1 Definition 
WHO defines latent tuberculosis infection (LTBI) as “a state of persistent immune 
response to stimulation by M. tuberculosis antigens with no evidence of clinically 
manifest active TB” [3, 32]. On average, 5-15% of latent TB infected individuals 
will progress to have TB disease over their lifetime, usually within the first five 
years after initial infection [3, 33]. People with HIV and with other risk factors 
such as immunosuppressive condition, under-nutrition, diabetes mellitus (DM), 
and smoking have a higher probability of developing TB disease compared to 
other groups [3, 32]. 
2.2.2 Global epidemiology of latent tuberculosis infection  
As there is no gold standard for LTBI, the global burden is not known; however, 
using mathematical modelling, Houben et al estimated that a quarter or 
approximately 1.7 billion of the world’s population have been infected with M. 
tuberculosis [2]. Figure 2.2 shows the regional and sub-regional variation in LTBI 
prevalence [2]. In 2014, around 80% of the number of people with LTBI were in 
the South Asia, Western Pacific, and Africa regions. At a country level, China and 
India have the highest LTBI burden with approximately 320 million people 
thought to be latently infected [2].  
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Figure 2.2 Global map of latent TB infection. Median estimated population 
prevalence of latent TB infection by country, 2014 [2]  
2.2.3 Latent tuberculosis infection in Indonesia  
With a LTBI prevalence estimate, in 2014, of around 46%, or 120 million people 
out of a total population of 261 million, Indonesia had the third highest LTBI 
burden in the world after China and India [2]. There are no data on age-specific 
prevalence of LTBI available for Indonesia. However, several studies have been 
conducted to investigate the prevalence of LTBI measured by tuberculin skin test 
(TST) or interferon-gamma release assays (IGRA) in some high-risk groups [34-
37]. One study reported that the IGRA and TST positivity rate in children (aged 6 
months to 9 years) who were living with a TB case in Bandung, Indonesia, was 
46% and 41%, respectively [34]. This is similar to a TST study in children in 
Yogyakarta (45%) [36]. In adult HIV-positive patients on Antiretroviral (ART) 
therapy, the IGRA positivity rate was 29% [35] and 39% of adult patients with 
diabetes mellitus were found to have a positive IGRA [37]. 
2.2.4 Testing for latent tuberculosis infection  
There is no diagnostic gold standard for LTBI, as described earlier and in Chapter 
one. For identification of LTBI, there are two accepted, but imperfect tests: TST 
and IGRA. These two existing tests can only identify individuals with the immune 
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response to TB antigens after a remote or recent infection [38] and do not 
measure the presence of M. tuberculosis itself [39].  
2.2.4.1 Tuberculin skin testing: overview and limitations 
TST consists of an intradermal injection of 5 tuberculin units (TU) of purified 
protein derivative (PPD)-S (Siebert) or 2 TU PPD research tuberculin (RT) 23 and 
is performed using the Mantoux technique [40]. These two types of TU are 
considered equivalent [41, 42]. Within 48 hours, a delayed-type hypersensitivity 
reaction will occur in individuals who have an immune response to these 
tuberculin antigens. This reaction will cause a localised induration of the skin at 
the injection site and trained staff measure the diameter of induration in 
millimetres (mm) [38].  
The interpretation of TST depends on two factors: 1) measurement of the 
induration (in mm) between 48 and 72 hours after injection, and 2) individual’s 
risk factors of being infected with TB and progression to disease. Centres for 
Disease Control and Prevention (CDC) recommend the following three cut-offs to 
be used to determine whether the TST reaction is considered positive: 1) >5 mm 
in people living with HIV, recent contacts with TB patients, patients with fibrotic 
changes on chest radiograph consistent with prior TB, patients with organ 
transplants and other immunosuppressed patients, 2) >10 mm in people who 
inject drugs, recent immigrants, persons with clinical conditions (diabetes 
mellitus, chronic renal failure, silicosis, hematologic disorders, and malignancies), 
patients, residents and employees in  health care facilities or the high-risk 
congregate settings (hospitals or other health care facilities, nursing homes, long 
term facilities for elderly, prisons, and jails), mycobacteriology laboratory 
personnel, all children <5 years of age, children and adolescents exposed to adults 
at high risk for developing active TB, and 3) >15 mm in persons with unknown 
risk factors for TB [43]. These cut-offs may differ in other countries, for example, 
the cut-off of >5 mm was used for HCWs in Brazil [44], compared with >15 mm in 
Turkey [45, 46]. 
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Even though TST is widely used and inexpensive, it has several known limitations. 
There are two main causes of false-positive results: prior Bacille Calmette-Guerin 
(BCG) vaccination and non-tuberculosis mycobacterial (NTM) infection [11]. The 
effect of earlier BCG on TST result depends on when BCG is given and how many 
doses are administered [11]. The effect is minimal after one year if BCG is given at 
birth or during infancy and not repeated. Meanwhile, if BCG is administered after 
infancy or repeated multiple times, the TST result is compromised [11]. The effect 
of NTM is most pronounced in populations with a high prevalence of NTM 
sensitisation and a very low prevalence of LTBI [11]. 
False-negative TST results occur due to limited sensitivity in some specific 
patients (such as immunosuppressed individuals, HIV infection, under-nutrition, 
or individual receiving immunosuppressive treatments) or due to pre-analytical or 
analytical sources of test variability (such as inappropriate handling or placing the 
TST, or incorrect measuring and interpreting the test results) [41]. Unfortunately, 
often individuals who are at increased risk of progression to TB disease if infected 
are immunocompromised and anergic to TST, causing false-negative TST results 
[41]. 
TST is additionally known to have an issue with inter- and intra-rater variability in 
measurements of induration [12]. If the test is repeated, boosting (immunologic 
recall of the previous hypersensitivity to mycobacteria, including M. tuberculosis), 
conversions (known as new infection), and reversions (the change from positive 
results to negative) could occur [12]. Originally, TST conversion was defined as a 
newly positive TST (induration ≥10 mm) after a negative-baseline TST (induration 
of <10 mm) at any time after a negative two-step baseline (giving a second TST 1-3 
weeks after an initial negative TST reaction), or one year or more after a negative 
single TST. Due to the interpretation of repeat testing being affected by 
immunological recall, cut-offs used for TST conversion are different from the cut-
offs used for the diagnosis of LTBI [38]. These include the definition of a baseline 
TST <10 mm and a follow up TST >10 mm plus a 6 mm or a 10 mm increase over 
the baseline as proposed by Menzies [12] and as recommended by the American 
Thoracic Society (ATS) [38]. 
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A further limitation with the use of TST is that there are also logistical issues, 
including the requirement for a return visit in two to three days to read the 
induration size by a specialist nurse or doctor. Self-reading is possible but has 
been associated with a high error rate [47]. Lastly, there is a global shortage of 
TST, attributed to market forces [32].  
2.2.4.2 Boosting phenomenon  
According to Menzies, “The phenomenon of increased tuberculin reactions upon 
re-testing in the absence of new infection, is believed to result from recall of 
waned cell-mediated immunity, akin to the anamnestic serologic response” [12]. If 
the interval between the first and second test is between one and five weeks, 
boosting could be maximal [48] and is minimal if the interval is less than 48 hours 
[49] or more than 60 days [48] although it can be observed one or more years 
after a negative-baseline TST (11,12). The prevalence of boosting is correlated 
with the initial tuberculin reaction, age, and BCG-vaccination [12]. 
2.2.4.3 Interferon gamma release assays: overview and limitations 
IGRAs are in vitro blood tests that measure the secretion of interferon-gamma 
(IFN-γ) by T-cell after stimulation by antigens that are fairly specific to the M. 
tuberculosis complex (with the exception of BCG sub-strains) [47]. Therefore, their 
specificity for M. tuberculosis is higher than with TST. There are two available 
commercial IGRA tests: The QuantiFERON-TB Gold In-Tube (QFT-GIT) assay (the 
third generation QFT assay produced by Cellestis/Qiagen, Carnegie, Australia) and 
the T-SPOT.TB assay (Oxford Immunotec, Abingdon, United Kingdom).  
The QFT assay is a whole-blood stimulation test that uses peptides from the three 
antigens that contributes to the virulence of M. tb: 1) 6kDa early secreted antigen 
target (ESAT-6), 2) 10kDa culture filtrate protein (CFP-10) and 3) peptides from 
one additional antigen (TB7.7) in an in-tube format. The IFN-γ response to TB 
antigens is measured in an enzyme-linked immunosorbent assay (ELISA), and is 
reported as quantification of IFN-γ in international units (IU) per millilitre. If the 
IFN-γ response to TB antigens in an individual is above the test cut-off as 
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recommended by the manufacturer, the QFT assay is considered positive [50]. A 
fourth generation of QFT assays, named QuantiFERON-TB Gold Plus (QFT-Plus), is 
currently available. The difference from the former generation is that QFT-Plus 
has two TB antigen tubes: TB antigen Tube 1 (TB1) and TB antigen Tube 2 (TB2) 
[51]. The TB1 tube contains peptides from the antigens ESAT-6 and CFP-10 that 
are intended to evoke cell-mediated immune responses from CD4+ T cells; 
meanwhile, the TB2 tube includes an additional set of peptides targeting cell-
mediated immune responses from CD8+ T cells. It’s known that CD4+ T cells play 
an essential role in immunological control through their secretion of the IFN-γ, 
and CD8+ T cells play a role in the host defence to M. tuberculosis by producing 
IFN-γ and other factors, which activate the phagocytosis of M. tuberculosis by 
macrophages [52, 53]. 
The T-SPOT.TB assay is performed on separated and counted peripheral blood 
mononuclear cells, which are incubated with ESAT-6 and CFP-10 peptides and 
measured in an enzyme-linked immunosorbent spot (ELISPOT) assay. The test 
result is reported as the number of IFN-γ producing T cells (spot-forming cells). If 
the spot counts in the TB antigen wells exceed a specific threshold relative to the 
negative-control wells, the test is considered positive [54].  
Despite having a higher specificity compared to TST [47], IGRA have higher rates 
of test reversion (the change from a positive to negative result) than seen with the 
TST [55]. Therefore, when used serially, clinical judgment must be considered in 
interpreting the results of the tests [3]. In addition, IGRA is more expensive, needs 
a blood draw from a patient and requires specific expertise in the laboratory [32, 
56]. Table 2.1 shows the advantages and disadvantages of TST and IGRA [56].  
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Table 2.1 Comparison of TST and IGRA according to Pinto et al [56] 
 
2.3 Tuberculosis prevention  
To reduce the burden of disease and death caused by TB globally, there is a crucial 
need for a strategy to prevent the new infections of M. tuberculosis and their 
progression to TB disease [57]. WHO has a target of 80% reduction in TB 
incidence from the 2015 level by 2030, and a 90% reduction by 2035 [1]. This is 
possible only if progression from LTBI to TB disease among the approximately 1.7 
billion people with LTBI globally [2] is significantly reduced [3, 33]. Currently, 
there are three major TB prevention strategies available: 1) treatment for LTBI, 2) 
TB infection control to prevent the transmission of M. tuberculosis, and 3) BCG 
vaccination in children [1]. However, other strategies could also help to reduce the 
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risk of progression from LTBI to TB disease. These include more effective, shorter 
and safer regimens for LTBI, and a vaccine to prevent LTBI for adults [1]. 
2.3.1 Treatment of latent tuberculosis infection 
WHO guidelines published in 2015 strongly recommended testing and treatment 
for LTBI in four high-risk groups: 1) HIV infected people (all countries), 2) 
children aged less than 5 years who are household contacts of bacteriologically 
confirmed pulmonary TB cases (all countries), 3) people aged 5 years or more 
who are household contacts of bacteriologically confirmed pulmonary TB cases 
(upper middle-income and high-income countries with a low incidence of TB), and 
4) other clinical risk groups (upper middle-income and high-income countries 
with a low incidence of TB) [17].  
Updated guidelines published in 2018 include an additional recommendation for 
countries with a high incidence of TB, to consider testing and treatment for people 
aged 5 years or more who are household contacts of bacteriologically confirmed 
pulmonary TB cases. It also expands the recommendation for clinical risk groups 
to all countries [3]. These clinical risk groups include: 1) patients initiating anti-
tumour necrosis factor treatment, receiving dialysis, or preparing for organ or 
haematological transplantation, and those with silicosis, and 2) prisoners, HCWs, 
immigrants from countries with a high TB burden, homeless people and people 
who use illicit drugs in countries with a low TB incidence [3].    
The current four options for treatment of LTBI are: 1) rifapentine and isoniazid in 
a weekly dose for three months, 2) rifampicin plus isoniazid in a daily dose for 
three months, 3) rifampicin in a daily dose for three or four months, and 4) 
isoniazid in a daily dose for at least six months [3]. The shorter regimens are 
preferred for better adherence and a higher treatment completion rate [1]. 
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2.3.2 TB Infection control practices 
2.3.2.1 International guidelines and policy  
TB infection control consists of a combination of practices aimed at minimising the 
risk of M. tuberculosis transmission and is one of the key components of the End 
TB Strategy [6, 57]. The risk of TB transmission in health care facilities is high [4, 
5]. This puts HCWs at higher risk of TB infection and disease. Health care students 
(HCSs) involved in clinical training in health facilities are likely to be exposed to 
similar risks as HCWs.  
In the most recent modification of the WHO guideline on monitoring and 
evaluation of collaborative TB and HIV activities [58], one of the key indicators to 
measure the effectiveness of TB infection control practices in health facilities is to 
compare the risk of TB disease and infection among HCWs with the risk in the 
general adult population. The relative risk of TB in HCWs compared with the 
general adult population should be near one, if TB infection controls are 
implemented adequately and are effective in health care facilities [1].  
The 2009 WHO guideline recommended that TB infection control should be part of 
the national infection control policy. The guideline recommended a 
comprehensive set of infection control practices, comprising four key components 
of protection namely, facility managerial level, administrative control, 
environmental control, and personal protection measures [6]. Periodic assessment 
of the implementation of TB infection control in health care facilities is crucial [6, 
7]. Facility managerial control should be focused on the establishment and 
oversight of TB infection control policies, ensuring that management structures 
are in place to support the implementation of TB infection control.  
In health-care facilities, as recommended by WHO, administrative controls should 
be implemented as the first line of infection control. The goal of administrative 
controls is to prevent previously unexposed HCWs, patients and visitors, from 
being exposed to TB and to reduce transmission of M. tuberculosis infection by 
applying a strategy for rapid diagnosis and treatment of people with TB 
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symptoms, and separation into an appropriate place if infectious. Potential 
exposure to people who are infectious can be minimised by reducing time spent in 
hospitals or clinics or avoiding hospitalisation where possible, reducing the 
number of visits, eliminating overcrowding in waiting areas and wards, and 
prioritising community-care approaches for TB management [6]. All HCWs should 
be given appropriate information about TB, and if they have signs and symptoms 
suggestive of TB, they should be encouraged to undergo TB diagnostic 
examination [59]. Moreover, all HCWs should also be given appropriate 
information and encouraged to undergo HIV testing and counselling, and they 
should be offered a package of prevention when they are diagnosed with HIV. 
They also should have access to treatment and care that includes regular 
screening for active TB and to antiretroviral therapy. Based on the appropriate 
evaluation, HCWs should be considered for LTBI or TB treatment [6]. 
The goal of environmental controls in health care facilities is to prevent the spread 
of M. tuberculosis by reducing the concentration of infectious particles in the air. 
Implementation will depend on the design, construction, renovation, use of the 
building, and also on the local climatic and socioeconomic conditions. Installation 
of ventilation systems (natural and mechanical ventilation systems or mixed 
mode) should be a priority in health care facilities. In areas where adequate 
ventilation is difficult to achieve, ultraviolet germicidal irradiation (UVGI) or high-
efficiency particulate air (HEPA) filtration for air-cleaning methods can be used 
[6]. 
In situations where there is an increased risk of transmission, personal respiratory 
protective equipment should be used in line with the implementation of 
administrative and environmental controls [6]. If properly fitted and used, a 
personal particulate respirator is sufficient in reducing the chance of inhaling M. 
tuberculosis. The WHO recommendations on TB infection control in health care 
facilities are shown in Box 2.1.  
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Box 2.1 World Health Organisation recommendations for health facility-level TB 
infection control [6] 
 
Knowledge of standard precautions for infection control in health care facilities is 
also essential for preventing transmission of infection, not only to the HCWs, but 
also to the general population [20]. Educating HCWs has been one of the WHO 
recommendations for effective TB infection control programmes [6]. HCWs with 
limited knowledge about TB and infection control can contribute to an increased 
risk of transmission [60]. 
2.3.2.2 TB infection control policy in Indonesia 
There is a national TB infection control policy adapted from WHO guidelines on TB 
infection control in Indonesia, published in 2010, which includes a comprehensive 
set of infection control practices in health care facilities comprising of 
administrative, environmental, and personal protection measures. Activities such 
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as TB surveillance among HCWs, education and training for HCWs, periodic 
assessment of TB infection control in healthcare facilities and operational research 
are also recommended in the guidelines [18].  
2.3.3 BCG vaccination in children and implications for health care workers 
The third current strategy for TB prevention is vaccination of children with BCG 
vaccine. BCG vaccination has been documented to be protective against 
disseminated disease, such as miliary TB and TB meningitis, which are known to 
be associated with high mortality in new born and young children [1]. The WHO 
continues to recommend that a single dose of the BCG vaccine should be given to 
all healthy infants as soon as possible after birth, as part of the childhood 
immunisation programmes in countries with a high TB burden. In countries with 
low TB incidence rates, BCG vaccine is given only to neonates and infants who are 
known to be in a high-risk group, or to older children in a high-risk group who test 
negative for TB infection [1].  
There is a need for a new vaccine that is more effective to reduce the risk of LTBI 
and TB disease in adults [1]. There are 12 new TB vaccines in phase I, II, and III 
trials as reported by WHO in August 2018 [1]. Regarding HCWs, in TB endemic 
countries, the majority would have received a BCG vaccination in infancy [61]. It is 
still debatable as to whether BCG revaccination would give any additional 
protection against LTBI or TB disease [62]. Previous studies conducted in high TB 
incidence countries suggested that there is likely to be a small percentage of HCWs 
who are M. tuberculosis uninfected [63, 64]. However, M. tuberculosis uninfected 
HCWs are at high risk of TB morbidity upon TB exposure. Therefore, for these 
high-risk groups, BCG revaccination or a novel vaccine might offer additional 
protection. Moreover, for HCSs, who are less likely to have M. tuberculosis infection 
before entering their clinical training than HCWs, their involvement in some 
studies assessing the benefit of BCG revaccination or a novel vaccine to reduce the 
risk of infection with M. tuberculosis may be desirable [62].  
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3 Latent tuberculosis infection in health care workers in low- 
and middle-income countries: An updated systematic review 
3.1 Introduction 
Health Care Workers (HCWs), especially in high tuberculosis (TB) incidence 
countries, are at increased risk of latent TB infection (LTBI) and TB disease due to 
exposure to TB cases and variable implementation of infection control practices 
[5, 10, 15]. World Health Organisation (WHO) guidelines (2009) advise regular 
screening for TB in HCWs and routine reporting [6]. A systematic review [5] of 51 
studies from low and middle-income countries (LMICs) published from 1999-
2005, reported the prevalence of LTBI (tuberculin skin test (TST) positive) among 
HCWs ranged from 33% to 79%. Reported independent risk factors for LTBI 
included a history of TB patient contact, participation in procedures such as 
sputum collection and autopsy, and working in medical wards. The annual 
incidence of LTBI ranged from 0.5% to 14.3%. Reported independent risk factors 
for TST conversion were: a higher level of clinical training; nursing occupation; 
and recent exposure to TB [5].  
Interferon-gamma release assays (IGRA) have been developed as an alternative to 
TST for the diagnosis of LTBI [13, 14]. They are not subject to sensitisation or 
boosting [15], but they have much higher rates of largely unexplained test 
conversions and reversions [15, 16]. Studies reporting the prevalence and 
incidence of LTBI in HCWs in LMICs conducted since the 2006 review have used 
TST, IGRA, or both, to diagnose LTBI [45, 63, 65-68]. While two systematic reviews 
have been carried out recently, one included only studies using TST [8] and the 
other included only studies with a comparison group of non-HCWs [10]. We 
conducted a comprehensive systematic review of the prevalence and incidence of 
LTBI in HCWs in LMICs, along with factors associated with LTBI. Including studies 
that used TST and/or IGRA, we aimed to describe the prevalence and incidence of 
LTBI in HCWs in LMICs and to identify associated risk factors, with a particular 
emphasis on infection control practices. 
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3.2 Methods 
This systematic review was reported according to Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines [69]. The protocol 
was registered in PROSPERO (CRD42017079494). 
3.2.1 Search strategy  
We searched the Medline, Embase, and Web of Science electronic databases for 
primary studies in any language. The previous systematic review was up to 
December 2005 [5], therefore, our search was limited to the period from 01 
January 2005 to 20 June 2017. Since this was an update, we did not wish to include 
any studies (such as those published in 2005 that had been included in the 
previous systematic review). If previously included, they were excluded from our 
review. 
Initially, three broad concepts were used to identify the medical subject headings 
(MESH) and keywords in the databases: “latent tuberculosis”, “health care 
workers”, and “occupational exposure”. Several key words were used for “latent 
tuberculosis” (“latent tuberculosis”, “tuberculin test”, “interferon-gamma release 
test”, “IGRA”); “health care workers” (“health care worker”, “health personnel”, 
“physician”, “doctor”, “medical staff”, “hospital staff”, “nurse”, “community health 
worker”, “nursing student”, “medical student”) and “occupational exposure” 
(“occupational exposure”, “infectious disease transmission”, “occupational 
disease”, “nosocomial exposure”). All key words were searched for in the title, 
abstract, and field keywords. Both key words and subjects identified in the 
databases were used together with “OR”. The key words for the concepts of 
“health care workers” and “occupational exposure” were used together with “OR”, 
then these results were combined using “AND” with “latent tuberculosis” to obtain 
the final result (details of the complete search strategy are provided in Appendix 
3. Table A.3.1).  
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In addition, we examined references cited in studies and reviews identified as 
being potentially relevant. We contacted authors of studies for further information 
if required.  
3.2.2 Study selection  
Two reviewers (LA and SM) independently screened the citations (title and 
abstract) identified. We obtained full text versions of all studies identified by 
either reviewer as being potentially relevant. The two reviewers independently 
assessed the full texts for inclusion, using pre-specified criteria. Differences were 
resolved by consensus. 
We included studies that reported data on the prevalence or incidence of LTBI in 
HCWs. Based on the World Health Report in 2006 [70], the term “health care 
workers” was defined as “all people engaged in actions whose primary intent is to 
enhance health”. There are two broad types of HCWs: those that deliver health 
services, either personal or non-personal, called “health service providers”; and 
those not engaged in the direct provision of health services, called “health 
management and support workers”. We included studies that reported any part-
time or full-time HCWs. We also included studies that reported data on health care 
students (HCSs) including nursing, medical, paramedical, pharmacy, and dental 
students. 
We included cross-sectional TST and IGRA surveys, cohort studies reporting TST- 
and IGRA-conversion rates, and retrospective or prospective studies on the 
incidence of LTBI.  
We excluded: 1) case reports or case series of LTBI, 2) studies with 10 or fewer 
participants, 3) commentaries, 4) editorials and reviews, 5) letters that did not 
report original data, 6) studies evaluating TST or IGRA for treatment monitoring in 
HCWs (i.e. not diagnostic purposes), 7) for incidence, short term serial testing 
studies (within one month), 8) non-commercial/in-house IGRAs, 9) TST or IGRA 
testing in the context of a known nosocomial outbreak or single point source 
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exposure or contact tracing following TB diagnosis, 10) conference abstracts, and 
11) immunological or diagnostic studies with no prevalence or incidence data.  
Included studies were conducted in one or more of the 139 countries classified by 
the World Bank as LMICs, with gross national income per capita less than US$ 
12,475 for the 2017 fiscal year [27].    
3.2.3 Data extraction  
The two reviewers independently extracted data from a subset of the studies 
(20%). The inter-rater agreement between the two reviewers was high ≥95%. Any 
disagreement was settled by consensus. Subsequently, one reviewer (LA) 
extracted data from the full set of included studies. Data extracted onto a Google 
Form included: author, country, survey year, TB incidence rate, study and 
participant type, number of participants, health care facility, test used, Bacille 
Calmette-Guerin (BCG) vaccination status, prevalence of LTBI (95% Confidence 
Interval (CI)), LTBI incidence (95% CI), results of analyses of occupational and 
non-occupational risk factors, TB infection control measures, demographic data 
and other relevant details about HCWs. All details of definitions for health care 
facility, HCW, LTBI prevalence (defined as test positivity), LTBI incidence (defined 
as test conversion), including test definitions of IGRA and TST positivity and 
conversion, and risk factor of exposures are described below. LTBI prevalence and 
incidence, or conversion, results were extracted and reported separately for TST 
and IGRA, in view of previously published evidence that results of these two tests 
may be discordant.  
Health care facility: as used by Joshi et al [5], all facilities where patients seek 
health care, including hospitals, clinics, dispensaries, health centres, imaging and 
laboratory facilities. Prisons, nursing home, correctional facilities, and other 
congregate settings were not included.  
Health care worker: any individual who works in a health care setting including 
physicians, nurses, allied health personnel (nursing assistants, operating theatre 
technicians, health educators, social workers, midwives, community health 
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workers based in hospitals or clinics, laboratory personnel, pharmacists, 
radiographers, volunteers, orderlies, and health-facility administrators) [5, 9, 70], 
and general services (cleaners, drivers, housekeepers). We also included studies 
that reported data on health care students (HCSs) including nursing, medical, 
paramedical, pharmacy, and dental students.  
LTBI prevalence: A positive TST done by any standard method using 1TU 
(tuberculin unit) or 2TU of purified protein derivative (PPD) of tuberculin RT23 or 
5TU of PPD-S, was defined as an induration size ≥10 mm on a single test [71]. 
However, the definitions used by the included studies were used in the first 
instance. For studies that used more than one definition, we used the national 
guidelines where the study was done or an induration size ≥10 mm if there was no 
such information available. A positive IGRA done by any commercial method using 
QuantiFERON-TB Gold or T-SPOT was as defined by the manufacturer [50, 54].  
LTBI incidence: TST conversion was defined as a newly positive TST (induration 
≥10 mm) after a documented negative-baseline TST (induration of <10 mm) at any 
time after a negative two-step baseline, or one year or more after a negative single 
TST. However, the definitions used by included studies were used in the first 
instance. These included the definition of a baseline TST <10 mm and a follow up 
TST >10 mm and a 6 mm or a 10 mm increase over the baseline as proposed by 
Menzies [12] and as recommended by the American Thoracic Society (ATS) [38]. 
There are no national guidelines in LMICs for the definition of IGRA conversion. If 
multiple definitions were presented in a study, conversion was defined as per the 
manufacturer’s definitions [50, 54]. For QFT-GIT, conversion was defined as a 
baseline test IFN-ɣ <0.35 IU/ml and a follow up test IFN-ɣ ≥0.35 IU/ml [50]. Some 
studies used the definitions for QFT-GIT as a baseline test IFN-ɣ <0.35 IU/ml and 
1) a follow up test IFN-ɣ ≥0.35 IU/ml, plus a 30% increase in IFN-ɣ over the 
baseline value as proposed by Veerapathran [72], or 2) a follow up test IFN-ɣ 
≥0.35 IU/ml, plus an absolute increase of 0.35 IU/ml, or 3) a follow up test IFN-ɣ 
≥0.7 IU/ml as proposed by Pai [73]. For T-SPOT.TB, conversion was defined as a 
negative test at baseline changing to a positive test using the ≥6 spot increment 
[54] or a definition of a baseline T-SPOT.TB negative and follow up positive using a 
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≥8 spot increment [63]. IGRA reversion was defined as a positive baseline test and 
a negative follow up test, by the manufacturer’s cut-off [50, 54]. 
Risk factors or determinants of exposures: occupational factors included years in 
work, job category, work location, procedure involved, contact with any TB 
patients, contact with undiagnosed or untreated TB patients, work duration, 
change of location, and other occupational factors. Non-occupational factors 
included age, age when started work as a HCW, gender, contact with family or 
friends diagnosed with TB, BCG vaccination, human immunodeficiency virus (HIV) 
status, and other non-occupational factors. TB Infection control policy and practice 
in the health facility (administration control, environmental control, personal 
protective equipment) was considered as an effect modifier. 
3.2.4 Quality assessment  
We assessed the quality of studies based on the Cochrane Group guidelines for 
observational studies [74], according to five criteria: 1) sampling strategy, 2) 
response rate of ≥80% for a cross-sectional study and retention rate of ≥90% for a 
cohort study, 3) method of measurement of TB exposure, 4) TST or IGRA 
performance and, 5) reported results (Appendix 3. Tables A.3.2, A.3.3, and A.3.3). 
Any disagreement was resolved by consensus. 
3.2.5 Data synthesis, meta-analysis, and meta-regression 
We evaluated the clinical heterogeneity of the studies – in particular with respect 
to the type of test used, TB incidence in the general population (classified as 0-24, 
25-99, 100-199, 200-299, and >300 per 100,000) [1], and type of participants 
included (HCWs or HCSs). We then evaluated the statistical heterogeneity as 
assessed by I2. Since significant heterogeneity (I2 >75%) was present, we carried 
out a stratified analysis and a meta-regression. We used random effects methods 
to obtained pooled estimates and 95% confidence interval (CI) [75]. Forest plots 
were generated for each sub-group analysis. The meta-regression was performed 
using logistic regression in a Generalised Estimating Equation framework to allow 
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for correlations between prevalence estimates from the same study [76]. Data 
were analysed using Stata® version 14.2 (Stata Corp LP, Texas, US).  
3.3 Results 
3.3.1 Description of included studies 
A total of 3537 records and four full-text articles from other systematic reviews 
were screened (Figure 3.1); 168 full-text articles were assessed for eligibility, and 
83 articles excluded. Eighty-five studies met the inclusion criteria, representing 
32,630 subjects from 26 LMICs [44-46, 63, 65-68, 73, 77-152] (Appendix 3. Table 
A.3.5). Annual TB incidence rates in countries included ranged from 8/100,000 in 
Cuba [80] to 977/100,000 in South Africa [115].  
3.3.2 Prevalence of LTBI measured by TST and IGRA  
The prevalence of LTBI was measured in 66 TST studies [44-46, 63, 65-68, 77, 79-
83, 85, 86, 88-91, 93, 94, 96, 99-110, 112-114, 116-120, 123-129, 131-135, 137-
139, 141, 142, 144-148, 150] and 36 IGRA studies [44-46, 63, 65-67, 78, 81, 89, 92, 
95, 98, 101-103, 106, 109-111, 116, 121, 122, 124, 129, 131, 135, 140, 142-147, 
149, 151, 152] (Appendix 3. Tables A.3.6 and A.3.7). The forest plot (Figure 3.2) 
shows the variability in the estimates of prevalence of LTBI using TST; estimates 
ranged from 1% to 98% and there was evidence of heterogeneity (P<0.0005). The 
prevalence of LTBI in HCWs ranged from 8-98% (mean 49%), and for HCSs from 




IGRA = interferon-gamma release assay, LMICs = low and middle-income countries, TST = 
tuberculin skin test 
 
Figure 3.1 Flow chart of literature search 
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ES: effect size (prevalence of LTBI in each study), with 95% confidence interval (CI) 
Figure 3.2 Forest plot for the prevalence of latent tuberculosis infection in health 
care workers and health care students in low and middle-income countries 
measured by tuberculin skin test (TST) 
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For IGRA, the overall range in prevalence estimates was 9% to 86% (Figure 3.3; P 
value for heterogeneity=0.01). The prevalence in HCWs ranged from 9-86% (mean 
39%), and in HCSs from 10-44% (mean 24%).  
 
ES: effect size (prevalence of LTBI in each study), with 95% confidence interval (CI) 
Figure 3.3 Forest plot for the prevalence of LTBI in health care workers and health 
care students measured by interferon-gamma release assay (IGRA) 
Nurses had the highest prevalence of positive TST (pooled estimate 54%, 95% CI 
46-61%) followed by physicians (48%, 95% CI 30-65%), allied health 
professionals (45%, 95% CI 35-55%), and general services (45%, 95% CI 30-60%) 
(Table 3.1). General services staff had the highest prevalence of positive IGRA 
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(60%, 95% CI 54-66%) followed by physicians (35%, 95% CI 22-49%), nurses 
(34%, 95% CI 22-46%) and allied health professionals (31%, 95% CI 23-40%) 
(Table 3.2).  
Studies conducted in high TB incidence countries (≥300/100,000 population) had 
the highest prevalence of positive TST (pooled estimate 55%, 95% CI 41-69%) 
and positive IGRA (56%, 95% CI 39-73%) (Table 3.1, Table 3.2, and Appendix 3. 
Figure A.3.1). After stratification by type of participants and then by TB incidence, 
studies conducted in countries with the lowest TB incidence had the lowest 
prevalence of LTBI in all types of HCWs and HCSs as measured by TST or IGRA 
(Appendix 3. Table A.3.8).  
When stratified by study quality, studies with high quality had the lowest 
prevalence (TST: pooled estimate 41%, 95% CI 34-49%; IGRA: 30%, 95% CI 19-
41%) compared with medium and low quality studies (Table 3.1 and Table 3.2). 
Twenty-six studies investigated the prevalence of LTBI using both TST and IGRA 
[44-46, 63, 65-67, 81, 89, 101-103, 106, 109, 110, 116, 124, 129, 131, 133, 135, 
142, 144-147]: the prevalence of LTBI measured by TST was higher (pooled 
estimate 52%, 95% CI 41-62%) compared with IGRA (38%, 95% CI 38-52%) 
(Appendix 3. Figure A.3.2).  
For comparison with Joshi’s review [5], we restricted our analysis to studies from 
five countries that were the same in both reviews (Brazil, India, South Africa, 
Thailand, and Turkey) resulting in six studies from Joshi’s review [64, 153-157] 
and 23 from our review [44-46, 63, 67, 81, 88, 90, 91, 96, 106, 108, 112, 117, 123-
125, 128, 132, 134, 137, 145, 148]. The LTBI prevalence measured by TST in 
HCWs in our review was slightly lower (pooled estimate 51%, 95% CI 44-58%) 
than Joshi’s estimate (55%, 95% CI 44-65%) (Appendix 3. Figure A.3.3). In HCSs, 
using the same approach, when restricted to four countries that were the same in 
both reviews, which Brazil, India, Iran, and Uganda, the prevalence of LTBI was 
higher in and five studies from our review [83, 93, 113, 114, 133] (pooled estimate 
29%, 95% CI 13-45%) than seven studies from Joshi’s review [156, 158-163] 





Table 3.1 Prevalence of LTBI measured by tuberculin skin test (differences by study quality) 
 
CI = confidence interval, IQR = inter quartile range, LTBI = latent tuberculosis infection, TB = tuberculosis 
 aGeneral services included cleaners, drivers, and housekeepers 
 
Study description 
Prevalence of LTBI - all studies 
Prevalence of LTBI - high and medium quality 
studies 




















1. Health care workers 53 39-61 49 43-55 29 34-59 47 40-54 
    - Physicians 11 41-55 48 30-65 6 28-55 46 19-73 
    - Nurses 20 44-65 54 46-61 10 48-64 54 43-65 
    - Allied health professionals 23 28-63 45 35-55 15 26-61 40 28-52 
    - General servicesa 7 40-53 45 30-60 5 51-53 45 28-63 




0-24 14 14-52 34 24-44 5 14-52 32 19-46 
25-99 31 43-61 51 43-59 20 43-61 45 36-54 
100-199 9 14-63 36 21-51 5 14-63 30 13-46 
200-299 7 46-60 51 40-62 4 46-60 56 45-66 
> 300 5 45-60 55 41-69 4 45-60 57 41-74 
Stratified by 
study quality 
High 22 22-57 41 34-49 22 22-57 41 34-49 
Medium 16 32-64 48 34-61 16 32-64 48 34-61 





Table 3.2 Prevalence of LTBI measured by interferon-gamma release assay (differences by study quality) 
 
CI = confidence interval, IQR = inter quartile range, LTBI = latent tuberculosis infection, TB = tuberculosis 
 aGeneral services included cleaners, drivers, and housekeepers 
 
Study description Prevalence of LTBI - all studies Prevalence of LTBI - high and medium quality 
studies 




















1. Health care workers 33 20-43 39 30-47 12 26-52 41 18-27 
     - Physicians 13 21-53 35 22-49 6 35-55 47  26-56 
     - Nurses 18 22-40 34 22-46 7 30-39 36  33-61 
     - Allied health professionals 21 17-38 31  23-40 9 19-58 34  18-54 
     - General servicesa 2 29-59 60 54-66 1 - 74  17-50 
2. Health care students 4 14-32 24 10-38 1 - 10 66-80 
Stratified by 
TB incidence 
per 100,000  
0-24 7 14-26 20  13-26 2 21-26 22  26-54 
25-99 16 28-46 41  28-53 8 24-51 39  42-53 
100-199 7 29-52 41  28-50 1 - 47  - 
200-299 3 36-44 38  26-50 0 - - 64-74 




High 8 28-48 30  19-41 8 28-48 30  7-15 
Medium 4 30-53 60  44-77 4 30-53 60  19-41 
Low 24 22-46 36  28-44 - - - 44-77 
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We fitted a meta-regression model to explore factors associated with 
heterogeneity in LTBI prevalence estimates. Studies conducted in high annual TB 
incidence countries (≥300/100,000 and 200-299/100,000 population) had a 
higher LTBI prevalence than in low annual TB incidence countries (0-24/100,000 
population) (OR 2.9, P=0.040 and OR 8.4, P<0.0001, respectively). LTBI prevalence 
in HCSs was lower than in allied health professionals (OR 0.3, P=0.003) (Table 
3.3).  
 
Table 3.3 Results of meta-regression to explore factors associated with 
heterogeneity in LTBI prevalence estimates 
Covariates Odds Ratio 95% CI P value 
Type of test (ref. IGRA) 1   
TST   1.2 0.8-2.0 0.37 
TB incidence in the population (ref. 0-24/100,000/year) 1   
25-99 1.9 0.8-4. 3 0.14 
100-199 0.9 0.4-2.3  0.91 
200-299 8.4 3.3-21.6 <0.0001 
> 300 2.9 1.1-8.2 0.040 
Type of participants (ref. allied health professionals) 1   
Physicians 0.9 0.5-1.7 0.81 
Nurses 1.2 0.8-1.8 0.40 
General services 1.2 0.7-2.1 0.41 
Health care students 0.3 0.1-0.6 0.003 
Others (combination) 1.5 0.9-2.6 0.15 
Type of settings (ref. tertiary/university/general hospital) 1   
Clinics/health centres 1.2 0.4-3.1 0.73 
TB/Chest disease hospital 0.9 0.4-1.9 0.84 
Specialized hospital 1.0 0.4-2.5 0.98 
Others (combination) 1.2 0.5-2.8 0.62 
Study quality (ref. low) 1   
High and medium 1.0 0.7-1.5 0.94 
CI = confidence interval, IGRA = interferon-gamma release assay, TB = tuberculosis,  
TST = tuberculin skin test 
 aGeneral services included cleaners, drivers, and housekeepers 
 
3.3.3 Risk factors associated with LTBI prevalence  
Twenty-eight studies reported on factors associated with a positive TST [44, 65, 
68, 77, 79, 80, 83, 85, 89, 91, 100-102, 106-109, 112, 113, 116, 118, 119, 127, 134, 
138, 145, 147, 150] (Appendix 3. Table A.3.9). In Table 3.4 we provide a summary 
of risk factors examined and those found statistically significant and not 
significant. Estimates are not provided due to the potential bias from selective 
reporting of statistically significant results. Among HCWs, occupational risk 
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factors of more years of work [44, 68, 77, 100, 101, 112, 116, 150] and work 
location [100, 118, 134, 150] were statistically significantly associated with LTBI 
prevalence. In some studies, job category [118, 119] and contact with a TB patient 
[77, 80] were independent occupational risk factors. In HCSs, years spent in health 
care after entry to clinical programmes [83] and contact with a TB patient [113] 
were independent risk factors. Male sex [77, 101, 108, 127], age [44, 100, 127, 
147], BCG scar/history of BCG vaccination [44, 100, 102, 108], education level 
[119, 134], household contact with a TB case [101, 134], smoking status [91, 102], 
chronic disease [118, 119], immunosuppression [79], and diabetes mellitus [118] 
were independent non-occupational risk factors in HCWs. Similarly in HCSs, male 
sex [108, 113], BCG scar/history of BCG vaccination [107, 108], older age [89], TB 
knowledge [89], and course of study [113] were associated with a higher LTBI 
prevalence. 
Twenty-one studies reported risk factors associated with higher prevalence of 
LTBI determined by IGRA [44, 46, 65, 66, 89, 92, 101, 102, 106, 109, 110, 116, 122, 
124, 129, 143, 145-147, 149, 152] (Appendix 3. Table A.3.9). In summary (Table 
3.5), among HCWs, a positive IGRA was associated with more years of work [44, 
46, 66, 101, 102, 116, 122, 149], job category [66, 122, 129, 146, 149], contact with 
a TB patient [109, 122], type of facility [46, 110], work location [92], contact with a 
co-worker with TB [101], and average daily time with direct patient contact in the 
preceding year [101]. No occupational factors were significantly associated with a 
positive IGRA in HCSs. Non-occupational factors significantly associated with 
positive IGRA in HCWs included older age [101, 116, 122, 129, 146], male sex [44, 
102, 106, 129], household contact [66, 129, 149], BCG scar/vaccination [44, 101], 
level of education [102, 110], body mass index (BMI) [110, 143], granulysin 
concentration [143], and diabetes mellitus [66]. While in HCSs, older age and Khat 
consumption were the only significant non-occupational factors [89]. Factors 






Table 3.4 Summary of risk factors associated with the prevalence of latent TB infection by tuberculin skin test  
Occupational Non-occupational 
Factors Number of 
studies 
assessed 











Factors Number of 
studies 
assessed 












Health care workersa 
Years of work 16 8 [44, 68, 77, 100, 
101, 112, 116, 150] 
9 [65, 79, 102, 109, 
118, 119, 134, 138] 
Male sex 22 4 [77, 101, 108, 
127] 
16 [44, 65, 68, 79, 
80, 91, 100, 102, 
106, 116, 118, 
119, 134, 138, 
145, 150] 
Work location  9 4 [100, 118, 134, 
150] 
5 [44, 68, 77, 127, 
138] 
Age 18 4 [44, 101, 127, 
147] 
14 [65, 79, 91, 
101, 102, 106, 
108, 116, 118, 
119, 134, 138, 
145, 150] 
Job category 13 2 [118, 119] 11 [44, 65, 68, 77, 
79, 100, 109, 116, 
127, 138, 145] 
BCG scar/vaccination 13 4 [44, 100, 102, 
108] 
9 [65, 79, 80, 101, 
106, 116, 134, 
138, 150] 
Contact with TB 
patient 
7 2 [77, 80] 5 [65, 79, 109, 116, 
119] 
Education level 8 2 [119, 134] 6 [65, 100-102, 
116, 150] 
Type of facility 4 1 [150] 3 [68, 77, 101] Household contact 
with TB 
5 2 [101, 134] 3 [44, 79, 145] 
Ever had co-workers 
with TB positive 
2 1 [101] 2 [79] Smoking status 9 2 [91, 102] 7 [44, 79, 100, 
101, 119, 138, 
150] 
Cared for TB patient 
in last year  







Factors Number of 
studies 
assessed 











Factors Number of 
studies 
assessed 













contact with PTB 
patients  
1 1 [112] - Immunosuppression 2 1 [79] 1 [134] 
Had TB Infection 
control or TB training 
3 1[101] 2 [134, 150] Diabetes mellitus 1 1 [118] - 
Aware of TB infection 
control guidelines 
1 1 [101] -     
Health care studentsb 
Time (years) spent in 
health care work 
after entry  
2 1 [83] 1 [89] Male sex  6 2 [108, 113] 4 [83, 85, 107, 
145] 
Contact with a case of 
TB  
3 1 [113] 2 [83, 107] BCG scar/vaccination  4 2 [107, 108] 2 [83, 89] 
    Age  7 1 [89] 6 [83, 85, 107, 
108, 113, 145] 
    TB knowledge  2 1 [145] 1 [113] 
    Course type 1 1 [113] - 
BCG = Bacille Calmette-Guerin, Refs. = references, TB = tuberculosis 
Factors assessed in studies that were not found to be significantly significant:  
a HIV status [68, 77, 145], alcohol consumption [44, 91, 150], income [100, 102, 150], TB knowledge score [145] 






Table 3.5 Summary of risk factors associated with the prevalence of latent TB infection by interferon-gamma release assay 
Occupational Non-occupational 
Factors Number of 
studies 
assessed 

























Health care workersa 
Years of work  16 8  [44, 46, 66, 101, 
102, 116, 122, 149] 
8 [65, 92, 106, 
109, 110, 124, 
129, 146] 
Age  15 5 [101, 116, 122, 
129, 146] 
10 [44, 66, 92, 102, 
106, 109, 110, 143, 
145, 149] 
Job category  13 5 [66, 122, 129, 
146, 149] 
8 [44, 65, 106, 
109, 110, 116, 
143, 145] 
Male sex  14 4 [44, 102, 106, 
129] 
 
[66, 92, 101, 109, 
110, 116, 122, 143, 
145, 149] 
Contact with TB 
patient 
4 2 [109, 122] 2 [65, 116] Household contact 
with TB  
5 3 [66, 129, 149] 2 [44, 145] 
Type of facility 3 2 [46, 110] 1 [101] BCG 
scar/vaccination 
9 2 [44, 101] 7 [66, 102, 106, 109, 
116, 122, 146] 
Work location  5 1 [92] 4 [44, 129, 143, 
149] 
Education level  7 2 [102, 110] 5 [101, 116, 122, 
129, 149] 
Ever had co-workers 
with TB positive 
1 1 [101] - BMI  4 2 [110, 143] 2 [122, 129] 
Average daily time in 
patient last year  
1 1 [101] - Granulysin 
concentration  
1 1 [143] - 
    Diabetes mellitus 1 1 [66] - 
Health care studentsb 
- - - - Age  2 1 [89] 1 [145] 
    Khat consumptionc 1 1 [89]  
BCG = Bacille Calmette-Guerin, BMI = body mass index, Refs = references, TB = tuberculosis. Factors assessed in studies that were not found to be significantly significant: acared for 
TB last year [101], had TB Infection control training [101], mask use [110], smoking status [44, 66, 101, 102], income [102, 129], comorbidity [44, 129], alcohol consumption [44], 
Hepatitis C virus [66], TB knowledge score [145], bnumber days spent working on medical wards [152], religion [89], BCG scar/vaccination [89], BMI [89], male sex [145], HIV [145], 
household contact with TB [145], TB knowledge score [145], cKhat: Catha edulis is plant grown commonly in the horn of Africa. People for its stimulant action chew the leaves of Khat.  
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3.3.4 Incidence of LTBI measured by TST and IGRA conversion 
The annual LTBI incidence (defined as test conversion after one year) was 
reported in 15 studies using TST [63, 73, 80, 82, 84, 85, 90, 93, 97, 102, 108, 112, 
117, 128, 136] and five studies using IGRA [63, 73, 95, 102, 130] (Appendix 3. 
Table A.3.10 and A.3.11). The forest plot (Figure 3.4) shows the variability in the 
estimates of incidence of LTBI using TST; estimates ranged from 1% to 38% and 
there was evidence of heterogeneity (P<0.009). The incidence of LTBI in HCWs 
ranged from 1-38% (mean 17%), and for HCSs from 3-8% (mean 5%). For IGRA, 
the overall range in incidence estimates was 8% to 30% (Figure 3.4; P value for 
heterogeneity=0.016). The incidence in HCWs ranged from 10-30% (mean 18%), 
and 8% in HCSs (one study).  
Among HCWs, in studies that used TST, allied health personnel had the highest 
annual LTBI incidence (pooled estimate 15%, 95% CI 3-27%) followed by 
physicians (9%, 95% CI 0-18%) and nurses (9%, 95% CI 6-12%) (Table 3.6). In 
studies that used IGRA, physicians had the highest annual incidence (pooled 
estimate 19%, 95% CI 15-23%) followed by nurses (10%, 95% CI 8-13%), and 
allied health professionals (10%, 95% CI 6-15%) (Table 3.7). 
Studies conducted in countries with TB incidence of ≥300/100,000 population had 
the highest annual incidence of LTBI among HCWs as measured by TST (pooled 
estimate 38%, 95% CI 24-55%) (Table 3.6). Whereas in studies that used IGRA, 
there was no clear trend, likely due to the low number of studies included (n=5) 
(Table 3.7 and Appendix 3. Figure A.3.5).  
In two studies using both TST and IGRA [63, 102], the annual incidence with TST 
was lower (pooled estimate 12%, 95% CI 9-15%) than with IGRA (20%, 95% CI 
12-27) (Appendix 3. Figure A.3.6). The annual IGRA reversion rate was 17% 
(pooled estimate) with 95% CI 7-26% in the five studies where it was reported 
[63, 73, 95, 102, 130] (Table 3.7 and Appendix 3. Table A.3.12).  
In studies that used TST, when stratified by study quality, high quality studies had 
the lowest incidence (pooled estimate 7%, 95% CI 3-11%) compared with 
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medium (11%, 95% CI 7-16%) and low quality studies (8%, 95% CI 1-16) (Table 
3.6). In studies that used IGRA, none were assessed as low quality (Table 3.7).  
 
ES: effect size (annual incidence of LTBI in each study), with 95% confidence interval (CI) 
Figure 3.4 Forest plot for the incidence of latent TB infection in health care workers 
and health care students in low and middle-income countries by tuberculin skin test 





Table 3.6 Annual incidence of latent TB infection measured by tuberculin skin test (differences by study quality) 
Study description 
Annual incidence of LTBI - all studies 
Annual incidence of LTBI - high and medium 
quality studies 


















Overall 15 4-21 10 7-13 11 5-22 10 7-13 
Stratified 
by type of 
participants 
1. Health care workers 8 10-23 17 9-24 6 14-24 18 9-27 
     - Physicians 3 6-14 9  0-18 1 - 11  9-15 
     - Nurses 2 12-24 9 6-12 0 - - - 
     - Allied health professionals 3 11-22 15  3-27 1 - 25 16-37 
     - General servicesa 0 - - - 0 - - - 






0-24 3 3-4 3 1-5 1 - 1 0-4 
25-99 5 11-22 16 9-22 4 19-23 19  11-26 
100-199 2 5-5 5 4-6 2 5-5 5 4-6 
200-299 4 7-13 10 2-19 3 5-10 7 2-13 




High 3 5-15 7 3-11 3 5-15 7 3-11 
Medium 8 7-21 11 7-16 8 7-21 11 7-16 
Low 4 4-9 8 1-16 - - - - 
CI = confidence interval, IQR = inter quartile range, LTBI = latent tuberculosis infection, TB = tuberculosis 





Table 3.7 Annual incidence of latent TB infection measured by interferon-gamma release assay (differences by study quality) and IGRA 
reversion rate 
Study description 
Annual incidence of LTBI - all studies 
Study data Pooled estimates 
Number of 
studies 
IQR for incidence 
estimates 
Annual incidence (%) 95% CI 
Overall 5 10-22 15  10-21 
Stratified by type of 
participants 
1. Health care workers 4 10-22 18 10-26 
     - Physicians 1 - 19 15-23 
     - Nurses 1 - 10 8-13 
     - Allied health   professionals 1 - 10 6-15 
     - General servicesa 0 - - - 
2. Health care students 1 - 8 5-12 
Stratified by TB incidence 
per 100,000 
0-24 0 - - - 
25-99 2 12-17 12  10-14 
100-199 1 - 30 16-48 
200-299 1 - 8 5-12 
> 300 1 - 22 15-31 
Stratified by study quality High 0 - - - 
Medium 5 10-22 15  10-21 
Low 0 - - - 
IGRA reversion rate (annual) 5 7-21 17 7-26 
CI = confidence interval, IGRA = interferon gamma release assay, IQR = inter quartile range, LTBI = latent tuberculosis infection, TB = tuberculosis 




3.3.5 Risk factors associated with the incidence of LTBI 
Ten studies reported information on risk factors associated with TST conversion 
[63, 84-87, 102, 115, 126, 136, 147] (Table S7). In summary (Table 3.8), among 
HCWs, TST conversion was associated with occupational risk factors including job 
category [136], contact with TB patient [87], years of work [102], engaged in 
counselling TB patient [63]. In HCSs, days spent caring for pulmonary TB patients 
[84], involvement in sputum collection [84], ever performed or assisted in sputum 
collection [84], and career type [126] were independent occupational factors. Non-
occupational factors in HCWs included male sex [136] and in HCSs, only older age 
[126] was associated with TST conversion. 
Six cohort studies reported factors associated with IGRA conversion [63, 102, 115, 
130, 147, 152] (Appendix 3. Table A.3.13). Among HCWs, IGRA conversion was 
associated with work location [130], engaged in counselling TB patient [63], and 
minutes spend on diagnosing one patient [115]. Increasing age was the only non-
occupational factor [164]. There were no statistically significant factors found in 
HCSs studies. Factors assessed in studies that were not found to be statistically 





Table 3.8 Summary of risk factors associated with the incidence of latent TB infection measured by tuberculin skin test and interferon-
gamma release assay 
Occupational Non-occupational 
Factors Number of 
studies 
assessed 












Factors Number of 
studies 
assessed 












Health care workers - TST a        
Job category 3 1 [136] 2 [63, 87] Male 3 1 [136] 2 [63, 87] 
Contact with TB patient 1 1 [87] -     
Years of work 1 1 [102] -     
Engaged in counselling TB patient 1 1 [63] -     
Health care students - TSTb        
Days spent caring for pulmonary 
TB patients 
1 1 [84] - Age 4 1 [126] 3 [84-86] 
Ever performed or assisted in 
sputum collection 
1 1 [84] -     
Type of career 1 1 [126] -     
Health care workers - IGRAc        
Work location 1 1 [130] - - - - - 
Engaged in counselling TB patient 1 1 [63] -     
Minutes spend on diagnosing one 
patient 
1 1 [102] -     
Health care students - IGRAd        
IGRA = interferon-gamma release assay, refs = references, TB = tuberculosis, TST = tuberculin skin test 
Factors assessed in studies that were not found to be statistically significant: a work location [87], BCG scar/vaccination [63, 87, 102, 136], age [102], education 
[102], smoking status [63, 102], income [102], diabetes mellitus [63], alcohol consumption [63], HIV status [63], b direct contact with sputum positive TB [165], 
days spent working on isolation ward [165], days spent working on pulmonary ward [165], TB contact history [126], male sex [85, 86, 126], BCG scar/vaccination 
[86, 165], education [165], smoking status [85], income [165], alcohol consumption [85], HIV status [86], household contact with TB [86], type of students [86], BMI  
[126], c years of work [102, 130], job category [63, 130], male sex [102, 130], age [102, 130], smoking status [63, 102], education [102], BCG scar/vaccination [102], 
income [102], diabetes mellitus [63], alcohol consumption [63], HIV status [63], d occupational exposures [152] 
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3.3.1 Infection control measures in health care facilities  
Of the 85 studies included in this review, only 15 reported on infection control 
measures in health care facilities (see Table 3.9 for summary) [68, 83, 87, 90, 95, 
96, 100, 104, 108, 112, 115, 127, 131, 152, 165]. None implemented a full 
programme of TB infection control measures. Nine studies reported inadequate 
implementation and no clear information was found in six studies. Five of the 15 
studies reported a TB infection control policy [68, 83, 87, 100, 165]. One study 
reported on TB infection control training [87]. Implementation of patient triage 
and management was reported in six studies [68, 83, 87, 100, 127, 131], sputum 
management in one study [127], staff protection (personal respiratory protection) 
in four studies [83, 87, 90, 96], and environmental control in four studies [68, 87, 
96, 100, 108, 127]. To assess the infection control measures, one study used the 






Table 3.9 Tuberculosis infection control measures in health care facilities 
Author, Year, 
Reference 



































Yes Yes Not stated Yes Not stated Yes Not stated No Not stated 
Christopher, 
2011 
Yes Yes Not stated No Not stated Not stated No No Not stated 
da Costa, 2009 Yes Yes Yes Yes Not stated Yes Yes Not clear Not stated 
de Miranda, 
2012 
Yes Not stated Not stated No Not stated Yes Not stated Not clear Not stated 
Escombe, 2010 Yes Not stated Not stated No Not stated No No No Not stated 
Franco, 2006 Yes Not stated Not stated Not stated Not stated Yes Yes No Not stated 
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CDC = Centres for Disease Control and Prevention, IC = infection control, TB = tuberculosis, WHO = World Health Organisation 
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3.4 Discussion 
In this systematic review, we have found a high prevalence and incidence of LTBI 
in HCWs and HCSs in LMICs measured by TST or IGRA. Nearly 50% of HCWs and 
32% of HCSs were found to have a positive TST, while 39% and almost 25% 
respectively had a positive IGRA. HCWs from countries with an annual TB 
incidence of >300/100,000 had the highest prevalence of LTBI with more than a 
half found to be TST or IGRA positive. The annual incidence of LTBI was 17% in 
HCWs and 5% in HCSs when estimated from serial TST, and 18% and 8%, 
respectively, when estimated with IGRA. 
Strengths of our study include that we used multiple sources and databases to 
retrieve relevant studies. Two independent reviewers conducted paper selection 
and data extraction, subgroup analyses were used to accommodate heterogeneity 
across studies and results were pooled only when studies were reasonably 
consistent in their methods. Our study does have some limitations. In the absence 
of a gold standard for diagnosing LTBI, there is no guarantee that prevalence and 
incidence estimates of LTBI are accurate. Both TST and IGRA have several 
limitations. Due to the complexity of the data, in the final analysis we used the 
definition of LTBI based on the national guideline where the study was done or the 
standard definition by the manufacturer’s recommendation. There was substantial 
heterogeneity, similar to previously published reviews [5, 8], reflecting the 
different tests, settings, and populations included in the review. Although we 
stratified the prevalence and incidence estimates, due to the heterogeneity in our 
results, the pooled averages should be interpreted with caution. Although studies 
published in non-English languages were eligible, five Turkish papers were not 
accessible, and could not be included in the final analysis [166-170]. We extracted 
data from their English abstracts and, apart from one study [169]; the overall 
results were similar to those in our review (Appendix 3 Table A.3.14). We were 
not able to conduct meta-analyses of the associations of risk factors with LTBI due 
to limited data. However, all associations are described in Appendix 3 (Tables 
A.3.13), in which all potential risk factors analysed by authors in each study are 
summarized along with details regarding which associations were statistically 
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significant. We did not include non-HCWs or non-HCSs in the analysis. A further 
limitation was not having general population estimates to compare with. The 
prevalence of LTBI in HCWs from our review was two times higher than the global 
LTBI prevalence of 23% estimated by Houben et al, [2], although the results of this 
modelling study may have limited comparability to the results of direct testing in 
the studies included in this review. Uden et al [10] found that HCWs and HCSs had 
more than two times the risk of LTBI than the general population, consistent with 
previous reports [5, 15]. Finally, estimating the prevalence and incidence of TB 
disease was beyond the scope of this review. 
This review adds to the evidence that whether measured by TST or IGRA, the 
prevalence of LTBI in HCWs in LMICs continues to be high, especially in high TB 
incidence countries. This is in keeping with previously published reports that have 
shown approximately half of HCWs were positive by TST [5, 8]. When measured 
by IGRA, our overall LTBI prevalence estimate was lower than that measured by 
TST but still high, and consistent with the previously published review in 
countries with a low and intermediate incidence of TB [15].  
Similarly, our review showed that the overall incidence of LTBI in HCWs continues 
to be high in LMICs. The annual incidence, however, was higher when estimated 
using IGRA compared with TST, which is similar to the previous review [15]. We 
also found a high rate of IGRA reversion, consistent with the previously published 
review in all countries, irrespective of the national TB incidence rates [15, 16]. The 
exact cause of the substantial rate of IGRA reversion is unexplained [15, 16] and 
raises concerns about the validity of serial IGRA to estimate new infections. 
Because of this, WHO has discouraged the use of IGRA for serial testing in HCWs in 
LMICs [164].  
For HCSs, the prevalence and incidence of LTBI was lower than that seen in HCWs 
and this was seen in studies that used TST and/or IGRA. This is most likely due to 
their shorter exposure time compared to other HCWs. They do however require 
attention, similar to that needed for other HCWs, as their risk of LTBI is higher 
compared with the general population [10], as was shown in a Brazilian study in 
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medical and nursing students where the risk of LTBI was more than three times 
greater than the general population [114].  
Across all studies included in our systematic review, occupational factors found to 
be significantly associated with LTBI in HCWs and HCSs were those that involved 
more direct contact with a TB patient or prolonged exposure. This is similar to 
that reported in previous reviews [4, 5, 8]. Hence, these risk factors, along with the 
continuing high prevalence and incidence of LTBI in HCWs are an indication that 
more needs to be done to ensure these workers and students receive the 
protection they require. The WHO released guidelines on TB infection control in 
health care settings in 2009 [6], yet in our review only 15 studies reported any TB 
infection control measures - the inadequacy of which was also reported by Joshi et 
al [5] and Nasreen et al [8]. In resource-limited countries, budget constraints may 
be cited as a reason for limited infection control measures. However, the basic 
control measures recommended in the 2009 WHO guidelines of early 
identification, isolation, and treatment of those with presumptive TB, as well as 
open window and door policies, education and training of HCWs are all low cost, 
and effective measures that should be feasible in all settings, and provide 
important protection for these seemingly forgotten workers. Other measures such 
as infrastructure modification to ensure appropriate natural ventilation and air 
flow, and provision of personal protective measures are more costly, but may also 
contribute towards a reduction of TB infection in HCWs. Moreover, it will be 
important to measure the effectiveness of implementation of infection control 
measures through monitoring and routine reporting of the number of HCWs who 
develop TB disease and infection each year in health care facilities.   
In conclusion, HCWs in LMICs, especially in high TB incidence settings continue to 
have an unacceptably high prevalence and incidence of TB infection. In resource-
limited settings, basic control measures as recommended by the WHO, which are 
low cost and effective are rarely implemented. TB programmes in high TB 
incidence countries must prioritise implementation of infection control measures 
in health care facilities to ensure protection for this highly vulnerable and 




4 Tuberculosis infection control practices in Primary Health 
Centres in Bandung, Indonesia 
4.1 Introduction 
Tuberculosis (TB) infection control consists of a combination of practices aimed at 
minimising the risk of M. tuberculosis transmission within populations [6]. Gaps in 
TB infection control implementation practice in health care facilities predispose 
health care workers (HCWs) to nosocomial M. tuberculosis transmission. HCWs in 
low and middle-income countries (LMICs), especially in high TB incidence settings, 
continue to have an unacceptably high prevalence and incidence of M. tuberculosis 
infection [5]. The World Health Organisation (WHO) released guidelines on TB 
infection control in health care settings in 2009 [6], yet in our review (Chapter 
three) only 15 of 85 studies reported any TB infection control measures – the 
inadequacy of which was also reported by Joshi et al [5] and Nasreen et al [8]. In 
resource-limited settings, basic control measures as recommended by the WHO, 
which are low cost and effective, are rarely implemented.  
HCWs with limited knowledge about TB and infection control can contribute to an 
increased risk of transmission not only to the HCWs themselves but also to 
patients and the general population [19, 20, 60]. Despite the education of HCWs 
being one of the WHO recommendations for effective TB infection control 
programmes [6], previous research in other countries has reported varied results 
in the level of knowledge among HCWs [21-23, 171].  
Evidence shows that TB can be a stigmatising condition [24], fed by a combination 
of fear and denial, which potentially aggravates delay in diagnosis and treatment 
[25]. Research on TB-related stigma has largely focused on affected people and the 
general population, with much less attention on HCWs. When HCWs contract TB 
and are (eventually) diagnosed, they frequently seek treatment in secret. They 
dread public disclosure of their TB diagnosis, fearing a backlash from colleagues, 
who themselves are afraid of contracting TB [172].  
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To date, no studies have reported on TB infection control practices, knowledge, 
and stigma among HCWs in Indonesia. This study, therefore, aimed to assess the 
implementation of TB infection control practices in health care facilities, 
knowledge, care-seeking behaviour, and stigma among HCWs in health care 
facilities that manage TB patients in Bandung, Indonesia.  
4.2 Methods 
4.2.1 Study design and population 
This was a cross sectional study conducted from May to November 2017 involving 
a stratified sample of the primary health centres (PHCs) that manage TB patients, 
and all HCWs in the selected PHCs. Seventy-three PHCs located in Bandung city 
provide general health services, including TB diagnosis and treatment. Five of 
these have inpatient facilities and 30 have TB laboratory facilities. This study was 
restricted to the 53 PHCs that manage more than five cases of TB per year. The 
number of HCWs at each PHC was identified from the Bandung Municipal Health 
Office database. HCW was defined as any individual working in a PHC and who 
provides health care services and/or support including doctors, dentists, general 
nurses, TB nurses, midwives, laboratory personnel, pharmacist, nutritionist, 
environmental health officers, public health officers, and administrators. 
Of the 53 PHCs, 24 were selected using stratified sampling to reach the number of 
390 HCWs (see section 4.2.3 sample size considerations). The strata were 
determined by: 1) presence of a TB laboratory facility, and 2) TB caseload, with 
the assumption that PHCs that are larger and better resourced might have better 
adherence to infection control practices. Information on TB caseload was obtained 
from the Bandung Municipal Health Office database from the average number of 
TB cases reported by each PHC with positive acid-fast bacilli for the three years 
from 2013 to 2015. The median case number was used as a cut off to classify PHCs 
as having high versus low TB caseload. 
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PHCs were randomly selected with a greater preference to PHCs with a laboratory 
and more TB cases, this was because of the interest in knowing TB infection 
control practices is more in PHCs with more of a TB burden; therefore the 
numbers of PHCS in each of the four groups was not the same. Thirty of the 53 
PHCs had a laboratory facility, 15 of which had high TB numbers and 15 low TB 
numbers. Of these, 11 with high TB numbers and 5 with low TB numbers were 
randomly selected, giving 16 PHCs with TB laboratory facilities that were 
included. Of the 23 PHCs with no laboratory facility, 10 had high TB numbers and 
13 had low TB numbers from which 4 PHCs were randomly selected from each 
caseload group (Table 4.1). Therefore, there were four groups of PHCs: 1) PHCs 
with laboratory facility and high TB numbers (n=11), 2) PHCs with laboratory 
facility and low TB numbers (n=5), 3) PHCs with no laboratory facility and high TB 
numbers (n=4), and 4) PHCs with no laboratory facility and low TB numbers 
(n=4). The location of each PHC, according to which group they are in, is shown in 
Figure 4.1.  
 
Table 4.1 Number of Primary Health Centres in each stratum 
  With laboratory facility No laboratory facility   
 Sub total Selected Sub total Selected Total 
High TB caseload  15 11 10 4 25 
Low TB caseload 15 5 13 4 28 
Total 30 16 23 8 53 




Figure 4.1 Map of Primary Health Centres (PHCs) in the Bandung municipality and 
the 24 PHCs included in the study 
4.2.2 Study procedures 
An initial meeting with the director of each PHC was organised to provide 
information and seek permission to carry out the study. Visits to each PHC and 
meetings with HCWs were then arranged, at which time trained research staff 
provided information about the study to all HCWs. 
a) TB infection control practices. For assessing the TB infection control 
practices, written informed consent was sought by the staff member responsible 
for infection control or senior administrator and director/head of each selected 
PHC. Trained research staff made direct observations of infection control practices 
(as described below), combined with information from both of the interviewees. If 
there was disagreement between the information from the different sources, 
priority was given to the researcher observation.  
The implementation of TB infection control was measured by using a 
questionnaire (Appendix 2) developed by the WHO and the Centres for Disease 
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Control and Prevention (CDC) on TB infection control in health care facilities and 
congregate settings [7, 173]. The questionnaire was piloted locally and refined 
before beginning the study.  
The questionnaire covered measures of four key components of TB infection 
control practices: 1) the implementation and availability of facility-level 
management (including a TB infection control plan, staff capacity building, facility 
assessment, surveillance on TB disease and participation in operational research), 
2) administrative controls and management (including patient triage and 
management, patient education and awareness, sputum management, TB 
treatment and referrals, and staff protection), 3) environmental controls (natural 
ventilation, mechanical ventilation, and air-cleaning methods), and 4) personal 
respiratory protection and history of infection control audits [6, 173, 174]. The 
questionnaire was administered through an interview with key staff. Most 
questions required a simple yes/no answer or a measurement with an option for 
additional information by free text if necessary. Giving an answer that was 
consistent with the guidelines earned a score of 1; if not, the score was 0 [173].  
b) Knowledge of TB infection control, TB, and LTBI. For assessing the HCWs 
knowledge, written informed consent was sought from all participants prior to 
undertaking a questionnaire (Appendix 2). Any staff absences or any reasons 
provided for non-consent were noted. Data on the demographic and work 
characteristics of the HCWs, including age, gender, profession, current working 
unit, educational status, service years in current/previous health facility, any 
experience (and years) of working in a TB clinic, formal and informal TB training, 
history of TB disease, and prior TST or IGRA test were collected. 
Investigation of the knowledge of HCWs covered three main subjects: 1) TB 
infection control, 2) TB, and 3) LTBI. A questionnaire, informed by related 
scientific literature [21, 171, 175, 176], was developed focusing on symptoms, 
transmission, treatment, and prevention. Each of the questionnaires were 
translated into the Indonesian language and pre-tested before beginning the 
study. The four research staff who carried out the interviews were trained 
according to a standard operating procedure to ensure the interviews were 
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standardised. For TB infection control knowledge, the questions required simple 
yes/no answers [171]. A “yes” answer was not automatically a correct answer. For 
TB and LTBI knowledge, some questions required a simple yes/no and some were 
from a multiple choice list [175, 176]. Giving a correct answer earned a score of 1; 
a wrong answer, a score of 0. Free text answers were described separately.  
Questions about TB attitudes, care-seeking behaviour, and stigma were developed 
from WHO guidelines [177]. Some questions required a simple yes/no answer. 
Some questions were open-ended for which all of the responses provided were 
noted by the interviewer on the questionnaire. Each question was treated 
separately as a binary or multinomial outcome for analysis.  
Ethics approval was obtained from the University of Otago Ethics Committees, 
New Zealand (H16/139) and the Universitas Padjadjaran Ethics Committees 
Bandung, Indonesia (No 44/UN6.C1.3.2/KEPK/PN/2017) (Appendix 1).  
4.2.3 Sample size considerations 
A previous study conducted in public health facilities in Addis Ababa, Ethiopia 
reported 64% of HCWs had good knowledge about TB infection control using the 
mean as a cut off [171]. Assuming 75% had good knowledge with a design effect of 
1.5 [21], a non-response proportion of 10%, and a finite population correction 
factor of 0.55, 390 HCWs would provide estimates of proportions with a margin of 
error of 5%.   
4.2.4 Data management and statistical analysis 
Questionnaires were collected on paper copies and administered by the field staff. 
All data were verified as the study progressed and entered into a database created 
in RedCap® [178]. Data were transferred into Stata®, and all analyses were 
conducted using version 14.2 (Stata Corp LP, Texas, US). 
All statistical analyses accounted for the stratified sampling and the total 
population size (number of PHCs) using statistical methods for survey data, as 
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implemented in the Stata survey commands (svy commands). Sampling weights 
were calculated from the selection probabilities of the PHCs in each group - more 
weight was assigned to PHCs with a TB laboratory facility and high TB caseload in 
calculating weighted proportions, as shown in Table 4.2. 
Table 4.2 Sampling weights for the selection probabilities of the PHCs in each group 







Selected Weighted Total 
High TB 
case load  
15 11 0.7 10 4 0.4 25 
Low TB 
case load 
15 5 0.3 13 4 0.3 28 
Total 30 16 0.5 23 8 0.4 53 
TB infection control practices in PHCs: the proportion of PHCs who reported 
implementation of each TB infection control measure and 95% confidence 
intervals were calculated. The total number of TB infection control measures 
implemented was calculated in each PHC and presented as median and inter 
quartile range (IQR). The Kruskal Wallis test was used to assess differences in 
median numbers between the four PHC groups.  
TB infection, TB, and LTBI knowledge in HCWs: the proportion of HCWs with 
correct knowledge responses and 95% confidence intervals were calculated; the 
total number of correct responses was calculated for each HCW and presented as 
median numbers with IQR. Linear regression was used to assess differences in the 
median number of correct knowledge responses across job categories.   
TB attitudes, care-seeking behaviour, and stigma: the proportion and 95% 




4.3.1 Description of the Primary Health Centres 
Table 4.3 shows the characteristics of PHCs included in the study. The majority of 
PHCs had no inpatient facility (91.7%). The median daily total patients and 
monthly TB cases were 120 (IQR 70-200) and 19 (IQR 10-40), respectively.  
 
Table 4.3 Characteristics of Primary Health Centres included in the study (N=24) 
Characteristics Frequency Percentage 
Any laboratory facility   
Yes 16 66.7 
No 8 33.3 
Any inpatient facility   
Yes 2 8.3 
No 22 91.7 
TB diagnosis facility using sputum   
On-site 16 66.7 
Off-site (requires referral) 8 33.3 
TB caseload*   
High TB case load 15 62.5 
Low TB case load 9 37.5 
Daily total patients (median, IQR) 120 (70-200) - 
Monthly TB cases (median, IQR) 19 (10-40) - 
IQR = interquartile range, TB = tuberculosis 
*Information on TB caseload was an average of the number of TB cases with positive acid-fast 
bacilli during the 3 years from 2013 to 2015 at each PHC. Median was used as a cut off to identify 
the PHCs with high and low TB caseload. 
 
4.3.2 Implementation of TB infection control practices in Primary Health 
Centres 
4.3.2.1 Facility level management measures 
Using a weighted percentage, a facility-based infection control officer was 
appointed in 21 PHCs (91.7%), yet only three (14.2%) had a written TB infection 
control plan. No PHC had done a TB infection control assessment in their PHCs or 
participated in operational research to improve TB infection control practices. 
Training provided for staff members about TB infection control had occurred in 
two PHCs (11.7%) (Table 4.4).  
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Table 4.4 Implementation of tuberculosis infection control practices in 24 Primary 
Health Centres – Facility level management measures (represented as proportion 
implementing the practice) 




TB IC plan 1. Appointment of facility based  
      IC officer 
21 91.7 76.7-97.3 
2. Written TB IC plan  3 14.2 3.9-40.3 
3. TB IC assessment has been 
done 
0 0.0** - 
4. Participation in operational 
research to improve TB IC 
practices 
0 0.0** - 
Staff capacity 
building 
5. Training provided for staff 
members about TB IC 
2 11.7 2.6-39.2 
CI = confidence interval, IC = infection control, TB = tuberculosis 
*Estimate of the population proportions obtained using sampling weights that were calculated 
from the selection probabilities of the PHCs in each group.  
**Survey 95% CIs were not available if the proportion was 0 or 1 
 
4.3.2.2 Administrative control measures 
The majority of PHCs (91.7%) had implemented screening of patients for cough 
and had an available staff member who screened patients for prolonged cough 
(longer than two weeks). Only 4 (20.0%) had a separated area in the waiting room 
for patients with cough and of the remaining PHCs with no separated area, only 4 
(16.6%) reported that patients with cough see doctors first to minimise the time 
spent in the waiting room. Tissues, pieces of cloth, or facemask for patients with 
cough were found in 17 PHCs (74.2%) and an enclosed wastebasket in 20 PHCs 
(88.3%). None of the PHCs had a symptom checklist to screen patients for TB. 
All PHCs reported that patients with cough were given advice on cough etiquette 
and respiratory hygiene and TB patients were educated on TB infection control 
practice (for example, using mask). Less than half (45%) had posters displaying 
cough etiquette and respiratory hygiene. Just over half (56.7%) had a designated 
area for patients to produce a sputum specimen. The majority of PHCs (88.3%) 
had a staff member to advise patients on how to produce a good sputum specimen 
and 83.3% had a register for those presumed to have TB and kept it in the facility. 
All PHCs had on-site TB treatment with a DOTS strategy and a TB patient register 
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kept in the facility. No PHCs had screened their staff members for TB, yet 10 
(48.3%) reported that staff were offered confidential voluntary HIV counselling 
and testing and Isoniazid (INH) preventive treatment against TB was available for 
HIV-infected staff members (Table 4.5).  
4.3.2.3 Environmental control measures 
Table 4.6 summarise the implementation of environmental control measures. The 
majority of the PHCs relied on their adequate natural ventilation (70.8%), with 
windows (89.2%) and doors (100%) kept open during the day. Adequate 
mechanical ventilation was found in half of PHCs. Two PHCs (11.7%) used high-
efficiency particulate air (HEPA) filtration for air-cleaning methods. All PHCs 
reported that staff did not monitor natural and mechanical airflow and only four 
PHCs (16.7%) reported that environmental controls were periodically maintained 





Table 4.5 Implementation of tuberculosis infection control practices in 24 Primary Health Centres – Administrative control measures 
(represented as proportion implementing the practice) 
Indicators Details Frequency Proportion of PHC 
(Weighted %)* 
95% CI 
Patient triage and 
management 
1. Screening of patient for cough 22 91.7 66.0-98.4 
2. Availability of staff member to screen patient for cough  22 91.7 66.0-98.4 
3. Separated area in the waiting room for patients with 
cough, 
4 20.0 6.9-45.9 
          If no separated waiting area, prioritisation of patients 
with cough  
4 16.7 5.0-43.1 
4. Availability of tissue, pieces of cloth or face mask for 
patients with cough 
17 74.2 50.3-89.1 
5. Availability of enclosed waste basket 20 88.3 72.4-95.6 
 6. Symptom checklist to screen patients for TB 0 0.0** - 
Patient education and 
awareness 
7. Patients with cough given cough etiquette and 
respiratory hygiene advice  
24 100.0** - 
8. Patients with cough given information about TB signs 
and symptoms 
23 97.5 82.1-99.7 
 9. TB patients educated on TB IC practices  24 100.0** - 
 10. Families educated on TB IC practices  23 94.2 63.8-99.3 
 11. TB patients are given educational material  21 89.2 66.9-97.1 
 12. Posters displaying cough etiquette and respiratory 
hygiene 
12 45 24.2-67.7 
Sputum management 13. Designated area for sputum specimen 12 56.7 37.1-74.4 
14. Advice to patients on how to produce a good sputum 
specimen 
20 88.3 72.4-95.6 
 15. Register for those presumed to have TB kept in the 
facility 
20 83.3 62.6-95.3 
 16. Availability of specimen tracking system 7 31.7 14.1-56.7 
TB treatment and 
referral 
17. On-site TB treatment with DOTS 24 100.0** - 
18. Availability of system to ensure adherence 18 82.5 69.4-90.7 





Indicators Details Frequency Proportion of PHC 
(Weighted %)* 
95% CI 
Staff protection 20. Staff members screened for TB 0 0.0** - 
21. Register of all staff who are diagnosed with TB disease 0 0.0** - 
 22. Staff offered VCT for HIV 10 48.3 28.0-69.3 
 23. HIV-infected staff offered ART 6 28.3 112.0-53.5 
 24. IPT available for HIV-infected staff  3 14.2 3.9-40.3 
ART = antiretroviral therapy, CI = confidence interval, DOTS = directly observed treatment short-course, HIV = human immunodeficiency virus, IC = infection 
control, IPT = Isoniazid preventive treatment, PHC = primary health centre, TB = tuberculosis, VCT = voluntary counselling and testing, *Estimate of the population 
proportions obtained using sampling weights that were calculated from the selection probabilities of the PHCs in each group.  





Table 4.6 Implementation of tuberculosis infection control practices in 24 Primary Health Centres – Environmental control measures 
(represented as proportion implementing the practice) 
Indicators Details Frequency Proportion of PHC 
(Weighted %)* 
95% CI 
1. Natural ventilation 
     Type of natural ventilation 
Adequatea 15 70.8 54.9-82.9 
- Open windows on opposite walls, unrestricted 
airflow 
15 70.8 54.9-82.9 
 - High ceiling height (>3m) 11 57.5 39.8-73.5 
 - Standard ceiling height (minimum 2.5m) 13 42.5 26.5-60.2 
 - Windows on one wall, restricted airflow 5 14.2 6.1-22.5 
 - Closed windows, doors always open 6 20.8 9.2-40.7 
2. Windows kept open during the day  21 89.2 65.4-97.3 
3. Doors kept open during the day  24 100.0** - 
4. Mechanical ventilation Adequateb 13 50.0 28.5-71.5 
     Type of mechanical ventilation - Enclosed room with re-circulating air conditioner 2 11.7 2.6-39.2 
 - Propeller fan 13 42.5 26.5-60.2 
 - Exhaust ventilation system 0 0.0** - 
5. Air-cleaning methods used Yes 2 11.7 2.6-39.2 
     Type of air-cleaning methods used - Ultraviolet germicidal irradiation 0 0.0** - 
 - HEPA filtration 2 11.7 2.6-39.2 
6. Natural and/or mechanical airflow 
monitored daily  
 0 0.0** - 
7. Signage for doors and windows   2 11.7 2.6-39.2 
8. Access to an engineer or other 
professional for assistance  
 6 28.3 12.1-53.1 
9. Environmental controls maintained   4 16.7 5.2-42.1 
CI = confidence interval, HEPA = high efficiency particulate air 
*Estimate of the population proportions obtained using sampling weights that were calculated from the selection probabilities of the PHCs in each group.  
**Survey 95% CIs were not available if the proportion was 0 or 1 
a Natural ventilation adequate: has open windows on opposite walls, unrestricted airflow with high or standard ceiling height  
b Mechanical ventilation adequate: use exhaust ventilation system or propeller fans with air should flow from low concentration of infectious particles, toward a 
high concentration. The health care workers (HCWs) should always be “upwind” of the patient – i.e. clean air should flow from behind the HCW towards the patient 
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4.3.2.4 Personal respiratory protection and previous infection control 
audits 
Table 4.7 presents the implementation of respiratory protection measures. Only 
seven PHCs (37.7%) had a written respiratory protection plan in their facility. 
Availability of particulate respirators that meet or exceed the N95 standards set by 
the United States Centres for Disease Control and Prevention/National Institute 
for Occupational Safety and Health (CDC/NIOSH) or filtering face piece 2 (FFP2) 
standards that are CE certified was reported in 15 PHCs (65.8%) and only three 
(14.2%) had training on proper fit of the mask.  
 
Table 4.7 Implementation of tuberculosis infection control practices in 24 Primary 
Health Centres – Personal respiratory protection (represented as proportion 
implementing the practice) 




Personal 1. Written respiratory protection 
plan in the PHC 
7 37.7 39.8-80.8 
 2. Availability of N95 or FFP2 mask 
for staff to use 
15 65.8 41.7-83.8 
 3. Staff members trained on proper 
fit of respiratory protection 
3 14.2 3.9-40.3 
CI = confidence interval, FFP = filtering face piece, PHC = primary health centre, TB = tuberculosis 
*Estimate of the population proportions obtained using sampling weights that were calculated 
from the selection probabilities of the PHCs in each group.  
 
Overall, in the 24 participating PHCs, the median number of TB infection control 
measures implemented was 21 out of 41 assessed (Table 4.8). Of the four key 
components: only one of the five facility level management measures was 
implemented, compared to 15 of 24 administrative controls, three of nine 







Table 4.8 Implementation of tuberculosis infection control practices in 24 Primary 
Health Centres, Median number of correct item 
Item Median number of correct 
items –weighted* (IQR) 
Maximum 
possible score 
All measures 21 (18-25) 41 
Four each key component   
1. Facility level management measures  1 (1-2) 5 
2. Administrative controls  15 (13-17) 24 
3. Environmental controls  3 (3-5) 9 
4. Personal respiratory protection  1 (0-2) 3 
IQR = inter quartile range 
*Estimate of the population proportions obtained using sampling weights that were calculated 
from the selection probabilities of the PHCs in each group.  
Implementation of TB infection control measures varied significantly between the 
groups of PHCs (P=0.003); notably PHCs with TB laboratory facilities and high TB 
case numbers had a higher median number of TB infection control measures 
implemented than the other PHCs (Figure 4.2). According to the four key 
components, differences in the implementation between the groups of PHCs were 
found in the facility level management measures (P=0.049), administrative control 
measures (P=0.01), and the environmental control measures (P=0.048). No 
statistically significant difference was found with respect to personal respiratory 





Group 1 = laboratory facility with high tuberculosis case, Group 2 = laboratory facility with low 
tuberculosis case, Group 3 = no laboratory facility with high tuberculosis, Group 4 = no laboratory 
facility with low tuberculosis case. Blue indicates the distribution number of correct responses in 
each PHC, and red indicates the median number of correct responses. Kruskal Wallis test was used 
to assess the differences across groups (P value: 0.003) 
Figure 4.2 Tuberculosis infection control measures in 24 Primary Health Centres 
  
  
Group 1 = laboratory facility with high tuberculosis case, Group 2 = laboratory facility with low 
tuberculosis case, Group 3 = no laboratory facility with high tuberculosis case, Group 4 = no 
laboratory facility with low tuberculosis case. Blue indicates the distribution number of correct 
responses, and red indicates the median of correct responses. Kruskal Wallis test was used to 
assess the differences across groups. P value for facility level management: 0.049, administrative 
control: 0.01, environmental control: 0.048, personal respiratory protection: 0.23 
Figure 4.3 Tuberculosis infection controls measures in 24 Primary Health Centres, 
by four key components   
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4.3.3 Individual HCWs  
A total of 433 HCWs were employed in the 24 PHCs within the study period. 
Among them, 398 (92.8%) were recruited, 31 were absences at the scheduled 
visits and four refused to participate. Table 4.9 shows the characteristics of the 
included HCWs. The median age was 34.4 (IQR 27.4-48.1), and 347 (87.1%) were 
female. There were 38 (8.9%) doctors, 27 (6.8%) dentists, 89 (21.1%) general 
nurses, 16 (4.3%) TB nurses, 102 (27.4%) midwives, 14 (3.8%) laboratory 
personnel, 30 (7.9%) pharmacists, 24 (5.6%) nutritionists, 23 (5.3%) sanitation 
personnel, 26 (6.5%) public health officers, and 9 (2.3%) administrators. Twenty-
seven (6.7%) HCWs worked in a TB clinic, 35.6% in an outpatient department, 
28% in a maternity and paediatric clinic/ward, 4.6% in a laboratory, 8.1% in a 
pharmacy, 5.4% in a nutrition room, and 11.6% in an administrative office or 
other section. 
Half (51.9%) of the HCWs had a diploma qualification as their highest educational 
level, 35.0% had a first degree, 4.0% had second degree and above, and 9.1% had 
completed high school. The median service years in the current health facility was 
4.5 years (IQR 0.5-9.0). Forty (9.5%) HCWs had experience working in a TB clinic 
with the median years of 5.5 (IQR 2.0-17.0). Most of the HCWs had neither formal 
nor informal TB training (82.8% and 80.3%, respectively). Fourteen HCWs (3.3%) 
had a history of TB disease.  
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Table 4.9 Characteristics of study participants in 24 Primary Health Centres 
(N=398) 
Variable Characteristics Frequency Percentage Weighted* 
Percentage 
Age Median, IQR - years - 36.9 (28.2-48.6) 34.4 (27.4-48.1) 
Gender Male 51 12.8 12.9 
 Female 347  87.2 87.1 
Profession Doctor 38 9.6 8.9 
 Dentist 27 6.8 6.8 
 General nurse 89 22.4 21.1 
 TB nurse 16 4.0 4.3 
 Midwife 102 25.6 27.4 
 Lab. personnel 14 3.5 3.8 
 Pharmacist 30 7.5 7.9 
 Nutritionist 24 6.0 5.6 
 Environmental health 
officer 
23 5.8 5.3 
 Public health officer 26 6.5 6.5 
 Administrator 9 2.3 2.3 
Current working 
site 
Outpatient department 146 36.7 35.6 
TB clinic 27 6.8 6.7 
 Maternity and paediatric 
clinic/ward 
104 26.1 28.0 
 Laboratory 18 4.5 4.6 
 Pharmacy 31 7.8 8.1 
 Nutrition room 23 5.8 5.4 
 Administrative 
office/other 
49 12.3 11.6 
Educational status High school 41 10.3 9.1 
 Diploma 200 50.3 51.9 
 First degree 142 35.7 35.0 
 Second degree and above 15 3.8 4.0 
Years in health 
facility 
Median, IQR - years - 5.0 (0.7-9.0) 4.5 (0.5-9.0) 
Experience working 
in a TB clinic 
Yes 40 10.1 9.5 
No 358 89.9 90.5 
Years in TB clinica Median, IQR - years - 6.0  (3.5-9.0) 6.0 (3.0-9.0) 
Years in previous 
health facility 
Median, IQR - years - 7.0 (2.0-18.0) 5.5 (2.0-17.0) 
Previous TB clinic 
work experience  
Yes 27 6.8 6.1 
No 371 93.2 93.9 
Previous TB clinic 
work experienceb  
Median, IQR - years - 6.0 (3.0-14.0) 6.0 (2.0-14.0) 
Formal TB training Yes 80 20.1 17.2 
 No 318 79.9 82.8 
Informal TB 
training 
Yes 83 20.9 19.7 
No 315 79.2 80.3 
History of TB 
treatment 
Yes 14 3.5 3.3 
No 384 96.5 96.7 
IQR = inter quartile range, TB = tuberculosis 
*Estimate of the population proportions obtained using sampling weights that were calculated 
from the selection probabilities of the PHCs in each group.  
aData available for participants who had experience working in a TB clinic (N=39), bData available 




4.3.4 Knowledge of TB infection control, TB, and LTBI 
As indicated in Table 4.10, most HCWs gave the correct answer for TB infection 
control knowledge items, except for the use of a surgical mask (57.8%) and fans to 
reduce TB transmission (35.3%). Almost 80% knew the cause of TB and 61.9% 
knew the most common symptom. Regarding LTBI knowledge, only 23.5% gave 
the correct answer that LTBI has no symptoms; 18.6% knew that LTBI did not 
spread from person to person; and 36.9% knew that treating LTBI prevented TB 
disease. More than half (55.0%) answered that LTBI was treated by prescribed 
LTBI medicine, but fewer (36.9%) knew the duration of treatment. Most (85.1%) 
knew that Bacille Calmette-Guerin (BCG) vaccination does not completely protect 
people from TB.  
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Table 4.10 Knowledge of tuberculosis infection control, tuberculosis, and latent 
tuberculosis infection in health care workers in 24 Primary Health Centres (N=398) 
- Proportion with correct responses 








Knowledge of TB infection control    
1. Every facility should establish an IC committee 373 93.9 90.9-95.9 
2. Every facility should establish a guideline for TB 
IC 
389 98.1 96.1-99.0 
3. The windows of a room should be left open 
whenever a patient suspected or confirmed to 
have TB is in the room 
329 82.8 78.5-86.4 
4. Patients suspected or confirmed to have TB 
should be kept separately from the rest of the 
patients while in the health facility 
376 95.1 92.5-96.9 
5. HCWs should try to minimise the time a TB 
patient spends in health facility 
300 76.1 71.5-80.3 
6. Surgical masks cannot protect the HCWs from TB 223 57.8 52.7-62.9 
7. Respirator can protect the HCWs from TB 377 95.0 92.2-96.8 
8. TB patients have to be educated to cover their 
mouth with a handkerchief or scarf 
384 97.0 94.7-98.3 
9. Fans can be used to reduce TB transmission in a 
TB ward 
150 35.3 30.6-40.4 
10. Regular screening of HCWs for TB is one of the TB 
infection control measures 
305 76.6 72.0-80.8 
11. Patients suspected or confirmed to have TB 
should be prioritised to see a nurse/doctor  
341 85.7 81.7-89.0 
Knowledge of TB     
1. What is the germ that causes tuberculosis? 315 79.4 74.9-83.3 
2. How is TB transmitted? 349 88.2 84.5-91.2 
3. What is the most common symptom of pulmonary 
TB? 
248 61.9 56.7-66.8 
4. Which is the most effective tool in the diagnosis of 
pulmonary TB in primary health centre? 
374 94.0 91.1-96.1 
5. Which is the most effective tool in the diagnosis of 
pulmonary TB in general? 
248 61.2 56.0-66.1 
6. Is it possible to cure TB? 394 98.9 97.0-99.6 
7. How long (in months) is a complete treatment for 
pulmonary TB under the primary scheme? 
366 92.4 88.9-94.7 
Knowledge of LTBI    
1. What is the main symptom that indicates LTBI? 92 23.5 19.4-28.2 
2. Can LTBI be spread from person to person? 71 18.6 14.9-85.1 
3. Do all people with the LTBI develop TB disease? 44 10.4 7.7-14.0 
4. LTBI can be treated with? 222 55.0 49.8-60.1 
5. What is the benefit of treating LTBI? 141 36.9 32.0-42.0 
6. How long does the treatment of LTBI last? 142 37.2 57.6-67.7 
7. Do you think BCG vaccine completely protects 
people from TB for their whole life? 
337 85.1 81.0-88.4 
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BCG = Bacille Calmette-Guerin, CI = confidence interval, HCWs = health care workers, IC = infection 
control, LTBI = latent tuberculosis infection, TB = Tuberculosis 
*Estimate of the population proportions obtained using sampling weights that were calculated 
from the selection probabilities of the PHCs in each group.  
 
 
The median number of correct responses was 18 out of 25 for all items; 10 out of 
11 for TB infection control; 6 out of 7 for TB knowledge; and 3 out of 7 for LTBI 
knowledge (Table 4.11).  
 
Table 4.11 Knowledge of tuberculosis infection control, tuberculosis, and latent 
tuberculosis infection in health care workers (N=398) – Median number of correct 
responses (weighted) 
Item Median number of correct 
items –weighted* (IQR) 
Maximum 
All knowledge 18 (17-20) 25 
Sub-knowledge   
1. TB infection control  10 (9-11) 11 
2. TB 6 (5-7) 7 
3. LTBI  3 (1-4) 7 
 
IC = infection control, IQR = interquartile range, LTBI = latent tuberculosis infection, TB = 
tuberculosis 
*Estimate of the population proportions obtained using sampling weights that were calculated 
from the selection probabilities of the PHCs in each group.  
 
 
In regression analyses across job categories, the median number of correct 
responses varied significantly between groups in all items and sub-item of 
knowledge (P<0.0001) (Figure 4.4). The major difference was TB nurses having 


















Linear regression was used to see the differences of the median number of correct responses for 
knowledge by job type. P value for all item of knowledge: <0.0001, TB infection control knowledge: 
<0.0001, TB knowledge: <0.0001, and LTBI knowledge: <0.0001. Blue indicates the distribution 
number of correct responses and red indicates the median number. Lab. = Laboratory, Env. = 
Environmental 
Figure 4.4 Distribution and median number of correct responses for all items of 
knowledge (A), for tuberculosis infection control (B), for tuberculosis (C), and for 
latent tuberculosis infection in health care workers (D), by job type  
 
Table 4.12 Median number of correct responses of knowledge by job type 
Job type Median number of correct responses of knowledge 
All items TB IC TB LTBI 
Doctor 19 9 6 4 
Dentist 16 9 5 2 
General Nurse 18 9 6 4 
TB Nurse 21 10 7 4 
Midwife 17 8 6 3 
Laboratory personnel 18 10 6 2 
Pharmacist 16 9 5 3 
Nutritionist 17 9 6 2 
Environmental health officer 18 9 6 3 
Public health officer 16 9 6 2 
Administrator 15 9 4 2 
IC = infection control, LTBI = latent tuberculosis infection, TB = tuberculosis 
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4.3.5 TB history, attitudes, care-seeking behaviour, and stigma 
Among 14 HCWs with a history of TB disease, eight (59.5%) had pulmonary TB 
diagnosed by chest x-ray and only one had sputum smear examination. Ten had 
TB disease before working in the current health facility and six had direct contact 
with family or a friend with TB prior to their TB treatment. Regarding attitudes 
and care-seeking behaviour, five HCWs (36.5%) said that they were accepting 
when they knew that they had TB, one was afraid, one was surprised, four were 
sad, one felt hopeless, and one was disappointed. Eight HCWs (54.1%) talked to 
the doctor or other HCWs in the other clinics, and only one talked to doctor or 
other HCWs in the same clinic (Table 4.13).  
Among 384 HCWs with no history of TB disease, the majority (96.5%) thought 
that they could develop TB. With respect to a possible TB diagnosis, 38.3% of 
HCWs said that they would feel acceptance it if they were found to have TB, 35.1% 
would be sad, 27.9% would be afraid, 14.0% would be surprised, and only 3.6% 
would feel hopeless. Unlike the HCWs with history of TB disease, HCWs with no TB 
disease were likely to talk to a doctor or other HCWs in the clinic if they had TB 
(82.4%), fewer (20.7%) would talk to doctor or other HCWs in other clinics. Most 
of the HCWs said that they would go to the health facility as soon as they realised 
that they had symptoms consistent with TB (86.8%). More than a fifth of HCWs 
(21.4%) reported that they had direct contact with a family or friend with TB 







Table 4.13 Tuberculosis history, attitudes, and health seeking behaviour in health 
care workers with past history of tuberculosis disease (N=14) 
Item Frequency Proportion 
(Weighted %)*  
95% CI 
Type of TB    
Pulmonary 8 59.5 26.7-85.4 
Extra pulmonary 6 40.5 14.6-73.1 
Diagnosis made by    
Sputum smear  1 9.5 0.9-5.4 
Sputum culture  0 0.0*** - 
Chest x-ray  8 64.9 33.1-87.3 
Biopsy 2 13.5 2.2-52 
Other 4 21.6 6.0-54.5 
Diagnosed with TB while working in this facility    
Yes 4 27.0 7.8-61.9 
No 10 73.0 38.1-92.2 
Cured or completed TB treatment    
Yes 11 77.0 39.9-94.4 
No 1 4.1 0.4-29.5 
Don't know 2 18.9 3.8-60.0 
Direct contact with family or friend with TB prior to 
your TB treatment  
   
Yes 6 45.9 17.8-76.9 
No 8 54.1 23.1-82.2 
What was your reaction when diagnosed with TB**    
Fear 1 4.1 0.4-29.5 
Surprise 1 4.1 0.4-29.5 
Shame 2 8.1 1.6-32.4 
Sadness 4 27.0 8.4-58.1 
Hopelessness 1 4.1 0.4-29.5 
Disappointment 1 9.5 0.9-54.3 
Acceptance 5 36.5 12.5-69.7 
Don’t know, it happened at young age 3 23.0 5.6-60.1 
Who did you talk to about your illness when you 
had TB** 
   
Doctor/other HCWs in the same clinic 1 9.5 0.9-54.3 
Doctor/other HCWs in another clinic 8 54.1 23.7-81.7 
Spouse 3 17.7 3.8-53.4 
Parent 5 41.9 15.8-73.4 
Other family member 0 0.0*** - 
Close friend 0 0.0*** - 
No one 1 4.1 0.4-29.5 
CI = confidence interval, HCWs = health care workers, TB = Tuberculosis 
*Estimate of the population proportions obtained using sampling weights that were calculated 
from the selection probabilities of the PHCs in each group.  
**Participants were able to answer more than one option and were provided with the “other” 
option if they had another answer; all information was reported 
***Survey 95% CIs were not available if the proportion was 0 or 1 
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Table 4.14 Tuberculosis history, attitudes, and health seeking behaviour in health 
care workers with no history of tuberculosis disease (N=384) 
Item Frequency Proportion 
(Weighted %)* 
95% CI 
Do you think you can get TB?     
Yes 369 96.5 94.1-98.0 
No 14 3.2 1.8-5.5 
Don't know 1 0.3 0.0-2.3 
What would your reaction be if you were found out 
to have TB** 
   
Fear 108 27.9 23.4-32.9 
Surprise 55 14.0 10.8-18.1 
Shame 41 10.6 7.8-14.4 
Sadness 132 35.1 30.2-40.3 
Hopelessness 15 3.6 2.1-6.2 
Acceptance 144 38.3 33.3-43.6 
Who you would talk to about your illness if you had 
TB** 
   
Doctor/other HCWs in the same clinic 303 78.9 74.3-83.0 
Doctor/other HCWs in another clinic 42 10.8 7.9-14.5 
Spouse 217 57.0 51.4-62.1 
Parent 93 25.7 21.3-30.6 
Other family member 99 27.0 22.5-31.9 
Close friend 26 7.5 5.1-10.9 
No one 0 0.0*** - 
What would you do if you thought you had TB 
symptoms** 
   
Go for examination in this clinic 312 82.4 78.2-86.1 
Go to other health facility for examination 84 20.7 16.8-25.2 
Go to pharmacy 2 0.7 0.2-2.6 
Go to traditional healer 1 0.3 0.0-2.3 
Pursue other self-treatment options (herbs, etc.) 4 0.9 0.3-2.7 
If you had symptoms of TB, at what point would you 
go to the health facility 
   
When treatment on my own does not work 14 3.3 1.9-5.7 
When symptoms that look like TB last for 3 weeks 35 9.8 7.0-13.5 
As soon as I realise that my symptoms might be 
related to TB 
333 86.8 82.7-90.0 
I will not go to the health facility  1 0.1 0.0-1.0 
Direct contact with family or friend with TB     
Yes 78 21.4 17.4-26.1 
No 306 78.6 73.9-82.6 
CI = confidence interval, HCWs = health care workers, TB = Tuberculosis 
*Estimate of the population proportions obtained using sampling weights that were calculated 
from the selection probabilities of the PHCs in each group.  
**Participants were able to answer more than one option and were provided with the “other” 
option if they had another answer; all information was reported 
***Survey 95% CIs were not available if the proportion was 0 or 1 
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Most of the HCWs (72.5%) reported that they did not know of a colleague who had 
TB. Regarding TB stigma, 61.5% felt/would feel compassion and desire to help 
colleagues with TB disease, 26.7% felt/would feel compassion but would tend to 
stay away from them, 4.6% were/would be afraid because their colleagues may 
infect them, 6.6% had/would have no particular feeling, and 2 (0.6%) thought that 
it was their colleagues’ problem and they could not get TB themselves.  More than 
half of the HCWs said that in their workplace, most staff support and help a fellow 
staff member with TB (56.5%), 30.4% said that most staff are friendly but they 
generally try to avoid a staff member with TB, 2.9% said that no special treatment 
was given to staff with TB, 2.8% said that most staff reject a staff member with TB, 
and 7.4% said they did not know how a staff member with TB is usually 
regarded/treated (Table 4.15).  
 
Table 4.15 Tuberculosis stigma in health care workers (N=398) 
Item Frequency Proportion 
(Weighted %)*  
95% CI 
Do you know of any colleagues who have/had TB    
Yes 71 17.8 14.1-22.1 
No 291 72.5 67.6-76.9 
Don't know 36 9.7 7.0-13.4 
Which statement is closest to your feeling about 
colleagues with TB disease 
   
I feel compassion and desire to help 247 61.5 56.3-66.4 
I feel compassion but I tend to stay away from these 
colleagues 
104 26.7 22.4-31.6 
It is their problem and I cannot get TB 2 0.6 0.1-2.5 
I fear them because they may infect me 18 4.6 2.8-7.4 
I have no particular feeling 27 6.6 4.4-9.7 
In your workplace, how is a staff member with TB 
usually regarded/treated? 
   
Most staff reject him or her 11 2.8 1.5-5.1 
Most staff are friendly, but they generally try to 
avoid him or her 
111 30.4 25.8-35.5 
Other staff mostly supports and helps him or her 227 56.5 51.3-61.6 
No special treat for him or her 16 2.9 1.7-4.8 
Don’t know 33 7.4 5.2-10.5 
CI = confidence interval, TB = Tuberculosis 
*Estimate of the population proportions obtained using sampling weights that were calculated 
from the selection probabilities of the PHCs in each group.  
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4.3.6 LTBI test and willingness for LTBI screening and treatment 
Among HCWs with no history of TB disease, a third reported that they had a 
previous TST or IGRA test prior to the study. Of those with no TST or IGRA test, the 
majority (90.9%) were willing to be tested for LTBI and 94.9% were willing to 
take LTBI treatment if tested positive for LTBI (Table 4.16). 
 
Table 4.16 Latent tuberculosis infection test and willingness for screening and 
treatment 
Item Frequency Proportion 
(Weighted %)* 
95% CI 
If there is a screening programme for TB disease, 
would you participate in this programme?  
   
Yes 366 95.4 92.6-97.2 
No 18 4.7 2.8-7.4 
Had a previous TST or IGRAa    
Yes 130 33.0 28.2-38.1 
No 253 66.7 61.6-71.4 
Don't know 1 0.3 0.0-2.3 
Willingness to be tested for LTBIb     
Yes 230 90.9 86.4-94.0 
No 18 6.7 4.1-10.7 
Don't know 6 2.4 1.0-5.5 
Willingness to take treatment if tested positive for 
LTBIc 
   
Yes 231 94.9 91.0-97.1 
No 9 3.9 2.0-7.5 
Don't know 3 1.2 0.4-4.1 
CI = confidence interval, HCWs = health care workers, IGRA = interferon-gamma release assays, 
LTBI = latent tuberculosis infection, TST = tuberculin skin test 
aData are for participants with no history of TB disease = 384, bData for participants with no TST or 
IGRA result = 254, cData for participants with no TST or IGRA result, missing data for 11 
participants = 243 
*Estimate of the population proportions obtained using sampling weights that were calculated 





This study in PHCs in Bandung, Indonesia, found that none had implemented a full 
programme of TB infection control measures. The median number of TB infection 
control measures implemented according to guidelines, was only 21 out of 43. 
PHCs with laboratory facilities and high TB case numbers were more likely to 
implement TB infection control measures compared to other PHCs. For HCWs, the 
median number of correctly answered questions of knowledge for TB infection 
control and TB was high, but low for LTBI – although this differed by job category, 
with TB nurses having the best knowledge. This is likely due to their greater 
exposure to TB training and workshops held by the Bandung Municipal Health 
Office and other organisations. It was also expected that the median number of 
correctly answered questions regarding LTBI knowledge would be low since the 
current National TB programme of Indonesia is currently more focussed on TB 
disease rather than LTBI. 
As recommended by the WHO, the first key component in TB infection control 
measures in health care settings is facility level management measures [6]. In this 
study, most of the PHCs had appointed a facility based infection control officer, yet 
fewer had a written TB infection control plan. This reflects a poorly established 
system for routine infection control and shows areas for improvement. In this 
study, none of the PHCs had an audit of TB infection control performed which 
might be due to the lack of directive, or understanding, from the person in charge 
of the importance of implementation of TB infection control measures. One of the 
WHO recommendations for effective TB infection control programmes is 
educating HCWs regarding standard precautions for infection control. In this 
study, we found that there was little in the way of training activities about TB 
infection control for staff members, similar to that found in previously published 
studies [179-181]. 
In regard to administrative control measures, screening of patients for a cough 
and the availability of a staff member to do so were implemented in most of the 
PHCs, although none had a symptom checklist for screening. Few had a separated 
area for patients with cough or provided an expedited priority service to minimise 
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the length of patient stay. Patient education and awareness were implemented 
well, except for a lack of posters displaying cough etiquette and respiratory 
hygiene. The lack of posters was also reported in another study conducted in 
Pakistan, addressing a weakness in poster supplies, and suggesting urgent 
measures need to be put in place [182]. Posters as educational support was one of 
the strong WHO recommendations that are minimal in cost and have potentially 
high benefits [6]. Only half of the PHCs had a designated area for a patient to 
produce a sputum specimen, similar to studies conducted in China [183] and 
Uganda [181].  
Regarding environmental control measures, more than half of the PHC buildings 
were first built 30 years ago, and at that time, no one considered the need for 
integrating infection control measures into their design. Over the last 20 years, 
some of the buildings have been rebuilt as TB clinics were incorporated. We found 
that natural ventilation was adequate in the majority of PHCs. Even though 
windows and doors were kept open during the day in most of the PHCs, few had 
signage to keep windows and doors open. None reported that they had a staff 
member monitoring natural/mechanical airflow, vital for reducing the 
concentration of droplet nuclei in the air inhaled by staff and visitors [6, 71].  
In addition to implementation of administrative and environmental controls, use 
of particulate respirators that meet or exceed the N95 standards by CDC/NIOSH or 
FFP2 standards that are CE certified is recommended for HCWs caring for patients 
or those suspected of having infectious TB. The particulate respirators are the 
special type of closely fitted facemask with the capacity to filter particles to 
protect against inhaling infectious droplet nuclei [6]. In this study, only a third of 
PHCs had a written respiratory protection plan, and two-thirds provided N95 or 
FFP2 masks for their staff. Although the use of N95 respirators among HCWs in 
this study was better than that reported in previous studies in Uganda [181] and 
in South Africa [174, 184] only a few of PHCs had training on their proper use. 
Undertaking audits for TB infection control appears to be poorly done nationally, 
with no report or data found available to date in Indonesia. This is similar to other 
countries, with an example of another study conducted in PHCs in South Africa 
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where they reported only seven out of 121 PHCs had an audit of TB infection 
control [174].  
HCWs with no history of TB disease thought that they could develop TB because of 
their frequent exposure to TB patients. Unlike the HCWs with a history of TB 
disease, HCWs with no history of TB disease reported they are likely to talk to a 
doctor or other HCWs in the clinic if they had TB. However, there is no assurance 
that this will be the case if they are actually faced with TB. Moreover, none of the 
PHCs had screened their staff members for TB infection or disease, yet the HCWs 
willingness for LTBI screening and treatment was high. Therefore, conducting 
LTBI screening and providing preventive treatment for HCWs should be more 
actively considered and discussed.  
More than a half of HCWs said that most staff support and help a fellow staff 
member with TB, a third HCWs said that they were generally trying to avoid a staff 
member with TB, and fewer said that most staff reject a staff member with TB. 
Despite the importance of this issue, there were no validated questionnaires 
available when this study was prepared and conducted. Since then, one South 
African study published in November 2017 reported the use of scales developed to 
measure TB and HIV stigma among HCWs, and they noted the need to fine tune the 
instruments and test them across different resource-limited countries [185]. 
Therefore, further studies regarding TB stigma in HCWs will be needed, and the 
use of the developed scales is worth pursuing further.  
To our knowledge, this is the first report assessing TB infection control in 
Indonesia. Although we only included 24 of 73 PHCs, by using stratified sampling, 
we are confident of the study’s representativeness. We interviewed two key 
persons and undertook observation in each site to reduce non-differential 
misclassification. Furthermore, the response rate was high, and we used statistical 
methods for survey data, calculated from the selection probabilities of the PHCs in 
each group.   
There were several limitations. We only assessed the availability of TB infection 
control measures and were unable to differentiate quality and implementation of 
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all measures at the assessed sites. For the environmental control measures, due to 
unavailability of anemometer and other equipment, we did not measure the air 
change per hour (ACH), as recommended by WHO to assess natural/mechanical 
ventilation adequacy [6]. Even though we used the knowledge questionnaire 
developed from the WHO and informed by related scientific literature [21, 171, 
175, 176], it is not straightforward how to classify the HCWs’ knowledge levels. 
The relatively high knowledge levels in our study (apart from LTBI), resulted in 
the median levels also equating to ‘good’ knowledge, making this issue ultimately 
relatively straightforward in our study. Also, we did not test HCWs for LTBI to 
estimate the burden of LTBI in the PHCs. We however noticed that based on our 
previous data from a randomised controlled trial in LTBI, the prevalence might be 
around 60-65% (unpublished data). Finally, systematic longitudinal research was 
outside the scope of this study.  
This study has some implications for practice. Measures including a written TB 
infection control plan, training for staff members about TB (especially LTBI), 
separation of suspected patients, symptom checklists to screen patients for TB, 
regular monitoring of infection control practices, and training on proper fit of 
respirators should be strengthened. Moreover, future investigations should 
consider measuring the effectiveness of implementation of infection control 
measures through monitoring and routine reporting of the number of HCWs who 
develop TB disease and infection each year in the facilities.   
In conclusion, our findings suggest that TB infection control practices were 
generally not implemented in the PHCs. This study highlights the importance of 
strengthening effective TB infection control practices to reduce TB transmission 





5 Latent tuberculosis infection in health care workers in a 
tertiary referral hospital in Bandung, Indonesia 
5.1 Introduction 
As described earlier (Chapter one), health care workers (HCWs) especially in high 
tuberculosis (TB) incidence countries are at increased risk of latent TB infection 
(LTBI) and TB disease due to greater exposure to TB cases and variable 
implementation of infection control practices [5, 10, 15]. The risk of LTBI in HCWs 
is approximately two to three times higher than the general population [10].  
Information on the current situation of LTBI in HCWs in Indonesia remains 
unknown. We conducted a study to estimate the prevalence of LTBI as measured 
by tuberculin skin test (TST) in HCWs employed in a public tertiary referral 
hospital in Bandung, Indonesia; to identify factors that are associated with positive 
TST, to assess knowledge of TB infection control, TB disease, and LTBI; and to 
assess TB attitudes, care-seeking behaviour, and stigma. 
5.2 Methods 
5.2.1 Study design and population 
This was a cross-sectional study conducted from April to August 2018 involving a 
stratified sample of the HCWs employed in Hasan Sadikin Hospital, Bandung, 
Indonesia. There are approximately 3,000 permanent workers employed at Hasan 
Sadikin Hospital. About two-thirds of them provide health services (e.g. doctor, 
dentist, nurse, midwife, laboratory personnel, pharmacist, nutritionist, and 
radiographer); the other one-third are management, administration and support 
workers. Our study included hospital workers who provide health services. 
Stratification was undertaken according to job category to allow sufficient 
numbers for description and comparison of the categories. The total number who 
provide health services (n=2045) was divided by the seven job categories to give 
71 required from each category to reach the minimum sample size of 500 (as 
described in 5.2.3 Sample size calculation). As the number of midwives, 
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nutritionists, radiographers were around, or less than 71, all workers in these 
categories were invited to participate. We then randomly selected 84-85 workers 
from each of the remaining categories. The numbers of HCWs employed in the 
hospital on 9 March 2018 and selected in this study according to job category are 
shown in Table 5.1. 
Table 5.1 Health care workers (HCWs) employed at Hasan Sadikin Hospital on 9 
March 2018 and number selected in the study according to job category  
Job category 
Number of HCWs 
employed  
Number of HCWs 
selected 
Provide health services 2045 500 
Doctor or dentist 382 84 
Nurse 1208 85 (188)* 
Midwife 79 79 
Laboratory personnel 111 84 
Nutritionist 37 37 
Pharmacist 182 85 
Radiographer 46 46 
Management, administration and support staff 1013 - 
Total  3058 500  
*After initial recruitment, due to insufficient numbers of HCWs from other strata, we decided to 
oversample nurses (the largest group) 
 
5.2.2 Study procedure 
A formal letter was sent to the hospital director and the head of 
departments/units to provide information and seek permission to carry out the 
study. HCWs were identified from the Hasan Sadikin Hospital database from which 
selection was undertaken. Scheduled visits to each department/unit and meeting 
with selected HCWs in each location were arranged at which time trained research 
staff provided information about the study and HCWs were invited to participate. 
The enrolment process required more than one visit due to shift work of the 
HCWs. Written informed consent was sought from all participants prior to 
undertaking the questionnaire and administering TST. Any staff absences, any 
reasons provided for non-consent, or refusal for TST were noted. 
A questionnaire (Appendix 2) was used to collect data about demographic 
characteristics, medical history, occupational TB exposure, community TB 
exposure, and information on formal or informal TB training. A second 
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questionnaire (Appendix 2) assessing the knowledge, attitude, care-seeking 
behaviour, and stigma was also administered (as described below).  
Assessment of LTBI in HCWs using TST 
LTBI was measured by TST using 0.1 ml Tubersol® bioequivalent to 5 TU and 
administered by an experienced and trained study nurse. It was given on the volar 
side of the forearm and the skin reaction was read 48-72 hours later. An 
induration size ≥10 mm was considered positive [71] and the result recorded on 
the participant’s form (Appendix 2).  
TST was administered following the interview. Participants were told about their 
induration size directly at the time of reading the TST followed by a printed formal 
TST result given to them in a sealed envelope, in person. Those with a positive 
result were assessed for symptoms of TB disease and referred for diagnostic 
evaluation for TB disease and appropriate treatment if necessary. TB disease was 
defined according to standard WHO definitions. It was expected that 
approximately 1% of participants might have active TB [1]. These individuals, 
according to local policy, were advised to take days off work until symptoms 
disappeared (usually at least two weeks). They were followed up to check that 
they had received appropriate treatment. According to local and international 
(low and middle income and/or high TB incidence countries) recommendations at 
the time of implementing this study, no LTBI treatment was offered to those with a 
positive TST result. LTBI treatment at the time was recommended only for 
children under 5 years of age living in a household of a person with 
bacteriologically confirmed pulmonary TB, and people living with HIV [17]. This 
has recently changed in 2018 to recommend LTBI treatment for people of any age 
who are living in a household of a person with bacteriologically confirmed 
pulmonary TB, and for people living with HIV, who are found not to have active TB 
by appropriate clinical evaluation [3]. For HCWs, WHO recommends a package of 
prevention and care interventions, including HIV prevention, antiretroviral 
therapy and isoniazid preventive therapy (IPT) for those who are HIV-positive [6]. 
Based on the very low rate of HIV positivity in Indonesia, HIV testing was not 
offered to all workers, but was offered to anyone who was diagnosed with TB. 
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Factors associated with LTBI as measured by positive TST 
A questionnaire (Appendix 2), developed based on the scientific literature, was 
used to identify factors associated with LTBI [4, 8, 68, 149, 186]. The 
questionnaire included information about: 1) demographic characteristics: age, 
gender, ethnicity, and educational status, 2) medical history: Bacille Calmette-
Guerin (BCG) vaccination, HIV status, other immunocompromised condition, 
smoking, alcohol consumption, and body mass index (BMI), 3) occupational TB 
exposure: profession, working area or procedure, service years in this or other 
facility, experience working in a TB clinic/pulmonary ward/isolation ward, any 
direct contact with TB patient, and direct contact with colleague with TB, 4) 
community TB exposure: any direct contact with family or friend diagnosed with 
TB, and 5) any formal or informal TB training. Some questions required a yes/no 
answer and some required a choice of one answer from several options.  
HCW knowledge, attitudes, care-seeking behaviour, and stigma 
Investigation of the knowledge of HCWs was measured by a second questionnaire 
and covered three main subjects (Appendix 2): 1) TB infection control, 2) TB 
disease, and 3) LTBI. A questionnaire informed by related scientific literature [21, 
171, 175, 176] was developed focusing on symptoms, transmission, treatment, 
and prevention. For TB infection control knowledge, the questions required a 
yes/no answer [171]. For TB disease and LTBI knowledge, some questions 
required a yes/no and some were a multiple choice list [175, 176]. Giving a correct 
answer earned a score of 1; a wrong answer, a score of 0. Each of the 
questionnaires were translated into the Indonesian language and pre-tested 
before beginning the study. The four research staff who carried out the interviews 
were trained according to a standard operating procedure to ensure the 
interviews were standardised. 
Questions about TB attitudes, care-seeking behaviour, and stigma were developed 
from WHO guidelines [177]. Some questions required a yes/no answer. Some 
questions allowed for multiple-choice options and the interviewer indicated on 
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the questionnaire all of the responses provided. Each question was treated 
separately as a binary or multinomial outcome for analysis.  
Ethics approval was obtained from the University of Otago Ethics Committees, 
New Zealand (HE17/023) and Hasan Sadikin Hospital Ethics Committees 
Bandung, Indonesia (No LB.04.01/AO5/EC/O14/I/2018) (Appendix 1).  
5.2.3 Sample size considerations 
Allowing for 10% non-response, a sample of 500 will provide estimates of the 
prevalence of LTBI with a margin of error of 5% (half the width of a 95% exact 
binomial confidence interval). Data from a randomised controlled trial in LTBI 
conducted in HCWs in Bandung suggested that the prevalence of LTBI might be 
around 60 – 65% (unpublished data). For evaluation of the factors associated with 
LTBI, we calculated that if the prevalence of exposure were between 20% and 
60%, the study would have 80% power to detect a prevalence ratio of 1.26 (odds 
ratio (OR) of 2.2) at the two-sided 5% level.  
5.2.4 Data management and statistical analysis 
Questionnaires were collected on paper copies and administered by the field staff. 
All data were verified as the study progressed and entered into a database created 
in RedCap® [178]. Data were transferred into Stata®, and all analyses were 
conducted using version 14.2 (Stata Corp LP, Texas, US). 
All statistical analyses accounted for the stratified sampling and the total 
population size using statistical methods for survey data, as implemented in the 
Stata survey commands (svy commands). Sampling weights were calculated from 
the selection probabilities of the HCWs selected/invited in each job category. This 
produced a weighted prevalence, which is the weighted average of the strata 
specific prevalence estimates.  
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The prevalence of LTBI in HCWs: To estimate LTBI prevalence, the number of 
HCWs who had a positive TST in the study was used as the numerator and the 
number total HCWs included in the study minus the number with a history of TB 
was used as the denominator. The prevalence is presented with 95% confidence 
intervals. 
The association between any factors associated with LTBI in HCWs: The association 
between any factors (characteristics, occupational TB exposure, community 
exposure, etc.) and TST positivity in HCWs was examined using univariate logistic 
regression. Estimates are presented as OR and adjusted for characteristics and 
exposures obtained using modified backwards-stepwise regression. This approach 
was used as it is considered the best to reduce the number of predictors, to check 
for confounding, reduce multicollinearity, and to resolve over-fitting. Age at hiring, 
gender, and job category were retained in the multivariate model because apriori 
knowledge suggested they were likely to be important confounders. Other 
variables were also retained in the model if P<0.2. A linear model was used for 
continuous variables. 
TB infection control, TB disease, and LTBI knowledge in HCWs: the proportions of 
HCWs with correct knowledge responses were calculated; the total number of 
correct responses was calculated for each HCW and presented as medians with 
IQR. Linear regression was used to assess differences in the median number of 
correct knowledge responses across job categories.  
TB attitudes, care-seeking behaviour, stigma and willingness: the proportion and 
95% confidence intervals are presented for each binary question; the proportions 
giving each answer (with 95% confidence intervals) for multinomial questions.  
5.3 Results 
5.3.1 Description of study participants 
A total of 455 HCWs were recruited. The response rate was high for nurses 
(100.0%), nutritionists (94.6%), and pharmacists (89.4%), medium for lab 
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personnel (66.7%), midwives (65.8%), doctors and dentists (50.0%), and low for 
radiographers (13.0%). The reason for low response in radiographers was that the 
coordinator of the unit was reluctant to arrange the meeting with the staff after 
several attempts, therefore we had difficulty with meeting and recruiting the 
radiographers. Figure 5.1 shows the study recruitment flow chart. Forty-two 
HCWs had a history of TB disease and 413 HCWs with no history of TB disease. 
Among 42 HCWs with history of TB disease, 40 had a past TB, one had current TB, 
and one was a new TB case. Of the 413 HCWs with no TB disease, 18 refused TST 
(mostly because of fear of needles), leaving 395 HCWs who were tested by TST, of 
whom 298 were TST positive and 97 negative.  
 
TB = tuberculosis, TST = tuberculin skin test 
HCWs with history of TB disease were asked when they had TB disease, whether it happened 
before or during working in this hospital 
 
Figure 5.1 Study profile: recruitment and tuberculin skin test results 
 
The characteristics of the included HCWs are presented in Table 5.2. The median 
age was 36.4 years (IQR 30.4-47.7). There were more females (82.9%) than males, 
and 70.5% were Sundanese (the main ethnicity in West Java Province). More than 
half (63.2%) of HCWs had a diploma qualification as their highest educational 
level. 
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A BCG vaccination scar was observed in 321 (71.6%) HCWs. None reported being 
HIV positive, 18 (4.3%) had an immunocompromised condition, 396 (89.7%) had 
never smoked, and 444 (98.2%) never drink alcohol. The median BMI was 24.0 
kg/m2 (IQR 21.2-27.1).  
Regarding job category, there were 42 (2.8%) doctors or dentists, 188 (18.5%) 
nurses, 52 (21.1%) midwives, 56 (17.2%) laboratory personnel, 76 (19.6%) 
pharmacists, 35 (20.4%) nutritionists, and six (0.5%) radiographers. The median 
service years in the current facility was 12.0 years (IQR 7.0-20.0). Fifty-five 
(13.4%) HCWs had experience working in a TB clinic/pulmonary ward/isolation 
ward and 189 (35.0%) were exposed to a high or very high TB risk working area 
or procedure. A total of 194 (61.3%) HCWs had some direct contact with a TB 
patient or participation in sputum collection or examination and 54 (9.6%) had 
some direct contact with a colleague with TB. Half (51.9%) of the HCWs had 
experience working in another health facility.  
Furthermore, 57 (12.0%) HCWs had previously had direct contact with family and 
28 (6.5%) had direct contact with a friend who was diagnosed with TB. Most of the 






Table 5.2 Demographic, medical history, and exposure to TB of health care workers included in the study (N=455) 
Variables  TB History  
N (Weighted %)* 
TST positive 
N (Weighted %)* 
TST negative 
N (Weighted %)* 
Unknown TST 
N (Weighted %)* 
Total 
N (Weighted %)* 
Total HCWs  42 (8.4) 298 (66.3) 97 (22.0) 18 (3.3) 455 (100.0) 
Demographic characteristics        
Age (years), median (IQR)  34.4 (29.9-44.0) 38.5 (31.7-47.9) 33.2 (26.3-42.4) 32.2 (28.1-37.9) 36.4 (30.4-47.7) 
Gender Female 29 (75.0) 227 (82.7) 77 (84.3) 17 (97.1) 350 (82.9) 
 Male 13 (25.0) 71 (17.3) 20 (15.7) 1 (2.9) 105 (17.1) 
Ethnicity Sundanese 38 (90.6) 206 (68.1) 68 (69.3) 13 (77.1) 325 (70.5) 
 Other 4 (9.4) 92 (31.9) 29 (30.7) 5 (22.9) 130 (29.5) 
Educational status High school 2 (6.7) 6 (2.1) 2 (2.6) 0 (0.0) 10 (2.2) 
 Diploma 24 (53.9) 178 (63.9) 60 (59.0) 9 (56.0) 271 (63.2) 
 First degree 11 (32.2) 73 (24.0) 25 (24.2) 5 (33.0) 114 (25.1) 
 >Second degree  5 (7.2) 41 (10.0) 10 (7.8) 4 (8.0) 60 (9.2) 
Medical history        
BCG vaccination Yes 33 (80.1) 206 (69.5) 72 (77.8) 10 (50.4) 321 (71.6) 
 No  9 (19.9) 92 (30.5) 25 (22.2) 8 (49.6) 134 (28.4) 
Diagnosed with HIV Yes 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 No 11 (21.4) 67 (24.5) 28 (34.9) 5 (28.6) 111 (26.6) 
 Do not know 31 (78.6) 231 (75.5) 69 (65.1) 13 (71.4) 344 (73.4) 
Immunocompromised condition Yes  2 (4.2) 10 (4.0) 4 (5.3) 2 (4.0) 18 (4.3) 
No 40 (95.8) 288 (96.0) 93 (94.7) 16 (96.0) 437 (95.7) 
Smoking Current/ex-smoker 11 (23.0) 44 (11.3) 4 (4.0) 0 (0.0) 59 (10.3) 
 Never 31 (77.0) 254 (88.7) 93 (96.0) 18 (100.0) 396 (89.7) 
Alcohol consumption Yes 1 (3.7) 10 (2.2) 0 (0.0) 0 (0.0) 11 (1.8) 
 No 41 (96.3) 288 (97.8) 97 (100.0) 18 (100.0) 444 (98.2) 
BMI (kg/m2), median (IQR)  22.9 (19.8-25.4) 24.4 (21.4-27.4) 23.2 (21.1-26.5) 23.2 (22.2-27.1) 24.0 (21.2-27.1) 
Occupational TB exposure   
Profession Doctor/dentist 4 (3.2) 25 (2.5) 9 (2.8) 4 (8) 42 (2.8) 
 Nurse 21 (24.6) 122 (18.1) 38 (17.0) 7 (20.5) 188 (18.5) 
 Midwife 3 (14.5) 37 (22.6) 8 (14.7) 4 (48.4) 52 (21.1) 
 Lab. personnel 5 (18.3) 37 (17.1) 14 (19.5) 0 (0.0) 56 (17.2) 
 Pharmacist 6 (18.5) 51 (19.8) 16 (18.8) 3 (23.1) 76 (19.6) 
 Nutritionist 3 (20.9) 22 (19.3) 10 (26.5) 0 (0.0) 35 (20.4) 





Variables  TB History  
N (Weighted %)* 
TST positive 
N (Weighted %)* 
TST negative 
N (Weighted %)* 
Unknown TST 
N (Weighted %)* 
Total 
N (Weighted %)* 
Risk classification (working area or 
procedures) 
Low-medium riska 27 (69.7) 182 (68.0) 50 (54.9) 7 (61.0) 266 (65.0) 
High-very high riskb 15 (30.3) 116 (32.0) 47 (45.1) 11 (39.0) 189 (35.0) 
In this health facility    
Service years, median (IQR)  12.4 (7.0-20.1) 14.0 (8.3-23.7) 7.4 (3.0-16.0) 10.0 (9.0-11.0) 12.0 (7.0-20.0) 
Working in a TB clinic/pulmonary 
ward/isolation ward 
Yes 6 (8.6) 32 (13.2) 17 (18.0) 0 (0.0) 55 (13.4) 
No 36 (91.4) 266 (86.8) 80 (82.0) 18 (100.0) 400 (86.6) 
Direct contact with TB patient or 
participation in sputum collection 
or examination 
Yes 19 (35.0) 130 (40.8) 42 (38.6) 3 (7.0) 194 (61.3) 
No 23 (65.0) 168 (59.2) 55 (61.4) 15 (93.0) 261 (38.7) 
Direct contact with colleague with 
TB 
Yes 8 (12.7) 33 (9.9) 11 (7.5) 2 (9.7) 54 (9.6) 
No 34 (87.3) 265 (90.1) 86 (92.5) 16 (90.3) 401 (90.4) 
In previous or other health facility    
Experience working in other health 
facility  
Yes 22 (58.9) 151 (47.1) 55 (62.2) 11 (62.1) 239 (51.9) 
No 20 (41.1) 147 (52.9) 42 (37.8) 7 (37.9) 216 (48.1) 
TB exposure in community   
Any direct contact with family with 
TB 
Yes 5 (12.7) 38 (12.7) 12 (10.1) 2 (9.7) 57 (12.0) 
No 37 (87.3) 260 (87.3) 85 (89.9) 16 (90.3) 398 (88.0) 
Any direct contact with friend with 
TB 
Yes 2 (2.3) 22 (8.2) 4 (3.8) 0 (0.0) 28 (6.5) 
No 40 (97.7) 276 (91.8) 93 (96.2) 18 (100.0) 427 (93.5) 
TB training    
Formal TB training Yes 4 (6.4) 20 (4.7) 7 (3.7) 2 (4.9) 33 (4.7) 
 No 38 (93.6) 278 (95.3) 90 (96.3) 16 (95.1) 422 (95.3) 
Informal TB training Yes 6 (8.4) 34 (8.2) 10 (7.9) 1 (2.0) 51 (8.0) 
 No 36 (91.6) 264 (91.8) 87 (92.1) 17 (98.0) 404 (92.0) 
BCG = Bacille Calmette-Guerin, BMI = body mass index, HCWs = health care workers, HIV = human immunodeficiency virus, IQR = inter quartile range, TB = tuberculosis, TST = 
tuberculin skin test.  
aLow-medium risk area/procedures = areas/procedures in health facility with limited/moderate likelihood of TB exposure. TB cases in medium risk areas/procedures may be 
present but short duration or with few such incidents likely. Low risk areas/procedures = administrative areas, non-TB lab, & TB cases surgery. Medium risk areas/procedures = 
emergency, maternity, nuclear medicine, & outpatient clinic. 
bHigh & very high-risk areas/procedures = area/procedure in health facility that have high/very high likelihood of TB exposure. These settings may also have high concentrated 
numbers of MDR/XDR-TB patients. High-risk areas/procedures = forensic med. Dept., inpatient ward, & intensive care unit. Very high risk = isolation ward, TB lab, TB & MDR-TB 
clinic. 
*Estimate of the population proportions obtained using sampling weights that were calculated from the selection probabilities of the HCWs in each job category.  
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5.3.2 Prevalence of positive tuberculin skin test and history of TB disease in 
health care workers 
The distribution of TST induration size in millimetres (mm) among HCWs is 
shown in Figure 5.2. Three-quarters of HCWs had a TST induration >10 mm. Using 
a cut-off of 10 mm, the weighted prevalence of positive TST was 75.1% (95% CI 
69.4-80.0%, n=395). History of TB disease was found in 42 HCWs (8.4% 95% CI 
5.8-12.0%, n=455). For twenty-five HCWs (4.6%), TB was diagnosed while 
working in Hasan Sadikin Hospital and 17 (3.8%) HCWs, TB was diagnosed before 
working in this hospital (Table 5.3). 
 
TST = tuberculin skin test 
Figure 5.2 Tuberculin skin test reaction size (mm) 
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Table 5.3 Prevalence of positive tuberculin skin test and history of TB disease in 
health care workers 
Definition n Weighted %* 95% CI 
HCWs tested by TST (N=395)    
Prevalence of positive TST 298 75.1 69.4-80.0 
History of TB disease (N=455)    
Overall 42 8.4 5.8-12.0 
New TB case 1 0.1 0.0-0.7 
Current TB 1 0.1 0.0-0.7 
Past TB  40 8.2 5.6-11.8 
TB diagnosed while working in this hospital 25 4.6 2.8-7.4 
TB diagnosed before working in this hospital 17 3.8 2.1-6.7 
CI = confidence interval, HCWs = health care workers, LTBI = latent tuberculosis infection, TB = 
tuberculosis, TST = tuberculin skin test 
*Estimate of the population proportions obtained using sampling weights that were calculated 
from the selection probabilities of the HCWs in each job category.  
 
5.3.3 Risk factors associated with TST positivity  
In the univariate and multivariate analysis, service years in this hospital was the 
only factor significantly associated with TST positivity (OR 1.06 and 1.07, 
respectively). There was another association, smoking, which was associated with 
higher risk (OR 3.58; p=0.06), of borderline statistical significance, but notably of 












Table 5.4 Association between demographic variables, medical history, TB exposure, and TST positivity in health care workers. Results of 
univariate and multivariate logistic regression (N=395) 




P value Adjusted odds 
ratio** (95%CI) 
P value 
Total number of the HCWs  298 (75.1)     
Age at hiring, median (IQR) - years  23.2 (22.8-23.6) 0.99 (0.91-1.07) 0.75 0.99 (0.93-1.06) 0.81 
Gender Male 71 (74.7) 1  1  
 Female 227 (76.5) 1.54 (0.66-3.60) 0.32 1.41 (0.62-3.21) 0.42 
Ethnicity Other 92 (75.8)  1  -   
 Sundanese 206 (74.6) 0.88 (0.44-1.75) 0.71    
Education status Diploma or below 184 (74.4) 1  -   
 First degree 73 (75.0) 1.25 (0.59-2.61) 0.56    
 Second degree or above 41 (79.5) 1.30 (0.29-5.69) 0.72    
BCG vaccination No 92 (80.5) 1  -   
 Yes 206 (72.8) 0.65 (0.34-1.25) 0.19    
Immunocompromised condition No 288 (75.3) 1    
 Yes  10 (68.8) 0.73 (0.17-3.10) 0.66 -  
Smoking Never 254 (73.5) 1  1  
 Current and ex-smoker 44 (89.3) 3.02 (0.97-9.44) 0.06 3.58 (0.94-13.68) 0.06 
Alcohol consumption No 288 (74.6) 1    
 Yes 10 (100.0) - - -  
Body mass index, median (IQR) - kg/m2  24.4 (21.4-27.4) 0.99 (0.92-1.07) 0.85 -  
Profession Nurse   122 (76.3) 1  -  
 Doctor and dentist 25 (73.5) 0.98 (0.20-4.83) 0.98 1.04 (0.33-3.29) 0.95 
 Midwife 37 (82.2) 2.16 (0.72-6.53) 0.17 1.71 (0.70-4.17) 0.24 
 Laboratory personnel 37 (72.6) 0.72 (0.27-1.93) 0.52 0.76 (0.35-1.65) 0.48 
 Pharmacist 51 (76.1) 1.25 (0.51-3.04) 0.62 1.24 (0.57-2.67) 0.59 
 Nutritionist 22 (68.8) 0.77 (0.27-2.20) 0.62 0.74 (0.32-1.69) 0.47 










P value Adjusted odds 
ratio** (95%CI) 
P value 
Risk classification (working unit and procedures) Low-medium riska 182 (78.8) 1  -  
High and very high riskb 116 (68.0) 0.86 (0.39-1.92) 0.51   
Service years, median (IQR) - years 12 (10.5-13.5) 53 (12.1) 1.06 (1.02-1.10) 0.004 1.07 (1.03-1.11) <0.0005 
Experience working in TB clinic/pulmonary 
ward/isolation ward 
No 264 (76.0) 1  -  
Yes 34 (68.9) 0.71 (0.25-2.01) 0.51   
Direct contact with TB patient or participation in 
sputum collection or examination 
No 168 (74.3) 1  -  
Yes 130 (76.0) 1.26 (0.61-2.57) 0.53   
Direct contact with colleague with TB No 265 (74.5) 1  -  
 Yes 33 (80.0) 0.99 (0.42-2.31) 0.97   
Experience working in other health facility No 147 (80.9) 1  -  
 Yes 151 (69.3) 0.71 (0.38-1.32) 0.28   
Direct contact with family with TB No 260 (74.4) 1  -  
 Yes 38 (79.1) 1.05 (0.43-2.58) 0.91   
Direct contact with friends with TB No 276 (74.1) 1  -  
 Yes 22 (86.2) 1.21 (0.64-6.57) 0.23   
Formal TB training No 278 (74.8) 1  -  
 Yes 20 (80.0) 1.33 (0.37-34.76) 0.66   
Informal TB training No 264 (75.0) 1  -  
 Yes 34 (75.5) 0.75 (0.21-2.66) 0.65   
BCG = Bacille Calmette-Guerin, HCWs = health care workers, HIV = human immunodeficiency virus, IQR = inter quartile range, TB = tuberculosis, TST = tuberculin skin test  
aLow-medium risk area/procedures = areas/procedures in health facility with limited/moderate likelihood of TB exposure. TB cases in medium risk areas/procedures may be 
present but short duration or with few such incidents likely. Low risk areas/procedures = administrative areas, non-TB lab, & TB cases surgery. Medium risk areas/procedures = 
emergency, maternity, nuclear medicine, & outpatient clinic. 
bHigh & very high-risk areas/procedures = area/procedure in health facility that have high/very high likelihood of TB exposure. These settings may also have high concentrated 
numbers of MDR/XDR-TB patients. High-risk areas/procedures = forensic medicine, inpatient ward, & intensive care unit. Very high risk = isolation ward, TB lab, TB & MDR-TB clinic. 
*Estimate of the population proportions obtained using sampling weights that were calculated from the selection probabilities of the HCWs in each job category.  
**Estimates adjusted for characteristics and exposures were obtained using modified backwards-stepwise logistic regression. Age and gender were retained in the model and other 
variables were retained if p<0.2. Age, body mass index, years of work were modelled and presented as continuous variables. For age and BMI the quadratic term was not retained in 
the model. 
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5.3.4 Knowledge of TB infection control, TB, and latent TB infection 
As indicated in Table 5.5, most HCWs gave correct responses for TB infection 
control knowledge, except for the use of fans to reduce TB transmission (20.6%), 
the open windows policy (58.1%), and the use of surgical masks (60.8%). For 
pulmonary TB, almost 80% knew the cause, only 47.0% knew the most common 
symptom and even fewer (21.0%) knew the most effective tool for diagnosis.  
Regarding LTBI knowledge, only 24.2% answered correctly that LTBI has no 
symptoms; 26.5% knew that LTBI does not spread from person to person; 16.5% 
knew that not all people with LTBI develop TB disease; and 19.3% knew that 
treating LTBI prevented TB disease. More than a third (38.3%) answered that 
LTBI is treated by prescribed medicine, and 37.7% knew the duration of 
treatment. Two thirds (66.9%) knew that BCG vaccination does not completely 
protect people from TB. 
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Table 5.5 Knowledge of TB infection control, TB, and latent TB infection (N=455) 
Knowledge item Frequency Proportion  
(Weighted %)* 
95% CI 
Knowledge of TB infection control    
1. Every facility should establish an IC committee 436 97.7 96.2-98.7 
2. Every facility should establish a guideline for 
TB IC 
442 98.3 96.4-99.1 
3. The windows of a room should be left open 
whenever a patient suspected or confirmed to 
have TB is in the room 
262 58.1 52.7-63.4 
4. Patients suspected or confirmed to have TB 
should be kept separately from the rest of the 
patients while in the health facility 
433 95.7 93.0-97.4 
5. HCWs should try to minimise the time a TB 
patient spends in health facility 
339 76.2 71.3-80.5 
6. Surgical masks cannot protect the HCWs from 
TB 
280 60.8 55.3-66.1 
7. Respirator can protect the HCWs from TB 433 95.4 92.7-97.1 
8. TB patients have to be educated to cover their 
mouth with a handkerchief or scarf 
446 96.7 93.3-98.4 
9. Fans can be used to reduce TB transmission in a 
TB ward 
92 20.6 16.5-25.5 
10. Regular screening of HCWs for TB is one of the 
TB infection control measures 
375 83.9 79.6-87.4 
11. Patients suspected or confirmed to have TB are 
coughing should be prioritised to see a 
nurse/doctor  
412 92.5 89.5-94.7 
Knowledge of TB     
12. What is the germ that causes tuberculosis? 371 78.6 73.7-82.9 
13. How is TB transmitted? 414 89.7 85.7-92.6 
14. What is the most common symptom of 
pulmonary TB? 
199 47.0 41.3-52.6 
15. Which is the most effective tool in the diagnosis 
of pulmonary TB in this hospital? 
99 21.0 17.0-25.6 
16. Which is the most effective tool in the diagnosis 
of pulmonary TB in general? 
123 24.1 19.9-29.0 
17. Is it possible to cure TB? 445 98.3 96.3-99.2 
18. How long (in months) is a complete treatment 
for pulmonary TB under the primary scheme? 
380 85.6 81.5-88.9 
Knowledge of LTBI    
19. What is the main symptom that indicates LTBI? 124 24.2 19.7-29.3 
20. Can LTBI be spread from person to person? 130 26.5 21.8-31.8 
21. Do all people with the LTBI develop TB disease? 71 16.5 12.6-21.3 
22. LTBI can be treated with? 175 38.3 33.0-43.9 
23. What is the benefit of treating LTBI? 74 19.3 15.0-24.4 
24. How long does the treatment of LTBI last? 166 37.7 32.4-43.3 
25. Do you think BCG vaccine completely protects 
people from TB for their whole life? 
295 66.9 61.5-71.8 
BCG = Bacille Calmette-Guerin, CI = confidence interval, HCWs = health care workers, IC = infection 
control, LTBI = latent tuberculosis infection, TB = tuberculosis   
*Estimate of the population proportions obtained using sampling weights that were calculated 
from the selection probabilities of the HCWs in each job category.  
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The median number of correct responses was 16 out of 25 for all items; 9 out of 11 
for TB infection control; 4 out of 7 for TB knowledge; and 2 out of 7 for LTBI 
knowledge (Table 5.6).  
 
Table 5.6 Knowledge of tuberculosis infection control, tuberculosis, and latent 
tuberculosis infection in health care workers (N=455) – Median number of correct 
responses (weighted) 
Item Median number of correct 
items –weighted* (IQR) 
Maximum 
All knowledge 16 (14-17) 25 
Sub-knowledge   
1. TB infection control  9 (8-10) 11 
2. TB 4 (4-5) 7 
3. LTBI  2 (1-3) 7 
 
IC = infection control, IQR = interquartile range, LTBI = latent tuberculosis infection, TB = 
tuberculosis 
*Estimate of the population proportions obtained using sampling weights that were calculated 
from the selection probabilities of the HCWs in each job category.  
 
 
In regression analyses across job categories, the median number of correct 
responses varied significantly between the groups in all items (P<0.0001), TB 
infection control knowledge (P=0.002), TB knowledge (P<0.0001), and LTBI 
knowledge (P<0.0001) (Figure 5.3). The major differences were that doctors had 
higher median number of correct responses of knowledge while pharmacists and 









IC = infection control, Lab. = laboratory, LTBI = latent tuberculosis infection, TB = tuberculosis. 
Blue indicates the distribution number of correct responses in each job category of HCWs, and red 
indicates the median number of correct responses.  
Linear regression was used to see the differences of the knowledge across job categories. P value 
for all items of knowledge: <0.0001, TB infection control knowledge: 0.002, TB knowledge: <0.0001, 
and LTBI knowledge: <0.0001 
 
 
Figure 5.3 Knowledge in health care workers according to job category for (A) all 
items of knowledge, (B) TB infection control knowledge, (C) TB knowledge, and (D) 
latent TB infection knowledge  
 
5.3.5 TB history, attitudes, care-seeking behaviour, and stigma 
Among the 42 HCWs with a history of TB disease, 22 (67.5%) had pulmonary TB 
and 25 had TB disease diagnosed while working in the Hasan Sadikin Hospital. 
With respect to their reaction upon diagnosis of TB, 24 HCWs said that they were 
sad, 15 afraid, seven felt ashamed, five were surprised, one expressed 
disappointment, and three were accepting of their diagnosis. Twenty-two HCWs 
(49.2%) talked to a doctor or other HCWs in the same hospital, and seven talked to 
a doctor or other HCWs in the other hospital. Twenty-five HCWs (54.7%) went for 
examination in this hospital and 15 went to another health facility for examination 
when they thought that they had symptoms of TB. Most of the HCWs said that they 
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went to the health facility as soon as they realised that they had symptoms 
consistent with TB (78.1%) (Table 5.7).   
Nearly a third of HCWs with a history of TB disease (29.7%) reported that they 
knew one of their colleagues who also had TB. Regarding TB stigma, more than 
half (56.6%) felt compassion and desire to help colleagues with TB disease, 30.6% 
felt compassion but would tend to stay away from them, and 11.6% were afraid 
because their colleagues may infect them. Most of HCWs said that most staff 
support and help a fellow staff member with TB in their workplace (72.7%). A 
much smaller proportion (12.2%) said that most staff are friendly but they 
generally try to avoid a staff member with TB and a very small proportion (1.2%) 
said that most staff reject a fellow staff member with TB. A relatively small 
proportion (13.9%) said they did not know how a staff member with TB is usually 









Table 5.7 TB history, attitudes, and health-seeking behaviour in health care workers with history of TB disease (N=42) 
Item Frequency Proportion  
(Weighted %)* 
95% CI 
TB history     
Type of TB    
Pulmonary 22 67.5 52.9-79.3 
Extra pulmonary 20 32.5 20.7-47.1 
Diagnosed with TB while working in this facility    
Yes 25 54.9 33.4-74.6 
No 17 45.1 25.4-66.6 
TB attitudes and health seeking behaviour    
What was your reaction when diagnosed with TB**    
Fear 15 33.6 16.3-56.7 
Surprise 5 9.3 93.5-22.3 
Shame 7 14.0 5.2-32.7 
Sadness 24 54.5 33.7-73.8 
Hopelessness 0 0.0*** - 
Disappointment 1 1.1 0.2-8.5 
Acceptance 3 5.6 1.3-21.1 
Don’t know, it happened at young age 4 16.8 5.1-43.2 
Who did you talk to about your illness when you had TB**    
Doctor or other health care worker in the same hospital 22 49.2 28.9-69.9 
Doctor or other health care worker in another hospital 7 16.1 5.3-39.7 
Spouse 14 29.7 16.6-47.2 
Parent 13 36.2 19.4-57.2 
Other family member 2 6.0 1.1-27.6 
Close friend 5 8.8 2.5-26.3 
No one 1 3.7 0.5-23.8 
Don’t know, it happened at a young age 4 9.9 2.8-29.6 
What did you do when you thought you had symptoms of TB**    
Went for examination in this clinic 25 54.7 33.9-73.9 

















Went to traditional healer 0 0.0*** - 
Pursued other self-treatment options (herbs, etc.) 0 0.0*** - 
Don’t know, it happened at a young age 4 9.9 2.8-29.6 
When you had symptoms of TB, at what point did you go to the health facility    
When treatment on my own did not work 0 0.0*** - 
When symptoms that looked like TB lasted for 3 weeks 7 12.6 5.1-27.8 
As soon as I realised that my symptoms might be related to TB 30 78.1 63.2-88.1 
Don’t know, it happened at a young age 4 9.9 2.8-29.6 
TB stigma    
Are there any of your colleagues who have/had TB    
Yes 15 29.7 16.6-47.2 
No 18 41.8 31.1-53.3 
Don’t know 9 28.6 15.3-47.0 
Which statement is closest to your feeling about colleagues with TB     
I feel compassion and desire to help 25 56.6 34.9-76.1 
I feel compassion but I tend to stay away from these colleagues 13 30.6 14.1-54.3 
It is their problem and I cannot get TB again 0 0.0*** - 
I fear them because they may infect me again 3 11.6 3.3-33.5 
Don’t know 1 1.2 0.2-8.5 
In your workplace, how are you, or how are staff, with TB usually 
regarded/treated? 
   
Most staff reject him/her/me 1 1.2 10.2-8.5 
Most staff are friendly, but they generally try to avoid him/her/me 7 12.2 4.9-27.5 
Other staff mostly support and help him/her/me 29 72.7 53.7-85.9 
No special treat for him/her/me 0 0.0*** - 
Don’t know 5 13.9 4.7-34.6 
CI = confidence interval, TB = tuberculosis 
*Estimate of the population proportions obtained using sampling weights that were calculated from the selection probabilities of the HCWs in each job category.  
**Participants were able to answer more than one option and were provided with the “other” option if they had another answer; all information was reported 
***Survey 95% CIs were not available if the proportion was 0 or 1 
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Among 413 HCWs with no history of TB disease, the majority (92.8%) thought 
that they could develop TB. With respect to a possible TB diagnosis, almost two-
thirds (62.3%) of HCWs said they would be sad if they were found to have TB, and 
half said that they would be afraid (50.0%). A much smaller proportion said they 
would be surprised (12.3%), ashamed (12.1%), feel hopeless (3.9%), or be 
disappointed (0.2%). A feeling of acceptance was reported by 11.5%. Most HCWs 
said that they were likely to talk to a doctor or other HCW in the same hospital if 
they had TB (84.7%), and fewer (21.4%) would talk to doctor or other HCWs in 
another hospital. Most of the HCWs (94.9%) said that they would go for 
examination in this hospital when they thought that they had symptoms of TB and 
would go to the health facility as soon as they realised that they had symptoms 
consistent with TB (82.1%) (Table 5.8).  
Nearly a third of HCWs with no history of TB disease (30.1%) reported that they 
knew one of their colleagues who had TB. Just over a half (52.5%) felt compassion 
and a desire to help colleagues with TB disease, and fewer felt compassion but 
would tend to stay away from them (38.2%). Only a small minority said they were 
afraid because their colleagues may infect them (4.9%), thought that it was their 
colleagues’ problem and they could not get TB (2.0%), or had no particular feeling 
about it (2.3%). Most HCWs said that most staff support and help a fellow staff 
member with TB in their workplace (79.5%). A small proportion said that most 
staff are friendly but they generally try to avoid a staff member with TB (15.0%), 
and a very small proportion said that most staff reject a staff member with TB 
(0.1%), or that they did not know how a staff member with TB is usually 






Table 5.8 TB attitudes, health-seeking behaviour in health care workers with no TB disease (N=413) 
Item Frequency Proportion  
(Weighted %)*  
95% CI 
TB attitudes and health seeking behaviour    
Do you think you can get TB?     
Yes 382 92.8 89.5-95.1 
No 8 1.0 0.5-2.3 
Don't know 23 6.2 4.0-9.5 
What would be your reaction if you were found out to have TB**    
Fear 203 50.9 45.1-56.6 
Surprise 54 12.3 9.1-16.3 
Shame 48 12.1 8.7-16.6 
Sadness 252 62.3 56.5-67.8 
Hopelessness 17 3.9 2.3-6.5 
Disappointment 2 0.2 0.0-0.7 
Acceptance 47 11.5 8.3-15.8 
Who you would talk to about your illness if you had TB**    
Doctor or other health care worker in the same hospital 344 84.7 80.0-88.4 
Doctor or other health care worker in another hospital 84 21.4 17.0-26.5 
Spouse 245 57.6 51.7-63.4 
Parent 132 31.2 26.2-36.8 
Other family member 93 21.4 17.1-26.4 
Close friend 77 18.0 13.9-23.0 
No one 0 0.0*** - 
What would you do if you thought you had TB symptoms**    
Go for examination in this hospital 389 94.9 92.1-96.7 
Go to other health facility for examination 84 18.7 14.7-23.6 
Go to pharmacy 3 0.5 0.0-1.7 
Go to traditional healer 0 0.0*** - 
Pursue other self-treatment options (herbs, etc.) 1 0.3 0.0-2.0 
    






Item Frequency Proportion  
(Weighted %)*  
95% CI 
 
If you had symptoms of TB, at what point would you go to the health facility 
   
When treatment on my own does not work 12 3.1 1.6-5.8 
When symptoms that look like TB last for 3- weeks 59 14.8 11.1-19.5 
As soon as I realise that my symptoms might be related to TB 340 82.1 77.2-86.1 
TB stigma    
Is there any one of your colleagues who have/had TB    
Yes 122 30.1 25.1-35.6 
No 173 41.5 36.0-47.2 
Don't know 118 28.4 23.4-34.0 
Which statement is closest to your feeling about colleagues with TB disease    
I feel compassion and desire to help 226 52.5 46.7-58.2 
I feel compassion but I tend to stay away from these colleagues 153 38.2 32.6-44.0 
It is their problem and I cannot get TB 6 2.0 0.8-5.2 
I fear them because they may infect me 19 4.9 2.9-8.5 
I have no particular feeling 9 2.3 9.8-5.3 
In your workplace, how is a staff who has TB usually regarded/treated?    
Most staff reject him or her 1 0.1 0.0-0.5 
Most staff are friendly, but they generally try to avoid him or her 63 15.0 11.4-19.5 
Other staff mostly supports and helps him or her 324 79.5 74.6-83.7 
Don’t know 25 5.4 3.4-8.3 
CI = confidence interval, TB = tuberculosis 
*Estimate of the population proportions obtained using sampling weights that were calculated from the selection probabilities of the HCWs in each job category.  
**Participants were able to answer more than one option and were provided with the “other” option if they had another answer; all information was reported 
***Survey 95% CIs were not available if the proportion was 0 or 1 
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5.3.6 Willingness for TB and LTBI screening and LTBI treatment 
Most HCWs (92.9%) reported being willing to undergo TB screening and testing, 
testing for LTBI (89.3%), and take LTBI treatment if tested positive (85.3%) 
(Table 5.9). 
Table 5.9 Willingness for TB and Latent TB infection screening and treatment 
(N=455) 
Item Frequency Proportion  
(Weighted %)*  
95% CI 
Willingness to be tested for TB    
Yes 419 92.9 90.1-95.0 
No 12 2.0 1.1-3.6 
Don't know 24 5.1 3.3-7.8 
Willingness to be tested for LTBI**    
Yes 359 89.3 85.9-91.9 
No 14 2.3 1.2-4.3 
Don't know 40 8.4 6.1-11.5 
Willingness to take LTBI treatment if tested 
positive for LTBI* 
   
Yes 345 85.3 81.2-88.6 
No 19 3.1 1.8-5.1 
Don't know 49 11.6 8.6-15.6 
CI = confidence interval, LTBI = latent tuberculosis infection TB = tuberculosis,  
*Estimate of the population proportions obtained using sampling weights that were calculated 
from the selection probabilities of the HCWs in each job category.  
**Data are available for participants with no TB disease, missing for one participant (N = 413) 
5.4 Discussion 
In our study, three-quarters of health care workers were positive for LTBI as 
measured by TST with duration of work-related exposure being the only factor 
independently associated with a positive TST. The level of knowledge about TB 
infection control was high but the level of knowledge about TB and LTBI was 
lower, with differences found according to job category.  
The prevalence of LTBI, based on TST positivity in other LMICs from general 
hospital settings that included all types of HCWs, as well as administrative 
personnel, ranges from 15.4% to 71.8% [67, 68, 79, 80, 91, 101, 106, 109, 118, 
120, 123, 124, 127-129, 137, 139, 142, 145, 150]. The prevalence in our study was 
surprisingly higher than the upper range (75.1%), although not as high as the 
report from a study in a specialist TB hospital and health centre in South Africa 
(83.7%)[63]. Our prevalence estimate was also considerably higher than the 
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pooled estimate of 49%, reported in our systematic review, and 55% in high TB-
incidence countries (Chapter three) irrespective of type of HCWs and type of 
settings. There were no data available to compare our prevalence estimate with 
the general population in age specific comparisons. However, our prevalence 
estimate was higher when compared to the only available modelled estimation of 
prevalence of LTBI in the general population in Indonesia (46%) and in another 
population with a similar age structure in the South East Asia region 
(approximately 40%) [2]. Our results most likely reflect the high rates M. 
tuberculosis exposure in the work environment in the presence of a high 
background incidence of TB in the community.  
Longer working experience as a HCW as a risk factor for TST positivity is 
consistent with a number of international studies [44, 68, 77, 100, 101, 112, 116, 
150]. We noted that smoking was a clinically important risk factor for TST 
positivity, consistent with other studies [91, 102], even though our result was not 
statistically significant, possibly due to the small numbers of smokers in our study. 
There was no association between prevalence of LTBI and job category suggesting 
that HCWs working in this facility had a similar risk of LTBI irrespective of their 
job category – indicating a high risk of transmission across the hospital. Some 
previous studies [44, 65, 68, 77, 79, 100, 109, 116, 127, 138, 145] in LMICs also 
reported a similar result even though some compared HCWs who provided health 
services to management, administration and support workers. Two other studies 
[118, 119] reported differently – when compared to management, administration 
and support workers, HCWs who provided health services had higher prevalence 
of LTBI.  
Compared to nurses, doctors had a higher median number of correct responses for 
knowledge, while pharmacists and radiographers had a lower median number of 
correct responses for knowledge. Compared to HCWs working in Primary Health 
Centres (reported in Chapter four), HCWs in this tertiary hospital had a lower 
median number of correct responses for knowledge. This discrepancy might be 
due to the lower exposure to TB training, as we noticed that most of the HCWs in 
the hospital reported having neither formal nor informal TB training. Therefore, 
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improving TB education for all types of HCWs is needed to increase their 
knowledge about TB and LTBI. Continuing to employ HCWs with limited 
knowledge about TB can contribute to an increased risk of transmission [60].  
Unlike the HCWs with a history of TB disease, HCWs with no history of TB disease 
were more likely to talk to a doctor or other HCWs in the clinic if they were found 
to have TB. However, this information might be biased because when they are 
actually diagnosed with TB, there is no assurance that this is the action they would 
take. Among HCWs with no history of TB disease, the majority thought that they 
could develop TB and the reason for this was mostly because they were exposed to 
TB patients in their work facilities, similar to that reported in Chapter four. Even 
though most HCWs in this hospital reported being willing to undergo LTBI 
screening and treatment, their willingness was lower than that reported in HCWs 
working in PHCs in Bandung (Chapter four). This might be due to having less 
knowledge of LTBI.  
Regarding TB stigma, both HCWs with a history of TB and with no history of TB 
disease had similar responses. More than a half of HCWs felt/would feel 
compassion and desire to help colleagues with TB disease although there was 
some stigma reported, such as tending to stay away from those with TB and 
thinking that it was their colleagues’ problem and they could not get TB 
themselves. These responses are similar to that reported in PHC staff in Chapter 
four. Nearly three-quarters of HCWs said that most staff support and help a fellow 
staff member with TB, and fewer said that they generally trying to avoid a staff 
member with TB and that most staff reject a staff member with TB. Similar to the 
study conducted in PHCs (Chapter four), we did not use the specific scales 
developed and reported in South African study to measure TB stigma among 
HCWs [185]. Therefore, further studies regarding TB stigma in HCWs will be 
needed, and the use of the developed scales is worth pursuing further. 
We did not assess the implementation of TB infection control measures in this 
facility as this was outside the scope of the study. Therefore, we were not able to 
assess the association between implementation of TB infection control measures 
and prevalence of LTBI. However, we noted that the Joint Commission 
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International accredited the hospital as an academic medical centre hospital in 
2016. For this, some improvements regarding the environmental control 
measures have recently been seen in some of the buildings, including the 
rebuilding of some facilities for TB care and management. We also did not assess 
the use of personal respiratory protection in HCWs. We observed, however, that 
HCWs working in high and very high-risk areas and procedures were mostly using 
respirator masks when caring for their patients whereas in other areas of the 
hospital they were rarely seen.  
This is the first study conducted in Indonesia assessing the prevalence of LTBI, 
measured by TST, in HCWs employed in a large tertiary referral hospital. Although 
we only included 455 of 3058 HCWs, we used stratified sampling to maximise the 
chance of obtaining a representative sample. Furthermore, we used statistical 
methods for survey data, calculated from the selection probabilities of the HCWs 
in each job category.  
This study has some limitations. We noted the potential for non-response bias due 
to the differences in response rates by job categories, particularly in radiographers 
who had a lowest response rate. It may be that the prevalence of LTBI is the same 
in responders and non-responders. Radiographers had a high refusal rate in this 
study, and those tested had a relatively low prevalence of TST positivity. 
Therefore, this may have led to a small overestimate of LTBI prevalence overall. 
We did not screen the HCWs using chest X-rays, as recommended by the WHO for 
HCWs with a positive TST. We only screened HCWs for symptoms and conducted 
sputum examination if indicated. A chest X-ray, of course, would be undertaken to 
rule out TB disease should LTBI treatment be offered. Therefore, there may be 
some misclassification of HCWs with LTBI and TB disease, but this would have 
little impact on the overall LTBI prevalence, as the numbers are likely to be very 
small. Our study was conducted in one tertiary hospital in West Java province, 
which is a large facility in an area of a high number of annual reported TB cases, 
and is one of the 13 facilities designated for MDR-TB patients in Indonesia. 
Therefore, our results may be different to other hospitals throughout the country, 
limiting their generalisability. We did not include non-HCWs as control group in 
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this study. A further limitation was not having general population estimates to 
compare with. However, when compared to another population with a similar age 
structure in the South East Asia region as stated above, our prevalence estimate 
was higher as stated above. In regard to the knowledge questionnaire, as 
described earlier in Chapter 4, even though we used the knowledge questionnaire 
developed from WHO recommendations and informed by related scientific 
literature [21, 171, 175, 176], there is an issue in selecting median levels versus a 
cut-off of adequate knowledge. This issue is negated when the median levels are 
relatively high. 
This study has some implications for practice. By seeing the high prevalence of 
LTBI and high number of HCWs who are willing to undergo LTBI screening and 
treatment, providing preventive treatment for this high-risk population should be 
more actively considered. In regards to the lack of knowledge of TB and LTBI, we 
identified the need for training, including health educational materials that are 
specifically tailored to address the knowledge of TB and LTBI amongst all types of 
HCWs in this health setting. 
In conclusion, the prevalence of LTBI as measured by TST in our study was high 
and showed association with duration of occupational exposure. The high rate of 
LTBI is alarming and serves as a convincing reason to do operational research to 
improve TB infection control to protect HCWs (especially in this era of escalating 
MDR-TB). HCWs in this setting might gain benefit from LTBI treatment to prevent 
TB disease. A package of TB infection control measures will also need to be 
implemented not only in specific areas (high or very high-risk working area) but 
also across the hospital, including personal respiratory protection and education 
regarding TB and LTBI for all HCWs. Regarding TB stigma, most HCWs in this 
study did not experience stigma related to TB which might be due to better levels 







6 Prevalence of positive interferon gamma release assays and 
tuberculin skin test and one-year conversion rates and 
associated risk factors in medical and nursing students in 
Bandung, Indonesia 
6.1 Introduction 
Health care students (HCSs), including medical and nursing students involved in 
clinical training in health care facilities, are likely to be exposed to similar 
occupational risks as health care workers (HCWs). The risk of latent tuberculosis 
infection (LTBI) and TB disease in HCWs and HCSs is approximately two to three 
times higher than the general population [10]. One study in Brazil, focused on 
medical and nursing students, reported that their risk of LTBI was more than 
three times greater than the general population [114].  
Several studies have been conducted in HCSs assessing the prevalence and 
incidence of LTBI [4, 73, 82-86, 89, 92, 93, 104, 107, 108, 113, 126, 133, 145, 152, 
161]. A systematic review [5] of seven studies that included medical and nursing 
students from low and middle-income countries (LMICs) published from 1999-
2005, reported a pooled prevalence of LTBI measured by tuberculin skin test 
(TST) positive of 11% (95% confidence interval (CI) 10-13%). The level of training 
and age were positively associated with the prevalence of LTBI in most studies 
included in this review. Another systematic review and meta-analyses [8] 
published in 2016 included four studies from high TB burden countries conducted 
during 2001-2015, reported a pooled prevalence of LTBI (measured by TST) 
among medical and nursing students of 26% (95% CI 6-46%). Joshi et al reported 
that in LMICs the annual incidence of LTBI in HCSs ranged from 3.9 to 5.3% [5].  
As described in Chapters one and two, there is no gold standard diagnostic test for 
LTBI. The intra-dermal TST has known limitations in accuracy and reliability [11, 
12]. Interferon-gamma release assays (IGRA) [13, 14],  as they are in vitro blood-
based tests, can be repeated any number of times, are not subject to sensitisation 
or boosting and they require only one visit to a health care facility [15]. However 
IGRA has a problem with reproducibility, with much higher rates of test reversion 
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than seen with the TST, even when adjusted cut offs are used for serial testing [15, 
16].  
To date no studies have reported the current situation of LTBI in HCSs in 
Indonesia. We undertook a study to estimate the prevalence of positive IGRA and 
TST, and one-year conversion rates for LTBI, in medical and nursing students 
entering their clinical experience in Bandung, Indonesia and to identify associated 
risk factors and assess agreement between the two LTBI tests.  
6.2 Methods 
6.2.1 Study design and population 
A cohort study was conducted at Universitas Padjadjaran, Bandung, Indonesia. 
Every year approximately 450 medical, nursing, and retrained nursing students 
from the Faculties of Medicine and of Nursing graduate with a bachelor degree 
after finishing their pre-clinical programme, and enter the clinical programme in 
Hasan Sadikin General Hospital. The pre-clinical programme is 3.5 years for 
medical students and 4 years for nursing students, while the clinical programme is 
1.5 years for medical students and one year for nursing students. Retrained 
nursing students already had a Diploma degree and had worked in health care 
facilities for several years before entering the degree programme in Universitas 
Padjadjaran. The pre-clinical programme was shorter (1.5 years) and they have 
one year for their clinical programme. All students who were entering their 
clinical programme in August 2016 and January 2017 were considered for the 
study.  
There were two batches of students who entered the clinical programme during 
the study period. Students who entered in the first batch (August 2016) were 
included in the first cohort and students who entered in the second batch (January 
2017) were included in the second cohort. All consenting students were screened 
and tested using the commercially available IGRA test (QuantiFERON-TB Gold Plus 
(QFT-Plus)) and TST, as follows:  
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- First cohort: students had IGRA at baseline, and for those with a negative 
result at baseline had IGRA and TST at one year follow up, 
- Second cohort: students had IGRA and TST at baseline, and for those with a 
negative result in both or either test at baseline had IGRA and/or TST at 
one year follow up accordingly. 
Prior to the recruitment of the second cohort it was decided to add TST at baseline 
and follow up to understand the concordance and discordance of the two tests. In 
the first cohort, TST was done at follow up for students who were IGRA negative at 
baseline and in the second cohort, TST was done at baseline and follow up. The 
schematic design of the study is shown in Figure 6.1.  
 
A. First cohort  IGRA Positive 
  
    
 IGRA Negative  Tested by IGRA and TST 
    
Time Baseline Exposure One year follow up 
    
Estimation of: 
 
Prevalence of positive 
IGRA 
 
IGRA conversion after one year 




IGRA and TST Positive   
     
   
IGRA Positive and TST 
Negative 
 Tested by TST only 
      
   
IGRA Negative and TST 
Positive 
 Tested by IGRA only 
     
   IGRA and TST Negative  Tested by both IGRA and TST 
     
 
  
Time Baseline Exposure One year follow up 
Estimation of: 
 
Prevalence of positive 
IGRA and TST 
 
IGRA and TST conversion after 
one year 
 
  IGRA = interferon-gamma release assay, TST = tuberculin skin test  
Figure 6.1 Schematic design of the study using IGRA and TST tests at the first cohort 
and second cohort 
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On the basis of this, we were able to estimate the prevalence of LTBI from baseline 
IGRA and TST, and to estimate the conversion rates from follow up of IGRA in both 
cohorts, and of TST in the second cohort. Also, comparing TST result information 
from students recruited in the first (who had only one TST at follow up) and 
second cohort (who had TST at baseline and follow up) will help understand the 
boosting effect of TST (TST at baseline could boost TST at follow up).  
6.2.2 Study procedures 
A meeting was organised with students during the pre-clinical programmes held 
by the Faculties of Medicine and of Nursing, at which time information about the 
study was provided to them. Trained staff provided written information about the 
study to the students, who were asked to give written informed consent to 
participate if they met eligibility criteria. Students were eligible if they had 
graduated with a Bachelor’s degree and were entering the clinical programme in 
Hasan Sadikin Hospital. They were not eligible if they had a positive prior TST 
and/or IGRA test or if they had a history of TB disease. We aimed to only include 
students who tested negative for M. tuberculosis infection by at least one test in 
our cohorts.  
At baseline, all students were tested by IGRA and, for the second cohort, TST. A 
questionnaire (Appendix 2) was used to collect data about demographics (age, 
gender, student type, housing, and ethnicity), clinical characteristics (Bacille 
Calmette-Guerin (BCG) vaccination, human immunodeficiency virus (HIV) status, 
immunocompromised condition, smoking, alcohol consumption), TB exposure 
(previous work in a health care facility, previous training in health care facility, 
direct contact with TB patient at health care facility, direct contact with family or 
friend who had been diagnosed with TB). BCG vaccination was confirmed by 
checking for a BCG scar. Information on TST and/or IGRA result prior to study 
enrolment was collected. Students were provided with logbooks, which they used 
to collect information on their participation in sputum collection or bronchoscopy 
procedures and any direct contact with TB patients over the course of the next 
year. 
 119 
At one year follow up IGRA and/or TST were performed. Data from logbooks were 
verified against university placement records. We also collected information on 
direct contact with a family member or friend who had been diagnosed with TB in 
the last year and use of personal protection during work in health care facilities 
using a questionnaire (Appendix 2).  
Participants were provided with their IGRA and TST result in a sealed envelope, in 
person. Those with positive results were asked for a review to reassess for 
symptoms of active disease, referral for diagnostic evaluation for TB disease, and 
appropriate treatment. It was expected that a small number of participants might 
have active TB (approx. 1%). In keeping with local and international guidelines 
(low and middle income and/or high TB incidence countries) at the time of 
implementing this study, no LTBI treatment was offered for HCWs with a positive 
result. LTBI treatment at the time was recommended only for children under 5 
years of age who are household contacts of people with TB, and people living with 
HIV [17]. This has recently been changed in 2018 to recommend LTBI treatment 
for people of any age who are living in a household where a household member 
has TB and for people living with HIV [3]. For HCWs (including HCSs), WHO 
recommends a package of prevention and care interventions, including HIV 
prevention, antiretroviral therapy and isoniazid preventive therapy (IPT) for 
those who are HIV-positive [6]. Based on the very low rate of HIV positivity in 
Indonesia, HIV testing was not offered to all students, but was offered to anyone 
who was diagnosed with TB.  
We obtained ethical approval from the University of Otago Ethics Committees, 
New Zealand (HE16/005) and the Universitas Padjadjaran Ethics Committees 
Bandung, Indonesia (No 820/UN6.C1.3.2/KEPK/PN/2016) (Appendix 1).  
6.2.3 Assessment of IGRA and TST 
QuantiFERON-TB Gold Plus (QFT-Plus) was used to measure IGRA in the 
Immunology Laboratory, Faculty of Medicine Universitas Padjadjaran as per the 
manufacturer’s instructions. Blood samples were collected into four tubes (Nil, 
TB1, TB2, and Mitogen), incubated at 370C for 24 hours, centrifuged and stored at 
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40C. The enzyme-linked immune sorbent assay (ELISA) was performed manually 
in batches. The interferon gamma (IFN-ɣ) response level, measured in IU/ml, was 
determined by measuring the amount of IFN-ɣ elaborated in response to the 
antigens ESAT-6 and CFP-10 (TB1 tube) and in responses to additional set of 
peptides (TB2) that are associated with M. tuberculosis infection. The 
interpretation of QFT-Plus results is described in Table 6.1 [51]. 
Table 6.1 Interpretation of QuantiFERON-TB Gold Plus results 
Nil (IU/ml) TB1 minus Nil or 
TB2 minus Nil (IU/ml) 
Mitogen minus Nil (IU/ml) QFT-Plus Result 
≤8.0 ≥0.35 and ≥25% of Nil Any Positive 
≤8.0 <0.35 ≥0.5 Negative 
≤8.0 ≥0.35 and <25% of Nil ≥0.5 Negative 
≤8.0 <0.35 <0.5 Indeterminate 
≤8.0 ≥0.35 and <25% of Nil <0.5 Indeterminate 
>8.0 Any Any Indeterminate 
IU = international unit, QFT-Plus = QuantiFERON-TB Cold Plus, TB = tuberculosis 
Nil tube: negative control to adjust for background IFN-ɣ, Mitogen tube: low response may indicate 
inability to generate IFN-ɣ. 
IGRA conversion was defined in the primary analysis as a negative baseline test 
and a positive follow up test. We conducted secondary analyses using a more 
stringent definition for conversion as defined as: a negative baseline test and a 
positive follow up test plus a 30% increase in TB1 minus Nil or TB2 minus Nil over 
the baseline value. This conversion definition was adopted from IGRA conversion 
definition for QFT-GIT as proposed by Veerapathran [72]. 
TST was performed using 0.1 ml (2 international units) tuberculin of purified 
protein derivative (PPD RT23 Biofarma® Bandung) and administered by an 
experienced and trained study nurse. Due to the unavailability of the PPD RT23 
from Biofarma® in Indonesia at the follow up time in 2018, TST was then 
performed using 0.1 ml Tubersol® bioequivalent to 5 TU PPD-S. It was given on 
the volar side of the forearm and the skin reaction read 48-72 hours after TST 
placement. An induration size ≥10 mm was considered as positive [71]. TST 
conversion was defined in the primary analysis as a baseline TST <10 mm with a 
follow up TST ≥10 mm and a 10 mm increase over the baseline as the most 
stringent definition [12]. To avoid a potential boosting effect of TST on the IGRA 
result, IGRA was performed prior to TST at each time point. 
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6.2.4 Sample size consideration  
It was expected that initial test positivity would be 20-30% and the conversion 
rate at one year should be approximately 10-15% [8]. We expected the response 
rate would be 90%, giving just over 400 study participants. With this number the 
prevalence of IGRA can be estimated with a margin of error of +/- 4%. For 
estimating conversion rates, we anticipate approximately 300 students with an 
initial negative test would give approximately 30-45 students who convert during 
the year. These numbers would enable estimation of conversion rates with a 
margin of error of +/- 4%. However, this relatively small number will likely limit 
the assessment of risk factors for test conversion.   
6.2.5 Data management and statistical analysis 
All data were verified as the study progressed and entered into a database created 
in RedCap® [178]. Data were transferred into Stata®, and all analyses were 
conducted using version 14.2 (Stata Corp LP, Texas, US).  
Descriptive statistics and the median (IQR) for age and body mass index (BMI) 
were calculated. The estimates of the prevalence of positive IGRA and TST at 
baseline and proportions of the students who become IGRA and TST positive at 
one year follow up were presented with 95% CI [187]. Agreement between the 
IGRA and TST results were assessed using the kappa statistic [188] in different 
cohorts and time points. Interpretation of Cohen’s kappa as suggested by McHugh 
was as follows: values 0.00–0.20 as none, 0.21–0.39 as minimal, 0.40–0.59 as 
weak, 0.60–0.79 as moderate, and 0.80–0.90 as strong and above 0.90 as almost 
perfect agreement [189].  
The relationship between risk of IGRA and TST positivity and the measures of 
exposure were examined using univariate logistic regression and estimates are 
presented as odds ratios (OR) for baseline analyses. The relationship between risk 
of one year IGRA and TST conversion and the measures of exposure were 
examined using generalised linear models in the Poisson family with log link and 
estimates are presented as relative risk (RR) for follow up analyses. Estimates 
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adjusted for characteristics and exposures were obtained using modified 
backwards-stepwise regression, for the same reasons as explained in Chapter 5. 
Age, gender, student type, and BCG vaccination were retained in the multivariate 
model. Other variables were also retained in the model if P<0.2. Continuous 
variables were retained in their linear forms because complex fractional 
polynomials did not improve model-fit for any of them. The retrained nursing 
students were excluded from the primary analysis and were analysed separately 
due to different in baseline characteristics.  
6.3 Results 
6.3.1 Description of the cohort 
Figure 6.2 shows the study recruitment flow chart for 461 medical and nursing 
students enrolled in the clinical programme in August 2016 and January 2017. Of 
these, 447 (97%) agreed to be considered for the study resulting in 414 who were 
eligible and entered the study. Reasons for non-eligibility were: history of TB 
(n=29); on TB treatment (n=2); and prior TST positivity (n=2).   
Of 414 students, 142 were included in the first cohort and 272 students in the 
second cohort. There were more nursing students in the first cohort and more 
medical students in the second cohort. Of 142 students in the first cohort, 42 were 
IGRA positive and 100 were IGRA negative at baseline. Of the 100 IGRA negative 
students, 81 had a repeat IGRA at one year and had additional TST, 1 had a repeat 
IGRA but no TST result, 11 had no IGRA available but had additional TST, and 7 
refused to be tested by both IGRA and TST at one year follow up (Figure 6.2).  
Among 272 students included in the second cohort and tested by both IGRA and 
TST at baseline, 33 were IGRA and TST positive, 13 were IGRA positive-TST 
negative, 55 were IGRA negative-TST positive, 170 were IGRA negative-TST 
positive, and I IGRA indeterminate-TST positive. Of thirteen students who were 
TST negative but IGRA positive at baseline, 12 had a repeat TST result at one year 
and 1 refused. Of 55 students who were IGRA negative but TST positive at 
baseline, all had a repeat IGRA at one year follow up. Of 170 IGRA and TST 
 123 
negative students, 168 were retested by both tests at one year, 1 refused, and 1 
developed active TB (pleural TB) (Figure 6.3).  
The characteristics of included students are presented by student type in Table 
6.2. In total, there were 248 medical students (59.9%), 131 nursing students 
(31.6%), and 35 retrained nursing students (8.5%). The median age was 21.7 
years (IQR: 21.2-22.3) in medical students, 22.4 years (IQR: 22.0-22.9) in nursing 
students and 36.5 years (IQR 30.4-38.5) in retrained nursing students. There were 
more female than male students (70.6% of medical students, 91.6% of nursing 
students, and 62.9% of retrained nursing students). Medical and nursing students 
were mostly living in student housing, while most of the retrained nursing 
students were living in family housing. Only a third of medical students were 
Sundanese (main ethnicity in West Java Province), while most nursing and 
retrained nursing students were Sundanese.  
A BCG vaccination scar was observed in 220 (88.7%) medical students, 108 
(82.4%) nursing students, and 25 (71.4%) retrained nursing students, given the 
total of 353 (85.3%). None reported being HIV positive, 8 (1.9%) were on steroid 
treatment, 375 (90.6%) had never smoked, and 389 (94.0%) had never consumed 
alcohol. The median BMI was 22.2 kg/m2 (IQR: 20.1-25.7) in medical students, 
21.3 (IQR: 19.3-23.7) in nursing students and 25.8 (23.9-28.1) in retrained nursing 
students. Due to the nature of the curriculum, 189 (76.2%) medical students and 
94 (71.8%) nursing students had been involved in other training in a health care 
facility prior to study enrolment. A total of 118 (47.6%) medical students and 67 
(51.2%) nursing students had some direct contact with a TB patient or 
participated in sputum collection or examination. Furthermore, 54 (21.8%) 
medical students and 32 (24.4%) nursing students had previously had direct 
contact with family or friends who were diagnosed with TB. Meanwhile, in 
retrained nursing students, all had been working in health care facilities prior to 
study enrolment, around 75% had direct contact with a TB patient or participated 
in sputum collection or examination and 28.6% had previously had direct contact 
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Table 6.2 Demographic characteristics, medical history, and exposure to TB of the students included at baseline, by student type (N=414) 
Variables Characteristics Medical students  
n (%) 
Nursing students  
n (%) 
Retrained nursing 
students n (%) 
Total 
Total students  248 (59.9) 131 (31.6) 35 (8.5) 414 (100.0) 
Demographic characteristics       
Cohort at entry First cohort 11 (4.4) 102 (77.9) 29 (82.9) 142 (34.3) 
Second cohort 237 (95.6) 29 (22.1) 6 (17.1) 272 (65.7) 
Age (years) median, IQR  21.7 (21.2-22.3) 22.4 (22.0-22.9) 36.5 (30.4-38.5) 22.1 (21.5-22.9) 
Gender Female 175 (70.6) 120 (91.6) 22 (62.9) 317 (76.6) 
 Male 73 (29.4) 11 (8.4) 13 (37.1) 97 (23.4) 
Housing Family housing 46 (18.6) 45 (34.3) 26 (74.3) 117 (28.3) 
 Student housing 202 (81.4) 86 (65.7) 9 (25.7) 297 (71.7) 
Ethnicity Sundanese 80 (32.3) 84 (64.1) 29 (82.9) 193 (46.6) 
 Other 168 (67.7) 47 (35.9) 6 (17.1) 221 (53.4) 
Medical history       
BCG vaccination Yes 220 (88.7) 108 (82.4) 25 (71.4) 353 (85.3) 
 No  28 (11.3) 23 (17.6) 10 (28.6) 61 (14.7) 
Has been diagnosed with HIV Yes 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 No 171 (68.9) 75 (57.3) 17 (48.6) 263 (63.5) 
 Do not know 77 (31.1) 56 (42.8) 18 (51.4) 151 (36.5) 
Immunocompromised condition Yes (Steroid therapy) 5 (2.0) 3 (2.3) 0 (0.0) 8 (1.9) 
None 243 (98.0) 128 (97.7) 35 (100.0) 406 (98.1) 
Smoking Current/ex-smoker 25 (10.1) 6 (4.6) 8 (22.9) 39 (9.4) 
 Never 223 (89.9) 125 (95.4) 27 (77.1) 375 (90.6) 
Alcohol consumption Yes 24 (9.7) 0 (0.0) 1 (2.9) 25 (6.0) 
 No 224 (90.3) 131 (100.0) 1 34 (97.1) 389 (94.0) 
BMI (kg/m2) median, IQR  22.2 (20.1-25.7) 21.3 (19.3-23.7) 25.8 (23.9-28.1) 22.2 (19.9-25.5) 
 Underweight (<18.5) 29 (11.7) 20 (15.3) 0 (0.0) 49 (11.8) 
 Normal (18.5-24.9) 152 (61.3) 92 (70.2) 15 (42.9) 259 (62.6) 
 Overweight (25.0-29.9) 56 (22.6) 14 (10.7) 17 (48.6) 87 (21.0) 







Variables Characteristics Medical students  
n (%) 
Nursing students  
n (%) 
Retrained nursing 
students n (%) 
Total 
Prior TB exposure      
Involved in other programme in 
health care facility 
Yes 189 (76.2) 94 (71.8) 35 (100.0) 318 (76.8) 
No 59 (23.8) 37 (28.2) 0 (0.0) 96 (23.2) 
Any direct contact with TB 
patient or participation in 
sputum collection or 
examination 
Yes 118 (47.6) 67 (51.2) 26 (74.3) 211 (51.0) 
No 130 (52.4) 64 (48.8) 9 (25.7) 203 (49.0) 
Any direct contact with family or 
friends who have been 
diagnosed with TB 
Yes 54 (21.8) 32 (24.4) 10 (28.6) 96 (23.2) 
No 194 (78.2) 99 (75.8) 25 (71.4) 318 (76.8) 




6.3.2 Prevalence of positive IGRA and TST and agreement of IGRA and TST 
result at baseline 
The prevalence of a positive IGRA was 21.3% (95% CI 17.4-25.5%, n=414) and of 
a positive TST was 32.7% (95% CI 27.2-38.9%, n=272) across all students tested 
(Table 6.3). When restricted to medical and nursing students only, the prevalence 
of positive IGRA was 18.5% (95% CI 14.7-22.7%, n=379) and positive TST was 
31.9% (95% CI 26.4-37.9%, n=266). While in retrained nursing students, the 
prevalence of IGRA positivity was 51.4% (95% CI 33.9-68.6%, n=35) and TST was 
66.7% (95% CI 22.3-95.7%, n=6).  
In a sensitivity analysis, we adjusted our prevalence estimate for TST after 
excluding 11 students who had a prior TST test (81.8% of them were TST positive 
at baseline). The prevalence of positive TST was then slightly lower than previous 
estimate stated above (30.7%, 95% CI 25.1-36.6%, n=261) across all students and 
30.1% (95% CI 24.5-36.1%, n=256) when restricted to medical and nursing 





Table 6.3 Interferon-gamma release assay and tuberculin skin test positivity at 
baseline 
Definition Total (N) Positive (n) % 95% CI 
IGRA positivity (for both cohorts)     
All students 414 88 21.3 17.4-25.5 
Medical and nursing students 379 70 18.5 14.7-22.7 
Medical students 248 41 16.6 12.1-21.8 
Nursing students 131 29 22.1 15.4-30.2 
Retrained nursing students 35 18 51.4 33.9-68.6 
IGRA positivity (first cohort)   
All students 142 42 29.6 22.2-37.8 
Medical and nursing students  113 27 23.9 16.4-32.8 
Medical students 11 1 9.1 0.2-41.3 
Nursing students 102 26 25.5 17.4-35.1 
Retrained nursing students 29 15 51.7 32.5-71.0 
IGRA positivity (second cohort)   
All students 272 46 16.9 12.7-21.9 
Medical and nursing students 266 43 16.2 12.0-21.2 
Medical students 237 40 16.9 12.3-22.3 
Nursing students 29 3 10.3  2.2-27.4 
Retrained nursing students 6 3 50.0 11.8-88.2 
IGRA positivity (for students who had a negative TST result prior to study enrolment) 
All students 18 7 38.9 17.3-64.3 
Medical and nursing students 14 4 28.6 83.9-58.1 
Medical students 9 3 33.3 7.5-70.1 
Nursing students 5 1 20.0 0.5-71.6 
Retrained nursing students 4 3 75.0 19.4-99.4 
TST positivity (second cohort)   
All students 272 89 32.7 27.2-38.6 
Medical and nursing students 266 85 31.9 26.4-37.9 
Medical students 237 75 31.6 25.8-38.0 
Nursing students 29 10 34.5 17.9-54.3 
Retrained nursing students 6 4 66.7 22.3-95.7 
TST positivity (for students who had a negative TST result prior to study enrolment) 
All students 11 9 81.8 48.2-97.7 
Medical and nursing students 10 8 80.0 44.4-97.5 
Medical students 9 8 88.9 51.8-99.7 
Nursing students 1 0 0.0 0.0-97.5 
Retrained nursing students 1 1 100.0 2.5-100.0 
TST positivity (second cohort, excluding students who had a negative TST result prior to 
study enrolment) 
All students 261 80 30.7 25.1-36.6 
Medical and nursing students 256 77 30.1  24.5-36.1 
Medical students 228 67 29.4 23.6-35.8 
Nursing students 28 10 35.7 18.6-55.9 
Retrained nursing students 5 3 60.0 14.7-94.7 







Table 6.4 shows the concordance and discordance between IGRA and TST 
positivity at baseline for all students included in the second cohort. Agreement 
between the two tests was 74.9% (kappa 0.35, 95% CI 0.23-0.46, P<0.0001) in all 
students included in the second cohort. Agreement and kappa were higher in 
retrained nursing students than in other types of students (83.3%, kappa 0.67, 
95% CI 0.10-1.00, P=0.042) (Table 6.5). When we excluded students who had a 
negative TST result prior to study enrolment, agreement and kappa were similar 
except for the retrained nursing students.  
 
Table 6.4 IGRA and TST positivity at baseline (restricted to all students who had 
both test results included in the second cohort) 
IGRA TST  
Negative Positive Total 
All students    
Negative 170 55 225 
Positive 13 33 46 
Total 183 88 271 
All students (excluding students who had a negative TST result prior to study enrolment)  
Negative 168 49 217 
Positive 13 30 43 
Total 181 79 260 
IGRA = interferon-gamma release assay, TST = tuberculin skin test 
 
Table 6.5 Kappa statistic for agreement between IGRA and TST positivity at baseline 
(restricted to those who had both test result included in the second cohort) 
Students N Agreement 
(%) 
Kappa 95% CI P value 
All students 271 74.9 0.35 0.23-0.46 <0.0001 
Medical and nursing students 265 74.7 0.33 0.21-0.45 <0.0001 
Medical students 236 74.6 0.33 0.20-0.45 <0.0001 
Nursing students 29 75.9 0.36 0.04-0.68 0.006 
Retrained students 6 83.3 0.67 0.10-1.00 0.042 
All students (excluding 
students who had a negative 
TST result prior to study 
enrolment) 
260 76.2 0.35 0.23-0.48 <0.0001 
Medical and nursing students 255 75.7 0.33 0.20-0.45 <0.0001 
Medical students 227 75.8 0.33 0.19-0.46 <0.0001 
Nursing students 28 75.0 0.36 0.04-0.67 0.007 
Retrained students 5 100.0 1.00 1.00-1.00 0.013 
CI = confidence interval, IGRA = interferon-gamma release assay, TST = tuberculin skin test 
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6.3.3 Risk factors associated with IGRA and TST positivity at baseline  
In the univariate and multivariate analysis, no factors were found to be 
significantly associated with IGRA positivity in medical and nursing students 
(Table 6.6). However, students who had BCG vaccination had a lower risk of LTBI 
of borderline significance (OR 0.54, P=0.081). Similar results were found when the 
analysis was restricted to retrained nursing students only; no factors were 
significantly associated with IGRA positivity at baseline in the univariate model 
(Table 6.7).  
For TST positivity (Table 6.8), students who had been involved in another training 
programme before study enrolment and who had direct contact with family or 
friends with TB had a lower risk of LTBI in the univariable analysis (OR 0.54, 
P=0.048; and OR 0.50, P=0.036, respectively). However, after adjusting for age, 
gender, student type, and BCG vaccination, only direct contact with family or 
friends with TB stayed significant in the multivariate analysis (AOR 0.51, 95% CI 
0.26-0.99, P=0.049), being unexpectedly negatively associated with test positivity. 
In the sensitivity analysis, this factor did not remain significant in the multivariate 
analysis. Unexpectedly, being involved in other training programme before study 








Table 6.6 Association between demographic characteristics, medical history, TB exposure, and IGRA positivity at baseline in medical and 
nursing students included in all cohorts. Results of univariate and multivariate logistic regression (N=378) 
Variable  Positive IGRA n (%) OR (95% CI) P value AOR (95% CI) P value 
Total students - 70 (18.5)     
Age, median (years)  - - 1.11 (0.88-1.39) 0.37 1.08 (0.85-1.38) 0.54 
Gender Male 11 (13.1) 1  1  
 Female 59 (20.1) 1.66 (0.83-3.34) 0.15 1.65 (0.79-3.41) 0.18 
Student type Nursing 29 (22.1) 1  1  
 Medical 41 (16.6) 0.70 (0.41-1.19) 0.19 0.83 (0.47-1.48) 0.53 
Housing Student housing 48 (16.7) 1    
 Family housing 22 (24.4) 1.62 (0.91-2.87) 0.099 -  
Ethnicity Other 40 (18.6) 1    
 Sundanese 30 (18.4) 0.99 (0.58-1.67) 0.96 -  
BCG vaccination No 14 (27.5) 1  1  
 Yes 56 (17.1) 0.54 (0.28-1.08) 0.081 0.54 (0.27-1.08) 0.082 
Smoking Never 67 (19.3) 1    
 Current/ex-smoker 3 (9.7) 0.45 (0.13-1.52) 0.19 -  
Alcohol consumption No 67 (18.9) 1    
 Yes 3 (12.5) 0.61 (0.18-2.11) 0.44 -  
BMI (kg/m2) median, IQR - - 1.02 (0.96-1.09) 0.54 -  
Involved in other programme in health care 
facility prior to recruitment 
No 18 (18.8) 1    
Yes 52 (18.4) 0.98 (0.54-1.78) 0.95 -  
Direct contact with TB patient or participation in 
sputum collection/ examination 
No 33 (17.1) 1    
Yes 37 (20.0) 1.21 (0.72-2.04) 0.47 -  
Direct contact with family or friends with TB No 60 (20.6) 1  1  
Yes 10 (11.6) 0.51 (0.25-1.04) 0.065 0.51 (0.24-1.05) 0.066 
AOR = adjusted odds ratio, BCG = Bacille Calmette-Guerin, BMI = body mass index, CI = confidence interval, IGRA = interferon-gamma release assay, IQR = inter 







Table 6.7 Association between demographic characteristics, medical history, TB exposures, and IGRA positivity at baseline in retrained 
nursing students included in all cohorts. Result of univariate logistic regression (N=35) 
Variable  Positive IGRA n (%) OR (95% CI) P value 
Total number of students  18 (51.4)   
Age (years)   - 0.9 (0.8-1.1) 0.64 
Gender Male 15 (38.5) 1  
 Female 13 (59.1) 2.3 (0.6-9.4) 0.24 
Housing Student housing 6 (66.7) 1  
 Family housing 12 (46.2) 0.4 (0.1-2.1) 0.29 
Ethnicity Other 3 (50.0) 1  
 Sundanese 15 (51.7) 1.1 (0.2-6.2) 0.94 
BCG vaccination No 7 (70.0) 1  
 Yes 11 (44.0) 0.3 (0.1-1.6) 0.17 
Smoking Never 14 (51.9) 1  
 Current and ex-smoker 4 (50.0) 0.9 (0.2-4.5) 0.93 
BMI (kg/m2) median, IQR  - 1.1 (0.9-1.3) 0.49 
Any direct contact with TB patient or participation in sputum 
collection or examination 
No 7 (77.8) 1  
Yes 11 (42.3) 0.2 (0.0-1.2) 0.081 
Any direct contact with family or friends who have been diagnosed 
with TB 
No 14 (56.0) 1  
Yes 4 (40.0) 0.5 (0.1-2.3) 0.39 








Table 6.8 Association between demographic characteristics, medical history, TB exposures and TST positivity at baseline in medical and 
nursing students included in second cohort. Result of univariate and multivariate logistic regression (N=266) 
Variable  Positive TST n (%) OR (95% CI) P value AOR (95% CI) P value 
Total students  85 (31.9) - - - - 
Age (years)   - 1.19 (0.94-1.49) 0.15 1.13 (0.88-1.44) 0.33 
Gender Male 22 (31.0) 1  1  
 Female 63 (32.3) 1.06 (0.59-1.91) 0.84 1.15 (0.63-2.10) 0.64 
Student type Nursing 10 (34.5) 1  1  
 Medical 75 (31.7) 0.88 (0.39-1.98) 0.76 0.77 (0.32-1.89) 0.57 
Housing Student housing 68 (31.9) 1    
 Family housing 17 (32.1) 1.01 (0.53-1.92) 0.98 -  
Ethnicity Others 60 (34.9) 1    
 Sundanese 25 (26.6) 0.68 (0.39-1.28) 0.17 -  
BCG vaccination No 11 (36.7) 1  1  
 Yes 74 (31.4) 0.79 (0.36-1.74) 0.56 0.73 (0.32-1.66) 0.45 
Immunocompromised condition No 81 (31.3) 1    
 Yes (steroid therapy) 4 (57.1) 2.93 (0.64-13.39) 0.17 -  
Smoking Never 75 (31.3) 1    
 Current and ex-smoker 10 (38.5) 1.38 (0.60-3.17) 0.46 -  
Alcohol consumption No 77 (31.6) 1    
 Yes 8 (36.4) 1.24 (0.50-3.08) 0.64 -  
BMI (kg/m2) median, IQR  - 1.03 (0.97-1.09) 0.31 -  
Involved in other programme in health care 
facility 
No 23 (43.4) 1  1  
Yes 62 (29.1) 0.54 (0.29-0.99) 0.048 0.58 (0.31-1.10) 0.098 
Direct contact with TB patient or participation in 
sputum collection or examination 
No 44 (34.7) 1    
Yes 41 (29.5) 0.79 (0.47-1.32) 0.37 -  
Direct contact with family or friends who have 
been diagnosed with TB 
No 70 (35.5) 1  1  
Yes 15 (21.7) 0.50 (0.26-0.96) 0.036 0.51 (0.26-0.99) 0.049 
AOR = adjuster odds ratio, BCG = Bacille Calmette-Guerin, BMI = body mass index, CI = confidence interval, IGRA = interferon-gamma release assay, IQR = inter 







Table 6.9 Association between demographic characteristics, medical history, TB exposures and TST positivity at baseline in medical and 
nursing students included in second cohort (excluding students who had a negative TST results prior to study enrolment). Result of 
univariate and multivariate logistic regression (N=256) 
Variable  Positive TST n (%) OR (95% CI) P value AOR (95% CI) P value 
Total students  77 (30.1)     
Age (years)   - 1.06 (0.81-1.38) 0.67 0.95 (0.71-128) 0.75 
Gender Male 19 (28.4) 1  1  
 Female 58 (30.7) 1.11 (0.61-2.07) 0.72 1.21 (0.64-2.28) 0.56 
Student type Nursing 10 (35.7) 1  1  
 Medical 67 (29.4) 0.75 (0.33-1.71) 0.49 0.58 (0.23-1.46) 0.25 
Housing Student housing 61 (29.9) 1    
 Family housing 16 (30.8) 1.04 (0.54-2.02) 0.90 -  
Ethnicity Others 53 (32.1) 1    
 Sundanese 24 (26.4) 0.76 (0.43-1.34) 0.34 -  
BCG vaccination No 11 (36.7) 1  1  
 Yes 66 (29.2) 0.71 (0.32-1.58) 0.40 0.72 (-.31-1.65) 0.44 
Immunocompromised condition No 75 (29.9) 1    
 Yes (steroid therapy) 2 (40.0) 1.56 (0.26-9.55) 0.63 -  
Smoking Never 68 (29.4) 1    
 Current and ex-smoker 9 (36.0) 1.35 (0.57-3.20) 0.50 -  
Alcohol consumption No 72 (30.4) 1    
 Yes 5 (26.3) 0.82 (0.28-2.36) 0.71 -  
BMI (kg/m2) median, IQR  - 1.03 (0.96-1.10) 0.42 -  
Involved in other programme in health care 
facility 
No 22 (42.3) 1  1  
Yes 55 (30.0) 0.50 (0.27-0.95) 0.033 0.49 (0.25-0.96) 0.037 
Direct contact with TB patient or participation in 
sputum collection or examination 
No 41 (33.1) 1    
Yes 36 (27.3) 0.76 (0.44-1.30) 0.31 -  
Direct contact with family or friends who have 
been diagnosed with TB 
No 62 (32.8) 1  1  
Yes 15 (22.4) 0.59 (0.31-1.13) 0.11 0.56 (0.29-1.11) 0.099 
AOR = adjuster odds ratio, BCG = Bacille Calmette-Guerin, BMI = body mass index, CI = confidence interval, IGRA = interferon-gamma release assay, IQR = inter 
quartile range, OR = odds ratio  
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6.3.4 TB exposures at follow up  
At one year follow up, most students reported direct contact with TB patient(s) in 
the last year (98.1% in medical students, 93.9% in nursing students, and 93.3% in 
retrained nursing students). Thirty-four (15.8%) medical students, 40 (40.8%) 
nursing students, and 7 (45.7%) retrained nursing students had participated in 
sputum collection or bronchoscopy procedures. Nearly half of medical students 
(48.8%), 65.3% of nursing students and 53.3% of retrained nursing students had 
direct contact with a family or friend who had been diagnosed with TB over the 
previous year. Regarding personal protection, 47 (22.0%) medical students, 21 
(21.4%) nursing students, and 4 (26.7%) retrained nursing students reported 
always used N95/FFP2 respirators or mask respirators during work in health care 
facilities (Table 6.10). 
6.3.5 IGRA and TST conversion rate at one-year follow up and agreement 
between two tests 
The IGRA conversion rate was 8.9% (95% CI 5.9-12.6%, n=305) and the TST 
conversion rate was 35.0% (95% CI 28.1-42.4%, n=180) in all types of students 
included in both cohorts. When restricted to medical and nursing students only, 
IGRA conversion was 8.9% (95% CI 5.9-12.7%, n=293) and TST conversion was 
35.4% (95% CI 28.4-42.9%, n=178). IGRA conversion rates in all students 







Table 6.10 TB exposures of students included at follow up, by student type (N=328) 
  Medical students  
n (%) 
Nursing students  
n (%) 




Total students  215 (65.5) 98 (29.9) 15 (4.6) 328 (100.0) 
TB exposure       
Any direct contact with pulmonary TB 
patient/s in the last year 
Yes 211 (98.1) 92 (93.9) 14 (93.3) 317 (96.7) 
No 4 (1.9) 6 (6.1) 1 (6.7) 11 (3.3) 
Participation in sputum collection or 
bronchoscopy procedures 
Yes 34 (15.8) 40 (40.8) 7 (45.7) 81 (24.7) 
No 181 (84.2) 58 (59.2) 8 (53.3) 247 (75.3) 
Any direct contact with family or friends 
diagnosed with TB in the last year 
Yes 105 (48.8) 64 (65.3) 8 (53.3) 177 (54.0) 
No 110 (51.2) 34 (34.7) 7 (46.7) 151 (46.0) 
Personal protection       
N95/FFP2 respirators or any other mask 
respirator during work 
Yes, always 47 (22.0) 21 (21.4) 4 (26.7) 72 (22.0) 
No or not always 167 (78.0) 77 (78.6) 11 (73.3) 255 (78.0) 







Table 6.11 IGRA and TST one-year conversion rates (using the most stringent 





% 95% CI 
IGRA conversion (for both cohorts)     
All students 305 27 8.9 5.9-12.6 
Medical and nursing students 293 26 8.9 5.9-12.7 
Medical students 203 22 10.8 6.9-15.9 
Nursing students 90 4 4.4 1.2-11.0 
Retrained students 12 1 8.3 0.2-38.5 
IGRA conversion (first cohort)     
All students 82 7 8.5 3.5-16.8 
Medical and nursing students 73 6 8.2 3.1-17.0 
Medical students 9 3 33.3 7.5-70.1 
Nursing students 64 3 4.7 0.9-13.1 
Retrained students 9 1 11.1 0.2-48.2 
IGRA conversion (second cohort)     
All students 223 20 8.9 5.6-13.5 
Medical and nursing students 220 20 9.1 5.6-13.7 
Medical students 194 19 9.8 6.0-14.9 
Nursing students 26 1 3.9 0.0-19.6 
Retrained students 3 0 0.00 0.0-70.8 
TST positivity at one year with no baseline TST and negative IGRA test at baseline (first 
cohort)* 
All students 92 31 33.7 24.2-44.3 
Medical and nursing students 81 26 32.1 22.2-43.4 
Medical students 9  5 55.6 21.2-86.3 
Nursing students 72 21 29.2 19.0-41.1 
Retrained students 11 5 45.5 16.7-76.6 
TST conversion after one year (second cohort) using the most stringent definition 
All students 180 63 35.0 28.1-42.4 
Medical and nursing students 178 63 35.4 28.4-42.9 
Medical students 159 57 35.9 28.4-43.8 
Nursing students 19 6 31.6 12.6-56.6 
Retrained students 2 0 0.0 0.0-84.2 
TST conversion after one year (second cohort with negative IGRA at baseline) using the 
most stringent definition 
All students 168 61 36.3 29.0-44.1 
Medical and nursing students 166 61 36.7 29.4-44.6 
Medical students 147 55 37.4 29.6-45.8 
Nursing students 19 6 31.6 12.6-56.6 
Retrained students 2 0 0.0 0.0-84.2 
CI = confidence interval, IGRA = interferon-gamma release assay, TST = tuberculin skin test 




Table 6.12 shows the concordance and discordance between IGRA and TST 
positivity at follow up time. In Table 6.13, agreement was 56.6% (kappa 0.12, 95% 
CI 0.05-0.19, P=0.0003) in students included in both cohorts. When restricted to 
the first cohort only (with no baseline TST), agreement was 70.4% (kappa 0.18, 
95% CI 0.00-0.37, P=0.013) and in the second cohort (with baseline TST) it was 
50.0% (kappa 0.11, 95% CI 0.04-0.17, P=0.002).  
Table 6.12 IGRA and TST positivity (induration size >10 mm) at follow up  
Cohort IGRA TST  
 Negative Positive Total 
Both cohorts Negative 123 105 228 
 Positive 3 18 21 
 Total 126 123 249 
First cohort Negative 52 22 74 
 Positive 2 5 7 
 Total 54 27 81 
Second cohort Negative 71 83 154 
 Positive 1 13 14 
 Total 72 96 168 
CI = confidence interval, IGRA = interferon-gamma release assay, TST = tuberculin skin test 
 
Table 6.13 Kappa statistic for agreement between IGRA and TST positivity 





Kappa 95% CI P value 
Both cohorts      
All students 249 56.6 0.12 0.05-0.19 0.0003 
Medical and nursing students 239 56.1 0.13 0.06-0.20 0.0001 
Medical students 156 50.0 0.11 0.03-0.19 0.005 
Nursing students 83 67.5 0.16 0.02-0.30 0.004 
Retrained students 10 70.0 -0.15 -0.45-0.14 0.70 
First cohort (with no baseline TST)      
All students 81  70.4  0.18 0.00-0.37 0.013 
Medical and nursing students 73 63.3 0.22 0.03-0.41 0.004 
Medical students 9 55.6 0.14 -0.44-0.72 0.32 
Nursing students 64 73.4 0.20 0.00-0.39 0.004 
Retrained students 8 62.5 -0.20 -0.57-0.17 0.73 
Second cohort (with baseline TST)      
All students 168 50.0 0.11 0.04-0.17 0.002 
Medical and nursing students 166 49.4 0.11 0.04-0.17 0.003 
Medical students 147 49.7 0.11 0.04-0.18 0.004 
Nursing students 19 47.4 0.08 -0.07-0.2 0.19 
Retrained students 2 - - - - 




6.3.6 Boosting phenomenon 
Figure 6.4 shows the distribution of TST induration size (mm) at baseline and 
after one year for students included in the second cohort, and at one year for 
students included in first cohort. The TST induration size shown in panels A and B 
are not in the same individuals (since anyone with a positive TST in panel A was 
not re-tested in panel B). It is important to note that, for the first cohort, TST 
follow up included individuals who would have been IGRA negative and TST 
positive if tested with TST at baseline (n=55; 20.2% in second cohort, or 24% of all 
IGRA negatives); and excluded people who were IGRA positive at baseline but 
would have been TST negative (n=13; 4.8% in second cohort, or 7% of all TST 
negatives). Therefore, comparisons of the cohorts with respect to boosting are 
affected by these differences, affecting 25% of individuals resulting in it being 
difficult to draw conclusions from the different distributions of TST induration at 







IGRA = interferon-gamma release assay, TST = tuberculin skin test 
 
Figure 6.4 TST induration (mm) A) at baseline and B) after one year for students 
included in the second cohort and C) at one year for students included in the first 
cohort 
We conducted an analysis to explore the possibility of the effect of age, BCG 
vaccination, prior TST, and student type on different definitions of TST conversion 
at one year follow up, noting that our stringent criterion for TST conversion was 
intended to account for the boosting phenomenon. Table 6.14 shows that, for the 
less stringent definitions, TST conversion was significantly associated with a TST 
being conducted at baseline. Whereas, for the most stringent criterion there was 
no significant association of TST conversion with a TST conducted at baseline, 
while there was a significant association with age. Together these results suggest 
that the most stringent criterion was successful in excluding those with boosting 
from being defined as TST converters. 
One would expect that, using the most stringent TST conversion criterion; 
agreement between the IGRA test at follow-up would become similar to agreement 
at baseline.  The kappa statistic for agreement between IGRA and TST conversion, 
using the most stringent definition, at one-year follow up for students included in 
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the second cohort was 0.18 (Table 6.15), which increased compared with 0.11 
when simply comparing positive and negative tests, and was the same as the first 
cohort at follow-up (0.18).  However, it was still substantially less than 0.35, which 
was the kappa statistic at baseline in the second cohort. Therefore, changing 








Table 6.14 Factors associated with different definitions of TST conversion  





Adjusted odds ratios (95% CI); P value 
n % Age     BCG vaccination 
    (Yes vs. No) 
   Prior TST  
   (5-9 mm vs. 0 mm) 
    Student type  
   (Nursing vs. Medical) 
Baseline TST <10 mm with a follow 
up TST ≥10 mm  
99 55.0 1.28 (0.91-1.81); 0.17 1.09 (0.37-3.21); 0.88 6.78 (3.08-14.92); <0.0001 1.06 (0.36-3.11); 0.92 
Baseline TST <10 mm with a follow 
up TST ≥10 mm and a 6 mm 
increase over the baseline 
86 47.8 1.15 (0.83-1.60); 0.39 
 
1.47 (0.53-4.04); 0.53 2.90 (1.40-6.00); 0.004 0.71 (0.25-1.97); 0.51 
Baseline TST <10 mm with a follow 
up TST ≥10 mm and a 10 mm 
increase over the baseline (most 
stringent) 
63 35.0 1.41 (1.01-1.97); 0.047 1.05 (0.51-2.19); 0.93 1.05 (0.51-2.19); 0.89 0.64 (0.22-1.84); 0.41 
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Table 6.15 Agreement between IGRA and TST conversion (using the most stringet 
definition) after one year for students included in the second cohort  
IGRA TST  Agreement Kappa statistic 
(95% CI), P value No conversion Conversion Total (%) 
No conversion 104 50 154 68.5 0.18 (0.06-0.30),  
P=0.003 Conversion 3 11 14  
Total 107 61 168   
CI = confidence interval, IGRA = interferon-gamma release assay, TST = tuberculin skin test  
6.3.7 Risk factors associated with one-year IGRA and TST conversion rates  
In the univariate analysis, no factor was found to be significantly associated with 
IGRA conversion (Table 6.16). Age, gender, student type, ethnicity, BCG 
vaccination and participation in sputum collection or bronchoscopy procedures 
were included in the multivariate analysis: medical student, (adjusted RR (ARR) 
5.15, P=0.002), being of Sundanese ethnicity (ARR 2.45, P=0.022), and 
participation in sputum collection or bronchoscopy procedures (ARR 2.74, 
P=0.008) were positively associated with IGRA conversion. There was a non-
significant trend to lower conversion among those with a history of BCG 
vaccination (ARR 0.68, P=0.45). 
We did a secondary analysis using the more stringent definition for IGRA 
conversion and found no factors significantly associated with IGRA conversion in 
the univariate analysis (Table 6.17). In the multivariate model, being a medical 
student (ARR 3.45, P=0.020) and participation in sputum collection or 
bronchoscopy procedures (ARR 2.67, P=0.012) were positively associated with 
IGRA conversion after adjusting for age, gender, and BCG vaccination. 
For one-year TST conversion, using the most stringent definition, age was the only 
significant factor in the univariate analysis (RR 1.20, P=0.030), and after 
adjustment for gender, student type, BCG vaccination, and direct contact with 
family or friends with TB, it stayed significant (ARR 1.22, P=0.017) (Table 6.18). 
The use of mask respirators was shown to be a clinically significant protective 
factor for TST conversion (P=0.05). We did an additional analysis to evaluate the 
association of risk factors with TST positivity at follow up time for students with 
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no baseline TST and found that medical students and those of Sundanese ethnicity 








Table 6.16 Association between demographic variables, medical history, TB exposure and one-year IGRA conversion in medical and 
nursing students included in all cohorts. Results of univariate and multivariate models (N=293) 
 Variable IGRA conversion (%) RR (95% CI) P value ARR (95% CI) P value 
Total number of students  26 (8.9)     
Age (years)    1.08 (0.79-1.48) 0.61 1.23 (0.94-1.60) 0.13 
Gender Male 6 (8.6) 1  1  
 Female 20 (9.0) 1.05 (0.44-2.51) 0.92 1.34 (0.58-3.09) 0.49 
Student type Nursing 4 (4.4) 1  1  
 Medical 22 (10.8) 2.44 (0.86-6.88) 0.092 5.15 (1.82-14.59) 0.002 
Housing Student housing 18 (7.8) 1    
 Family housing 8 (12.7) 1.62 (0.74-3.56) 0.23 -  
Ethnicity Other 12 (7.1)  1  1  
 Sundanese 14 (11.3) 1.59 (0.76-3.32) 0.22 2.45 (1.14-5.26) 0.022 
BCG vaccination No 4 (11.4) 1  1  
 Yes 22 (8.5) 0.75 (0.27-2.04) 0.57 0.68 (0.25-1.83) 0.45 
Immunocompromised condition No 25 (8.8) 1    
Yes  1 (12.5) 1.43 (0.22-9.29) 0.71 -  
Smoking Never 23 (8.3) 1    
 Current/ex-smoker 3 (12.5) 1.46 (0.47-4.53)  0.51 -  
Alcohol consumption No 22 (8.1) 1    
 Yes 4 (19.1) 2.4 (0.89-6.21)  0.084 -  
BMI (kg/m2) median, IQR  - 1. 05 (0.97-1.14) 0.19 -  
Direct contact with TB patient No 1 (10.0) 1    
Yes 25 (8.8) 0.88 (0.13-5.91) 0.89 -  
Participation in sputum collection or 
bronchoscopy procedures 
No 17 (7.6) 1    
Yes 9 (13.2) 1.75 (0.82-3.75) 0.15 2.74 (1.29-5.79) 0.008 
Direct contact with family or friends with TB No 14 (10.4) 1    
Yes 12 (7.6) 0.73 (0.35-1.53) 0.41 -  
N95/FFP2 respirators or any other mask 
respirator during work 
No and not always  22 (9.6) 1    
Yes, always 4 (6.4) 0.66 (0.24-1.85) 0.43 -  
TST result at baseline (n=220) No 14 (8.4) 1    
 Yes 6 (11.1) 1.32 (0.53-3.27) 0.55 -  
ARR = adjusted relative risk, BCG = Bacille Calmette-Guerin, BMI = body mass index, CI = confidence interval, FFP = filtering face piece, IQR = inter quartile range, 







Table 6.17 Association between demographic variables, medical history, TB exposure and one-year IGRA conversion using more stringent 
definition for conversion in medical and nursing students included in all cohorts. Results of univariate and multivariate models (N=293) 
 Variable IGRA conversion n (%) RR (95% CI) P value ARR (95% CI) P value 
Total number of students  24 (8.2)     
Age (years)    1.08 (0.77-1.50) 0.67 1.16 (0.88-1.54) 0.29 
Gender Male 5 (7.1) 1    
 Female 19 (8.5) 1.19 (0.46-3.08) 0.72 1.41 (0.54-3.64) 0.48 
Student type Nursing 4 (4.4) 1    
 Medical 20 (9.9) 2.22 (0.78-6.31) 0.14 3.45 (1.22-9.75) 0.020 
Housing Student housing 17 (7.4) 1    
 Family housing 8 (11.1) 1.50 (0.65-3.47) 0.34 -  
Ethnicity Other 12 (7.1)  1    
 Sundanese 12 (9.7) 1.36 (0.63-2.94) 0.43 -  
BCG vaccination No 4 (11.4) 1    
 Yes 20 (7.8) 0.68 (0.52-1.87) 0.45 0.53 (0.19-1.53) 0.25 
Immunocompromised condition No 23 (8.1) 1    
 Yes (steroid therapy) 1 (12.5) 1.55 (0.24-10.13) 0.65 -  
Smoking Never 21 (7.8) 1    
 Current and ex-smoker 3 (12.5) 1.60 (0.51-4.99) 0.42 -  
Alcohol consumption No 20 (7.4) 1    
 Yes 4 (19.1) 2.59 (0.97-6.90)  0.057 -  
BMI (kg/m2) median, IQR  - 1.06 (0.97-1.14) 0.19 -  
Direct contact with TB patient No 1 (10.0) 1    
 Yes 23 (8.1) 0.81 (0.12-5.45) 0.83 -  
Participation in sputum collection or 
bronchoscopy procedures 
No 15 (6.7) 1    
Yes 9 (13.2) 1.98 (0.91-4.34) 0.086 2.67 (1.24-5.74) 0.012 
Direct contact with family or friends with 
TB 
No 12 (8.9) 1    
Yes 12 (7.6) 0.85 (0.40-1.84) 0.69 -  
N95/FFP2 respirators or any other mask 
respirator during work 
No and not always  21 (9.2) 1    
Yes, always 3 (4.8) 0.52 (0.16-1.69) 0.28 -  
TST result at baseline (n=220) No 14 (8.4) 1    
 Yes 5 (9.3) 1.10 (0.41-2.91) 0.85 -  
ARR = adjusted relative risk, BCG = Bacille Calmette-Guerin, BMI = body mass index, CI = confidence interval, FFP = filtering face piece, IQR = inter quartile range, 







Table 6.18 Association between demographic characteristics, medical history, TB exposures and one-year TST conversion in medical and 
nursing students included in second cohort using the most stringent definition. Results of univariate and multivariate models (N=178) 
 Variable TST conversion n (%) RR (95% CI) P value ARR (95% CI) P value 
Total number of the students  63 (35.4)     
Age continues (years)    1.20 (1.02-1.41) 0.030 1.22 (1.03-1.44) 0.017 
Gender Male 14 (29.8) 1  1  
 Female 49 (37.4) 1.26 (0.77-2.06) 0.37 1.41 (0.84-2.38) 0.19 
Student type Nursing 6 (31.6) 1  1  
 Medical 57 (35.9) 1.14 (0.57-2.28) 0.72 1.34 (0.67-2.70) 0.41 
Housing Student housing 51 (35.9) 1    
 Family housing 12 (33.3) 0.93 (0.56-1.55) 0.78 -  
Ethnicity Other 40 (36.7)  1    
 Sundanese 23 (33.3) 0.91 (0.60-1.38) 0.65 -  
BCG vaccination No 6 (31.6) 1  1  
 Yes 57 (35.9) 1.14 (0.57-2.28)  0.72 0.98 (0.50-1.92) 0.96 
Immunocompromised condition No 62 (35.4) 1    
Yes  1 (33.3) 0.94 (0.19-4.74) 0.94 -  
Smoking Never 60 (36.8) 1    
 Current/ex-smoker 3 (20.0) 0.54 (0.19-1.53) 0.25 -  
Alcohol consumption No 59 (36.0) 1    
 Yes 4 (28.6) 0.79 (0.34-1.87) 0.59 -  
BMI (kg/m2) median, IQR  - 1.01 (0.97-1.06) 0.61 -  
Direct contact with TB patient No 2 (66.7) 1    
Yes 61 (34.9) 0.52 (0.23-1.20) 0.13 0.49 (0.18-1.32) 0.16 
Participation in sputum collection or 
bronchoscopy procedures 
No 51 (34.2) 1    
Yes 12 (41.4) 1.21 (0.74-1.97) 0.45 -  
Direct contact with family or friends with TB No 35 (40.2) 1    
Yes 28 (30.8) 0.77 (0.51-1.14) 0.19 -  
N95/FFP2 respirators or any other mask 
respirator during work 
No and not always  53 (39.0) 1  1  
Yes, always 9 (22.0) 0.56 (0.30-1.04) 0.068 0.55 (0.30-1.00) 0.050 
ARR = adjusted relative risk, BCG = Bacille Calmette-Guerin, BMI = body mass index, CI = confidence interval, FFP = filtering face piece, IQR = inter quartile range, 







Table 6.19 Association between demographic characteristics, medical history, TB exposures and TST positivity at one year for medical and 
nursing students included in first cohort with negative IGRA and no TST at baseline. Results of univariate and multivariate models (N=81) 
Characteristic Variable TST positivity (%) RR (95% CI) P value ARR (95% CI) P value 
Total number of the students  26 (32.1)     
Age continues (years)    1.23 (0.98-1.54) 0.070 1.44 (0.99-2.07) 0.052 
Gender Male 4 (36.4) 1    
 Female 22 (31.4) 0.86 (0.37-2.04) 0.74 2.33 (0.94-5.79) 0.068 
Student type Nursing 21 (29.2) 1    
 Medical 5 (55.6) 1.91 (0.95-3.80) 0.067 3.74 (1.27-8.93) 0.003 
Housing Student housing 20 (33.9) 1    
 Family housing 6 (27.3) 0.81 (0.37-1.75) 0.58 0.56 (0.26-1.23) 0.15 
Ethnicity Other  8 (25.0) 1  1  
 Sundanese 18 (36.7) 1.47 (0.72-2.98) 0.29 2.73 (1.25-5.97) 0.012 
BCG vaccination No 4 (30.8) 1  1  
 Yes 22 (32.4) 1.05 (0.43-2.56) 0.91 1.67 (0.68-4.07) 0.26 
Smoking Never 25 (32.1) 1    
 Current and ex-smoker 1 (33.3) 1.04 (0.20-5.38) 0.96 -  
Alcohol consumption No 25 (31.7) 1  1  
 Yes 1 (50.0) 1.58 (0.38-6.62) 0.53 0.44  (0.06-3.09) 0.41 
BMI (kg/m2) median, IQR - - 0.95 (0.85-1.07) 0.39 -  
Direct contact with TB patient No 1 (25.0) 1    
Yes 25 (32.5) 1.30 (0.23-7.39) 0.77 -  
Participation in sputum collection or 
bronchoscopy procedures 
No 14 (31.8) 1    
Yes 12 (32.4) 1.02 (0.54-1.93) 0.95 -  
Direct contact with family or friends with TB  No 9 (31.0) 1    
Yes 17 (32.7) 1.05 (0.54-2.06) 0.88 -  
N95/FFP2 respirators or any other mask 
respirator during work 
No and not always  23 (35.4) 1  1  
Yes, always 3 (18.8) 0.53 (0.18-1.56) 0.25 0.55 (0.21-1.46) 0.23 
ARR = adjusted relative risk, BCG = Bacille Calmette-Guerin, BMI = body mass index, CI = confidence interval, FFP = filtering face piece, IQR = inter quartile range, 




In this study, nearly a fifth of medical and nursing students were initially positive 
for LTBI when measured by IGRA with no factors found to be significantly 
associated with IGRA positivity, while a third of students were TST positive, which 
surprisingly was negatively associated with direct contact with family or friends 
with TB. The one-year risk of LTBI was high when measured by IGRA conversion 
(8.9%) and very high when measured by TST conversion (35.4%). Concordance 
between the two tests was low at baseline and lower at follow-up, even when the 
most stringent criterion for TST conversion was used to counter the effect of 
boosting. Being a medical student and involvement in sputum collection or 
bronchoscopy procedures were associated with IGRA conversion, while TST 
conversion increased with increasing age. 
The prevalence of IGRA positivity in our study (18.5%) was lower than that 
reported in Ethiopia (44%) [89] and India (28%) [152] but higher than in Russia 
(10%) [92] and in South Africa (15%) [145] and it was slightly lower than the 
pooled estimate reported in our review (24%) (Chapter three). These differences 
may be due to a variety of factors such as different selection methods, the make-up 
of study participants to include both nursing and medical students [152], only 
medical students [92, 145], or medical and paramedical students [89], or the 
timing of recruitment such as the first year of clinical training [145], any year of 
clinical training [89, 152] or in the final two years [92]. When restricted to studies 
of medical students only and to those recruited at the beginning of the clinical 
years to be comparable to our study, our estimate (17%) was only slightly higher 
than reported in South Africa (15%) [145]. Unlike other previous studies that used 
Quantiferon Gold in Tube (QFT-GIT), our study used the new version of QFT-Plus 
(which has four tubes with the additional ‘CD8’ readout). However, a study in 
HCWs in the USA showed a comparable result between these two versions of QFTs 
[190]. 
When measured by TST, our prevalence estimate (31.9%) was higher than that 
measured by IGRA. This is consistent with our review reported in Chapter three 
and with the previously published review in countries with a low and 
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intermediate incidence of TB [15]. The prevalence of TST positivity in our study 
was lower than that reported in studies in India (50%) [83], Zimbabwe (52%) 
[86], Ethiopia (47%) [89], Thailand (74%) [107] (65%) [108], and Uganda (45%) 
[113]; but higher than that reported in Iran (7%) [93], Peru (21%) [104] (1%) 
[126], Brazil (19%) [114], and South Africa (27%) [145]. Similar to studies using 
IGRA, the heterogeneity of results is likely due to differences in background TB 
prevalence, clinical conditions, TB infection control practices, and also due to the 
composition of study participants and timing of recruitment. The pooled estimates 
reported in our review in Chapter three (32%), however, were similar to our 
prevalence estimate (31.9%). When restricted to medical students only and those 
recruited before the clinical year, our prevalence estimate (31.7%) was slightly 
higher than in South Africa (27%) [145], but considerably lower than reported in 
Thailand (74%) [107]. The reason for the large difference with the Thailand study 
is not clear, particularly as it was also conducted in a high TB prevalence setting 
and they applied the same cut off values for TST positivity (>10 mm).  
Our annual risk of LTBI when measured by IGRA conversion was similar to that 
reported in India [73]. However, unlike other HCSs studies that used TST [73, 82, 
84, 85, 93], we found a much larger proportion of students underwent TST 
conversion. Our result in this study was contrary to the findings from our review 
(Chapter three), which showed the annual incidence of LTBI in HCWs was slightly 
higher when estimated using IGRA compared with TST. We also observed that 
agreement of the two tests was low at baseline, with a kappa statistic of 0.35 (95% 
CI 0.23-0.46) and lower at follow-up, at 0.12 (95% CI 0.05-0.19), and even lower 
when we applied the strict TST conversion criteria, which led the kappa statistic at 
follow-up to change to 0.18 (95% CI 0.06-0.30). These results were consistent 
with an earlier review by Lamberti et al. [191] that reported a low agreement 
between QFT and TST in 29 studies with a kappa statistic of 0.28 (95% CI 0.22-
0.35).  
The large difference between IGRA and TST conversion rates in our study was 
similar to that reported among newly employed nurses in Korea [192] and in the 
rural population in China [193], used both IGRA and TST. In the Korean study 
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[192], the annual incidence as measured by IGRA conversion (14.4%) was lower 
than that measured by TST conversion (21.3%). However, agreement between the 
two tests increased between baseline and follow up time with kappa statistics of 
0.15 and 0.42, respectively. The Korean study applied a two-step baseline TST, 
although this only added 8 (7.9%) TST positive individuals to the 93 already 
positive. A Chinese population-based study [193] reported the annual conversion 
rate of IGRA among four rural study sites that ranged from 2.1% to 4.9% (average 
3.1%), while TST conversion ranged from 6.0% to 31.1% (average 14.5%). Similar 
to our study, the agreement between the two tests was lower at follow up time 
(0.08) than at baseline. (0.49).  
What are the possible explanations for the very different test conversion rates in 
our study? From our analysis, the effect of a previous TST on TST conversion 
disappeared when the most stringent TST conversion criterion was applied, and 
BCG vaccination in the past did not affect TST conversion. A systematic review by 
Farhat et al. [11] indicated that false-positive TST results due to NTM were very 
uncommon, and thus most pronounced in populations with a high prevalence of 
NTM sensitisation and a very low prevalence of LTBI. Therefore, the high TST 
conversion found in our study, relative to the IGRA conversion rate, is unlikely to 
be explained just by the boosting phenomenon or by new NTM infection. However, 
the adjustment for boosting is likely not to be perfect, excluding for example some 
individuals who were true converters. TST has antigens that are less specific to M. 
tuberculosis, while IGRA have higher rates of test reversion (the change from a 
positive to negative result) [55] and there is the issue of small changes around the 
cut-off for IGRA positivity between repeat tests. IGRA reversion after new 
infection has been demonstrated in a study conducted in Bandung, including 
children (aged six months to nine years) who were living with a TB case [34]. The 
IGRA reversion rate was 20% at three months. Therefore, some students may have 
converted their IGRA, if tested, at any time during follow up but undergone 
reversion by the one-year follow up. We used different types of TST at baseline 
and follow-up, although 2 TU PPD RT23 and 5 TU of PPD-S are considered to be 
equivalent [41, 42], but using two different types of PPD might produce some 
‘pseudo-conversion’ as shown in the US study [194]. Finally, performance of the 
 
 153 
two tests might differ at baseline (measuring both remote and recent infection) 
and at follow up time (mostly measuring new infection) if they have differing 
abilities to detect remote versus recent infection.  
Further studies that could help address the unresolved differences in conversion 
rates and test discordance include: 1) repeat the studies using the same 
tuberculin, applying the two-step baseline (if possible) in similar and different 
settings. Comparator cohorts could have the same mix of medical and nursing 
students, 2) conduct large studies with TB disease as an outcome to assess the 
positive and negative predictive value of the two tests, and 3) conduct studies with 
more frequent IGRA testing (3-6 monthly) and compare cumulative IGRA 
conversion to TST conversion.  
Similar to our result, in other previous studies in HCSs conducted in LMICs no 
occupational factors were significantly associated with a positive IGRA, while age 
and Khat (a plant commonly grown in the horn of Africa) consumption were the 
only significant non-occupational factors [89]. Several studies have reported the 
association between a positive TST with occupational factors such as years spent 
in health care after entry to clinical programme [83] and contact with a TB patient 
[113]; and non-occupational factors, such as: male sex [108, 113], BCG 
scar/history of BCG vaccination [107, 108], older age [89], TB knowledge [89], and 
course of study [113]. Our study did not identify any of these associations. 
However, students who had BCG vaccination had a lower risk of LTBI as measured 
by IGRA positivity, of borderline significance. Unexpectedly a positive TST was 
negatively associated with any direct contact with family or friends with TB (with 
a borderline P value). This is contrary to what would be expected and the reasons 
are not entirely clear. One possible contributor could be that these students were 
more aware of TB disease, its symptoms and means of prevention before entering 
the clinical training programme, providing some degree of protection. In the 
sensitivity analysis, however, this factor did not continue to be significant, but 
being involved in other training before study enrolment was negatively associated 
with TST positivity, which is also an unexpected finding without clear explanation. 
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A possible reason for this could be that these students were more aware of TB 
disease and were therefore more likely to use protection. 
There were no statistically significant factors found to be associated with test 
conversion in any previously reported IGRA study [152]. In our study, being a 
medical student, Sundanese ethnicity, and participation in sputum collection or 
bronchoscopy procedure were associated with IGRA conversion (RR 4.4, 2.7, and 
3.2, respectively). Older age was the only non-occupational factor found to be 
significantly associated with TST conversion in our study, similar to that reported 
in Peru [126], and could be regarded as a surrogate for cumulative mycobacterial 
exposure, which can cause boosting. Other previous studies reported that days 
spent caring for pulmonary TB patients [84], involvement in sputum collection 
[84], ever performed or assisted in sputum collection [84], and career type [126] 
were independent occupational factors associated with TST conversion. In our 
study, we noted that the use of a mask respirator (including N95) reduced the risk 
of TST conversion by approximately 45%.  As recommended by the WHO, personal 
respiratory protective equipment should be used in situations where there is an 
increased risk of transmission. If properly fitted and used, a personal particulate 
respirator is sufficient in reducing the chance of inhaling M. tuberculosis. A key 
question is whether there is any part of the hospital where the risk is not 
increased. 
In our study, one-year IGRA conversion was higher in medical students than 
nursing students. This is contrary to what would be expected in many countries 
where nurses are likely to have longer time exposed to patients. In Indonesia, 
nursing students have a shorter duration of clinical work in internal medicine 
(three weeks) whereas medical students have nine weeks with frequent night 
shifts. Nursing students also work eight hours a day for six days a week, while 
medical students work eight hours a day for five days with an additional 14 hours’ 
night shift, or 12 hours on the weekends depending on the programme.  
This is the first prospective study of its type conducted in Indonesia, and had high 
participation (90%) and retention rates (97%). However, there were some 
limitations. In the absence of a gold standard for diagnosing LTBI, there is no 
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guarantee that prevalence and one-year conversion estimates of LTBI are 
accurate. Even though both TST and IGRA are acceptable and widely used, they are 
imperfect and have several limitations as described above and in Chapter two. Due 
to limited stock of the IGRA test at the follow-up time for students recruited in the 
first cohort, 11 students were not tested by IGRA but had TST; therefore, we lost 
some potential students who might have undergone IGRA conversion. The 
national shortage of TST at the end of the study period resulted in a different type 
of tuberculin being used at follow-up time. This may contribute to the differences 
of tests conversion rates as stated above. Some students reported that it was 
difficult to take the logbooks with them every day, which may have led to 
incomplete capture of potential exposures. Having an application on their mobile 
phone might be a good alternative to logbooks for capturing this information. We 
did not perform a baseline two-step TST [12], the first TST may have boosted the 
follow-up TST result [73]. Boosting is much less frequent if the interval is more 
than 60 days [48]. Because repeated TST was performed one year after the 
baseline TST, the effect may be limited. Of course, to avoid a potential boosting 
effect of TST on the IGRA result, IGRA was performed prior to TST at each time 
point. The stringent criterion appeared to be successful in excluding those with 
boosting from being defined as TST converters, although this can potentially lead 
to the exclusion of some true converters.  
This study has some implications for practice. The use of both IGRA and TST in our 
study may create uncertainty regarding the diagnosis of LTBI. A review by 
Salgame et al [195] recommended that in a case where TST and IGRA are in 
disagreement, individuals are usually considered to have LTBI unless there is a 
strong suspicion of a false positive result (such as in repeated BCG vaccination and 
known NTM infection). Hence, when using both tests for LTBI screening, if either 
test is positive, preventive treatment should be considered after undertaking a 
clinical examination [195]. We noted a trend at both baseline and follow-up for 
BCG protection against LTBI, as measured by IGRA. This is consistent with other 
IGRA studies in HCWs [44, 101] where prior BCG vaccination protected against TB 
infection. BCG vaccination or re-vaccination could be a promising avenue for 
protection and is worthy of further investigation [62]. Similarly, new vaccines 
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could be trialled for protection against LTBI in this population. In addition, as 
recommended by the WHO, HCWs including students working in health facilities 
may gain additional protection from TB through the use of particulate respirators 
that meet standards when caring for patients or those suspected of having 
infectious TB [6].   
In conclusion, the annual incidence of TB infection in students in our study is high 
and showed association with occupational exposures. The unresolved differences 
in IGRA and TST conversion rates in our study and the low concordance between 
the two tests warrant further investigation. This study highlights the importance 
of an effective programme to protect students from acquiring LTBI in health care 
facilities. BCG vaccination or re-vaccination with a combination of infection 





7 Summary, conclusions, recommendations, and future studies 
7.1 Summary of research findings and conclusions 
The overall goal of this thesis was to: 1) describe the prevalence and incidence of 
latent tuberculosis infection (LTBI) in health care workers (HCWs) and health care 
students (HCSs) in low and middle-income countries (LMICs), including studies 
that used tuberculin skin test (TST) and/or interferon-gamma release assays 
(IGRA) and to identify associated risk factors through a systematic review 
(Chapter three), 2) assess TB infection control practices TB in primary health 
centres (PHCs) in Indonesia and knowledge of TB infection control, TB, and LTBI 
in HCWs working in PHCs (Chapter four), 3) estimate the prevalence of LTBI 
measured by TST and identify factors that are associated with LTBI in HCWs, 
including their knowledge of TB infection control, TB, and LTBI in a tertiary 
referral hospital in Indonesia (Chapter five), and 4) estimate the prevalence of 
LTBI by IGRA and TST, the one-year test conversion rates and identify associated 
risk factors in medical and nursing students (Chapter six). 
In the systematic review there was a high prevalence and incidence of LTBI in 
HCWs and HCSs in LMICs measured by TST or IGRA. Nearly 50% of HCWs and 
32% of HCSs had a positive TST, while 39% and almost 25% respectively had a 
positive IGRA. HCWs from countries with an annual TB incidence of >300/100,000 
had the highest prevalence of LTBI. This review adds to the evidence that 
regardless the measurement methods (TST or IGRA), the prevalence of LTBI in 
HCWs in LMICs continues to be high, especially in high TB incidence countries. 
When measured by IGRA, our overall LTBI prevalence estimate was lower than 
that measured by TST, but still high. The annual incidence of LTBI was 17% in 
HCWs and 5% in HCSs when estimated from serial TST, and 18% and 8%, 
respectively, when estimated with IGRA. We also found a high rate of IGRA 
reversion, consistent with the previously published review in all countries, 
irrespective of the national TB incidence rates [15, 16]. The exact cause of the 
substantial rate of IGRA reversion is unexplained [15, 16] and raises concerns 
about the validity of serial IGRA to estimate new infections, while TST is subject to 
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the boosting phenomenon which compromises its interpretation in serial testing. 
Occupational factors significantly associated with LTBI in HCWs were those that 
involved more direct contact with a TB patient or had a prolonged exposure, 
indicating that more effort on TB infection control needs to be done to protect 
HCWs. The WHO released guidelines on TB infection control in health care settings 
in 2009 [6], yet in our review less than a fifth of studies reported any TB infection 
control measures – the same inadequacy was also reported by Joshi et al [5] and 
Nasreen et al [8]. In resource-limited settings, even low cost and effective basic 
control measures, such as early identification, isolation, and treatment of those 
with presumptive TB, as well as open window and door policies, education and 
training of HCWs recommended by the WHO are rarely implemented. 
In 24 selected PHCs and in 398 HCWs, we found that TB infection control 
measures were generally not implemented. None of the PHCs had implemented a 
full programme of TB infection control measures. PHCs with laboratory facilities 
and high TB case numbers were more likely to implement TB infection control 
measures compared to other PHCs. For HCWs, the median number of correctly 
answered questions of knowledge for TB infection control and TB was high, but 
low for LTBI. Knowledge differed by job category, with TB nurses having the best 
knowledge, which is likely due to their greater exposure to TB training and 
workshops held by the Bandung Ministry Health Office and other organisations. It 
was also expected that the LTBI knowledge would be low since the National TB 
programme of Indonesia is currently more focussed on TB disease rather than 
LTBI. This study highlights the importance of strengthening effective TB infection 
control measures to reduce TB transmission not only to HCWs but also to other 
patients and visitors in health care facilities (Chapter four).  
From 395 HCWs working in a tertiary referral hospital, we found that three-
quarters were positive for LTBI by TST, with duration of work-related exposure 
being the only factor associated with a positive TST. There was no association 
between prevalence of LTBI and job category suggesting that HCWs working in 
this facility had a similar risk of LTBI irrespective of their job category – indicating 
a high risk of transmission across the hospital. The level of knowledge about TB 
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infection control was high but much less so for knowledge about TB and LTBI, 
with differences found according to job categories. Compared to nurses, doctors 
had higher median number of correct response of knowledge while pharmacists 
and radiographers had lower median number of correct response of knowledge. 
HCWs in this setting might benefit from LTBI treatment to prevent them 
developing TB disease. With respect to the lack of knowledge of TB and LTBI, we 
identified the need for training, including health educational materials that are 
specifically tailored to address the knowledge of TB and LTBI amongst all types of 
HCWs in this health setting. A package of TB infection control measures will also 
need to be implemented not only in a specific area (high or very high risk working 
area) but also across the whole hospital. This includes personal respiratory 
protection and education regarding TB and LTBI for all HCWs (Chapter five). 
In 379 medical and nursing students entering their clinical experience at baseline, 
we found that nearly a fifth were initially positive for LTBI when measured by 
IGRA with no factors found to be significantly associated with IGRA positivity. In 
272 students, a third were TST positive, which unexpectedly was negatively 
associated with direct contact with family or friends with TB. In 328 students at 
one year follow up the one-year risk of TB infection was high when measured by 
IGRA conversion (8.9%) and very high when measured by TST conversion 
(35.4%). Occupational exposure was associated with IGRA conversion, while TST 
conversion increased with increasing age. Concordance between the two tests was 
low at baseline and even lower at follow-up. The effect of a previous TST on TST 
conversion disappeared when the most stringent TST conversion criterion was 
applied. The high TST conversion found in our study, relative to the IGRA 
conversion rate, and increasing discordance are unlikely to be explained just by 
the boosting phenomenon or by NTM infection. Possible explanations include: 
different types of TST used at baseline and follow-up; imperfections in the 
adjustment for boosting; different antigen specificities of the two tests; known 
high rates of IGRA test reversion and small changes around the cut-off for IGRA 
positivity; and differing performance characteristics of the two tests in relation to 
detecting remote versus recent M. tuberculosis infection. This study, however, 
highlights the importance of an effective programme to protect students from 




- TB programmes in LMICs especially in high TB incidence countries should 
prioritise implementation of infection control measures in health care 
facilities to ensure the protection of HCWs. The findings of our review and 
studies conducted in Bandung, Indonesia would help the National TB 
programme of Indonesia to understand the current situation of LTBI in 
HCWs and the inadequate implementation of TB infection control in health 
care facilities. Therefore, collaboration with the National TB programme of 
Indonesia is vital to ensure reliable LTBI estimates, develop effective 
policies and guidelines designed to support, implement, and evaluate 
programmes for improving the implementation of TB infection control 
including screening and treatment for LTBI and TB disease in HCWs.  
- In PHCs that manage TB patients, measures should be implemented, 
including a written TB infection control plan, training for staff members 
about TB (especially LTBI), separation of patients suspected of having TB, 
symptom checklists to screen patients for TB, regular monitoring of 
infection control practices, and training on proper fit of respirators. The TB 
research group Universitas Padjadjaran Bandung, Indonesia to which the 
candidate belongs, already has an established working relationship with 
PHCs through other studies conducted in Bandung which could help to 
translate the knowledge and help the PHCs and Bandung Municipal Health 
Office to formulate an effective programme for better practices of TB 
infection control in PHCs. The findings of the study, of course, will be 
disseminated to the Bandung Municipal Health Office and all PHCs, thereby 
providing an initial opportunity for formulating such a programme.  
- Future investigations should consider measuring the effectiveness of 
implementation of infection control measures through monitoring and 
routine reporting of the number of HCWs who develop TB disease and 
infection each year in the facilities.  Therefore, we recommend that the 
National TB programme of Indonesia, in collaboration with TB researchers, 
conduct a longitudinal study by comparing the number of HCWs who 
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develop LTBI before and after a package of interventions on TB infection 
control in health care facilities to measure the effectiveness of such an 
intervention.  
- Providing LTBI screening for HCWs and HCSs should be more actively 
considered in Indonesia. Either TST or IGRA could be used, particularly as 
there is no diagnostic gold standard for LTBI and both of these tests agree 
with the new recommendation by WHO. With the current globally and also 
national shortage of TST in Indonesia, there is some potential to substitute 
IGRA for TST. However, we have to consider the cost associated with using 
IGRA can be higher than using TST. IGRA also requires a blood draw and 
more specific laboratory services for analysis, therefore this test is not 
available in all practice settings. Therefore, the programme manager or 
clinician could choose which test is available and affordable in their health 
care facility. Moreover, we recommend the National TB programme of 
Indonesia to prioritise the allocation of TST usages in all TB care centres. 
Priorities should be for individual who are at high risk for being exposed to 
TB, this includes HCWs as described in Chapter two. Screening of LTBI for 
newly employed HCWs, new HCSs, and current HCWs, and regular repeat 
screens if necessary, are advisable. As an example, a routine serial test for 
LTBI is necessary in some surveillance programs for assessing the 
effectiveness of TB infection control measures in health care facilities.  
- Both TST and IGRA have their limitations. Therefore, when used serially, 
clinical judgment must be used in interpreting results of these tests. For 
repeated examination, the more stringent definition for test conversion is 
preferable. Due to the low concordance between the two tests as shown in 
our student cohort study, the use of both tests may create uncertainty 
regarding the diagnosis of LTBI. In a case where TST and IGRA are in 
disagreement, individuals are usually considered to have LTBI unless there 
is a strong suspicion of a false positive result. Hence, when using both tests 
for LTBI screening, if either test is positive, preventive treatment should be 
 
 162 
considered after undertaking a clinical examination and a chest X-ray to 
rule out TB disease.    
- For HCWs, WHO recommends a package of prevention and care 
interventions, including HIV prevention, antiretroviral therapy and 
isoniazid preventive therapy (IPT) for those who are HIV-positive. 
Providing treatment for HCWs with LTBI should be more actively 
considered in Indonesia irrespective of HIV status. This is indicated from 
our study by the high prevalence of LTBI and the high number of HCWs 
who would be willing to undergo LTBI screening and treatment. 
Approximately 5-15% of individuals with LTBI will progress to TB disease 
during their lifetime – a risk that can be reduced by taking preventive 
treatment. The new recommendation for LTBI treatment, including shorter 
course of rifampicin could also be implemented. Results from previous 
work in a multi-centre trial which included Bandung, reported that four 
months of rifampicin was not inferior to nine months of isoniazid and was 
associated with higher rates of treatment completion and better safety. 
HCWs therefore, are likely to benefit from treatment to prevent TB disease. 
The treatment of LTBI should be done in parallel with improvements to the 
facility, administrative, environmental and personal respiratory protection 
controls practices.  
- In the event of uptake of screening and treatment of LTBI, HCWs receiving 
treatment for LTBI should be monitored routinely for adverse events and 
to ensure that they are completing their treatment. With no current 
national guideline or implementation of a routine programme for LTBI 
management in HCWs, they could participate in intervention trials with the 
assurance of close monitoring such as a trial for a shorter course of 
rifampicin vs. isoniazid, or vs. very short-course high dose rifampicin. To be 
able to conduct any future study, we will disseminate the study findings to 
the director of Hasan Sadikin Hospital and head of the units, at which time 
further collaboration will be addressed (as stated in 7.3 Future studies). 
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- In regards to the lack of knowledge in TB and LTBI, there is a need for 
training or health educational materials that are specifically tailored to 
address the knowledge of TB and LTBI among all types of HCWs in Hasan 
Sadikin Hospital Bandung, Indonesia. Such education materials could also 
be of benefit at other similar health facilities throughout the country.  
- For protection in HCWs and HCSs who are M. tuberculosis uninfected, BCG 
vaccination or BCG revaccination could be a promising avenue and 
warrants further investigation. Similarly, new vaccines could be trialled for 
protection against LTBI in this population. Therefore, we recommend trials 
for this high-risk group, along with other infection control measures such 
as personal respiratory protection. For HCSs, we will disseminate the 
results of our study to the Deans of Faculties of Medicine and of Nursing 
Universitas Padjadjaran Bandung, Indonesia at which time the possibility of 
future studies will be addressed (as stated in 7.3 Future studies).  
- In our student cohort study, the use of logbooks had limitations. We 
therefore recommend, and plan to develop and apply a mobile phone 
application for collection of exposure information for any future studies.  
- The unresolved differences in IGRA and TST conversion rates in our study 
and the low concordance between the two tests warrant further 
investigation (as stated in 7.3 Future studies). 
7.3 Future studies 
The following studies are planned to be conducted in Bandung, Indonesia: 
1. A trial of BCG vaccination/revaccination to prevent LTBI  
This study will assess the effectiveness of BCG vaccination/revaccination 
compared to placebo to reduce the risk of LTBI as measured by IGRA in M. 
tuberculosis uninfected medical and nursing students. Due to the problems 
with IGRA tests, specifically higher rates of test reversion we intend to add an 
extra IGRA test at 6 months of follow up providing the ability to see more 
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clearly those who are true converters or persistently negative. This study will 
be a collaboration between researchers in the TB research group, Universitas 
Padjadjaran the University of Otago, New Zealand, and Radboud University, 
Nijmegen, The Netherlands. This study will be funded by the Otago University 
Foundation Trust (2019-2020). 
 
2. A trial of 2 months high dose rifampicin to prevent active TB 
This trial will assess the effectiveness of 2 months high dose rifampicin 
compared to 4 months rifampicin to prevent active TB for high-risk groups 
who are positive for LTBI. This includes HCWs and HCSs who participated in 
previous, and participate in future studies, who are found to be positive by 
either TST or IGRA. Even though the aim of this trial is not aimed solely for 
HCWs and HCSs, their participation will provide specific information towards 
the management of LTBI in HCWs in Indonesia. This trial is a collaboration 
between researchers in the TB research group Universitas Padjadjaran and 
McGill University, Canada. It will be funded by the Canadian Institutes of 
Health Research (2019-2022). 
Unlike other high-risk groups for TB acquisition, HCWs and HCSs can act as 
effective agents for change through awareness, advocacy, and, critically by acting 
to implement changes at the front lines. They also have understanding and 
awareness of the importance of protection against LTBI and TB disease. Therefore, 
their enthusiastic involvement in these trials is likely.  
Further studies that could help address the unresolved differences in IGRA and 
TST conversion rates and test discordance include:  
1. Repeat the studies using the same tuberculin, applying the two-step baseline 
(if possible) in similar and different settings. Comparator cohorts could have 
the same mix of medical and nursing students,  
2. Conduct large studies with TB disease as an outcome to assess the positive 
and negative predictive value of the two tests, 
3. Conduct studies with more frequent IGRA testing (3-6 monthly) and compare 
cumulative IGRA conversion to TST conversion.  
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Further studies that could help understand the situation of LTBI in HCWs in PHCs 
and the implementation of TB infection control include: 
1. Studies to estimate the prevalence of LTBI in HCW in PHCs, using both TST 
and IGRA. 
2. Qualitative studies with engagement of HCWs, the head of PHCs and the 
Bandung Municipal Health Office to explore in depth attitudes, issues of 
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granted ethics approval, including any amendments required to be made to the proposal by
the Human Research Ethics Committee.
Inform the Human Research Ethics Committee immediately of anything which may warrant
review of ethics approval of the research project, including: serious or unexpected adverse
effects on participants; unforeseen events that might affect continued ethical acceptability of
the project; and a written report about these matters must be submitted to the Academic
Committees Office by no later than the next working day after recognition of an adverse
occurrence/event. Please note that in cases of adverse events an incident report should also
be made to the Health and Safety Office:
http://www.otago.ac.nz/healthandsafety/index.html











A.1.3  Chapter six: Infection control and latent tuberculosis infection in 





Manager, Academic Committees, Mr Gary Witte
HE16/005
Professor P Hill
Department of Preventive and Social Medicine
Dunedin School of Medicine
University of Otago Medical School
Dear Professor Hill,
I am writing to let you know that the Ethics Committee has now considered under the ‘Health
Expedited’ provisions your proposal entitled “Infection Control and Latent Tuberculosis
Infection in Indonesian Health Care Workers”.
As a result of that consideration, the current status of your proposal is:- Approved
For your future reference, the Ethics Committee’s reference code for this project is:-
HE16/005.
While approving the application, the Committee would be grateful if you would respond to the
following:
The Committee asks if in the event a nursing or medical student was confirmed as having a
positive interferon gamma release assay (IGRA) and they were referred to the TB clinic,
would there be any follow up about whether they attended and received treatment or not.
Would there be any concern that they would begin practicing as a trained health professional
and were putting others at risk?
Please provide the Committee with copies of the updated documents, if changes have been
necessary.
The standard conditions of approval for all human research projects reviewed and approved
by the Committee are the following:
Conduct the research project strictly in accordance with the research proposal submitted and
granted ethics approval, including any amendments required to be made to the proposal by














Manager, Academic Committees, Mr Gary Witte
HE16/005
Professor P Hill
Department of Preventive and Social Medicine
Dunedin School of Medicine
University of Otago Medical School
Dear Professor Hill,
I am again writing to you concerning your proposal entitled “Infection Control and Latent
Tuberculosis Infection in Indonesian Health Care Workers”, Ethics Committee reference
number HE16/005.
Thank you for your request for amendment of 16th December 2016 notifying the committee
that you would like to add the tuberculin skin test (TST) to the study for the next round of
recruitment which is expected to start in February 2017.
The Committee accepts and approves the amendment and thanks you for providing the
revised documentation.
Your proposal continues to be fully approved by the Human Ethics Committee. If the nature,
consent, location, procedures or personnel of your approved application change, please













Appendix 2. Forms and questionnaires 
A.2.1  Chapter four: Tuberculosis infection control practices in primary 
health centres in Bandung, Indonesia 
1. TB INFECTION CONTROL PRACTICES IN PRIMARY HEALTH CENTRES  
FACILITY ASSESSMENT 
1 Date of interview |__|__|/|__|__|/|__|__| 
Day/Month/Year 
2 Interviewer initials |__|__|__| 
A. PHC DETAILS 
3 PHC’s number  |__|__| 
4 Information supplied by (job description of 
the person) 
 
5 Daily patient (total patients, not just TB 
patient) visit (average) 
|__|__|__|__| Patients 
6 Monthly TB cases (including follow up) visit 
(average) 
|__|__|__| Cases 
7 Any laboratory facility |__| 
1 = Yes, 0 = No 
8 Any inpatient facility 
If no, go to Q.10 
|__| 
1 = Yes, 0 = No 
9 If yes, number of beds |__|__| beds 
B. FACILITY-LEVEL MANAGEMENT MEASURES 
1. TB INFECTION CONTROL PLAN, ASSESSMENT, SURVEILLANCE 
10 Is there someone responsible for TB 
infection control at the PHC? 
If no, go to Q.12 
|__| 
1 = Yes, 0 = No 
11 If yes, who is this person?  
 
12 Is there a written TB infection control plan 
that is kept on site? 
 
If there is a TB infection control plan, obtain 
a copy for review (see last page to review 
the plan in detail) 
|__| 
1 = Yes, 0 = No 
13 Has a TB infection control assessment been 
done? 
|__| 
1 = Yes, 0 = No 
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14 Is “on-site“ surveillance on TB disease 
among staff being conducted (including 
monitoring and evaluation of TB infection 
control)?  
|__| 
1 = Yes, 0 = No 
15 Does the facility participate in operational 
research (OR)? 
|__| 
1 = Yes, 0 = No 
2. STAFF CAPACITY BUILDING 
16 Is training provided for staff members 
about TB infection control practices?  
If no, go to Q.20 
|__| 
1 = Yes, 0 = No 




18 How often is training done? (please 
describe in every days or weeks or months 
or years?) 
 
19 What groups of employees are included in 
this training? 
 
C. ADMINISTRATIVE CONTROLS 
1. PATIENT TRIAGE AND MANAGEMENT 
20 When patients come into the PHC, is there 
any screening for cough? 
If no, go to Q.24 
|__| 
1 = Yes, 0 = No 
21 Observe whether there a staff member who 
screens patients for prolonged (longer than 
2 weeks) duration of cough immediately 
after they arrive at the facility 
If no, go to Q.24 
|__| 
1 = Yes, 0 = No 
22 If yes, who is this person?  
23 Where does the screening take place 
(describe)? 
 
24 Is there any separated area in the waiting 
room for patients with cough?  
If yes, go to Q.26 
|__| 
1 = Yes, 0 = No 
25 If no separated waiting area, do these 
patients see a doctor first to minimize the 
time spent waiting in the health facility? 
|__| 
1 = Yes, 0 = No 
26 Are tissue, pieces of cloth, or face masks 
available for patients who are coughing? 
|__| 
1 = Yes, 0 = No 
27 Is there an enclosed waste basket where 
used tissue and face masks can be 
discarded? 
|__| 
1 = Yes, 0 = No 
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28 Is there any symptom checklist in place to 
screen patients for TB? 
If no, go to Q.31 
|__| 
1 = Yes, 0 = No 
29 If yes, what items are included in this 
checklist? 
(thick all that apply) 
|__| cough >2 weeks 
|__| weight loss 
|__| night sweets 
|__| fever 
|__| close contact with someone with 
TB in the past year 
|__| history of TB treatment 
|__| other, specify ________________ 
30 Who completes/administers the checklist? 
(thick all that apply) 
|__| data clerk 
|__| nurse 
|__| medical officer 
|__| other, specify ________________ 
2. PATIENT EDUCATION AND AWARENESS 
31 Are patients with cough given advice on 
cough etiquette and respiratory hygiene? 
|__| 
1 = Yes, 0 = No 
32 Are patients given any information about 
TB signs and symptoms? 
|__| 
1 = Yes, 0 = No 
33 Are TB patients educated on TB infection 
control practices? (such as provide sputum, 
using mask, living in the house with natural 
ventilation) 
|__| 
1 = Yes, 0 = No 
34 Are their families educated on TB infection 
control practices? (such as provide sputum, 
using mask, living in the house with natural 
ventilation) 
|__| 
1 = Yes, 0 = No 
35 Are patients given educational material 
(observe)?  
If no, go to Q.37 
|__| 
1 = Yes, 0 = No 
36 If yes, describe the materials and keep a 
copy for review 
 
37 Are posters displaying cough etiquette and 
respiratory hygiene displayed in the PHC? 
|__| 
1 = Yes, 0 = No 
3. SPUTUM MANAGEMENT 





39 If off-site, describe the process by which 
referral information and results of the 
diagnostic workup are transferred between 
the facility and the referral site 
 
40 Is there a designated area for patients to 
produce sputum specimens?  
If no, go to Q.42 
|__| 
1 = Yes, 0 = No 
41 If yes, describe (inside, unventilated toilet, 
exam room, waiting room, outside, etc.) 
And go to Q.43 
 
42 Describe where sputum specimens are 
usually produced?  
 
43 Does a staff member advise the patient who 
is asked to produce a sputum specimen on 
how to produce a good specimen? 
|__| 
1 = Yes, 0 = No 
44 Does a staff member observe the patient 
who is asked to produce a sputum specimen 
on-site? 
|__| 
1 = Yes, 0 = No 
45 Do staff use any personal respiratory 
protection when observing a patient 
produce sputum? 
|__| 
1 = Yes, 0 = No 
46 Where are sputum specimens kept?  
47 Is a TB suspect register kept in the facility? |__| 
1 = Yes, 0 = No 
48 If a TB suspect register is available, record 
the data for the previous calendar year (see 
section H, page 6 to record the data in 
detail) 
 
49 Is there a specimen tracking system? |__| 
1 = Yes, 0 = No 
4. TB TREATMENT AND REFFERALS 
50 Where do patients from this facility receive 
TB treatment?  
 
If on-site only, go to Q.52 
|__| on-site 
|__| off-site 
|__| both on-site and off-site 
 
51 If both on-site and off-site, what are the 
criteria to refer them off-site 
 
52 If on-site, is directly observed therapy 
(DOT) as per the national guidelines 
available? 
|__| 
1 = Yes, 0 = No 
53 What systems are in place to ensure 
adherence/follow up TB patients? 
|__| 
1 = Yes, 0 = No 
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54 Is a register kept for all TB patients 
reported to the national programme? 
 
If a TB register is available, record the data 
for the most recent calendar year (see 
section I, page 7 to record the data in detail)  
|__| 
1 = Yes, 0 = No 
5. STAFF PROTECTION 
55 Are staff members screened for TB?  
If no, go to Q.59 
|__| 
1 = Yes, 0 = No 
56 If yes, describe procedures used and 
frequency of screening 
 
57 Is a log kept of all staff who are diagnosed 
with TB disease in this facility? 
If no, go to Q.59  
|__| 
1 = Yes, 0 = No 
58 If yes, please provide more details (category 
of staff, workplace, type of TB etc.) 
 
59 Do you know of any staff member who has 
developed active TB in the past two years? 
If no, go to Q.61 
|__| 
1 = Yes, 0 = No 
60 If yes, please provide more details (category 
of staff, workplace, type of TB etc.) 
 
61 Are staff offered confidential voluntary HIV 
counselling and testing? 
|__| 
1 = Yes, 0 = No 
62 Are HIV-infected staff members offered 
ART? 
|__| 
1 = Yes, 0 = No 
63 Is Isoniazid (INH) preventive treatment 
(IPT) available for HIV-infected staff 
members?  
|__| 
1 = Yes, 0 = No 
D. ENVIRONMENTAL CONTROLS (Especially in waiting rooms, sputum collection 
room if available, and at least one exam room) 
64 Describe the natural ventilation (thick all 
that apply) 
|__| Open windows on opposite 
walls, unrestricted airflow 
|__| High ceiling height (>3m) 
|__| Standard ceiling height 
|__| Windows on one wall, restricted 
airflow 
|__| Closed windows, doors always 
open  
65 Are windows kept open during the day?  |__| 
1 = Yes, 0 = No 
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66 Are doors kept open during the day |__| 
1 = Yes, 0 = No 
67 Is there mechanical ventilation?  
If no, go to Q.68 
|__| 
1 = Yes, 0 = No 
68 If yes, describe (thick all that apply) 
 
|__| Enclosed room with re-
circulating air conditioner 
|__| Propeller fans 
|__| Exhaust ventilation  
69 What air-cleaning methods are used? |__| None 
|__| Ultraviolet germicidal irradiation  
|__| HEPA filtration  
|__| Do not know 
70 Does the natural and/or mechanical airflow 
is monitored daily by staff? 
|__| 
1 = Yes, 0 = No 
71 Is signage to keep doors and windows open 
when feasible in place? 
|__| 
1 = Yes, 0 = No 
72 Does the facility have access to an engineer 
or other professional for assistance on 
design, installation, maintenance and 
assessment of environmental controls? 
|__| 
1 = Yes, 0 = No 
73 Are environmental controls periodically 
maintained with results written down in 
registers? 
|__| 
1 = Yes, 0 = No 
E. PERSONAL RESPIRATORY PROTECTION 
74 Is there a written respiratory protection 
plan in the PHC? 
|__| 
1 = Yes, 0 = No 
75 Are staff involved in sputum induction 
procedures?  
If no, go to Q.76  
|__| 
1 = Yes, 0 = No 
76 Do staff use any personal respiratory 
protection when doing sputum induction? 
|__| No 
|__| Yes: surgical mask 
|__| Yes: N95 or FFP2 mask 
|__|Yes: other-please specify ________ 
77 Are there N95 or FFP2 mask (personal 
respirator) available for staff to use? 
If no, go to Q.79 
|__| 
1 = Yes, 0 = No 
78 If yes, describe the situations in which N95 
or FFP2 mask are used in the facility 




79 Are staff trained on proper fit of respiratory 
protection? 
|__| 
1 = Yes, 0 = No 
F. PREVIOUS INFECTION CONTROL AUDITS 
80 Has a TB infection control audit been 
performed at the PHC 
|__| 
1 = Yes, 0 = No 
81 If yes, when |__|__|/|__|__| Month/Year 
G. TB SUSPECT REGISTER (Please record the following numbers for the previous 
calendar year) 
82 How many TB suspects were identified?  
83 How many TB suspects had sputum smear 
sent? 
 
84 How many TB suspects had culture sent?  
85 For how many TB suspects were smear 
results available? 
 
86 For how many TB suspects were culture 
results available? 
 
87 How many TB suspects had a positive 
smear? 
 
88 How many TB suspects had a positive 
culture? 
 
89 How many suspects with positive smears 
were started on TB treatment? 
 
90 How many suspects with positive cultures 
were started on TB treatment? 
 
H. TB REGISTER (Please record the following numbers for the most recent 
calendar year) 
91 How many TB patients (all type of TB) were 
registered? 
 
92 How many pulmonary TB patients (PTB) 
were registered? 
 
93 How many PTB patients had a sputum 
smear or culture result at diagnosis? 
 
94 How many PTB patients had a sputum 
smear result at diagnosis? 
 
95 How many PTB patients had a culture result 
at diagnosis? 
 
96 How many smear positive PTB patients 
became smear negative after 3 months of 
treatment? 
 
97 How many smear positive PTB patients 




98 How many smear positive PTB patients 
were cured? 
 
99 How many smear positive PTB patients 
completed treatment without proof of cure? 
 
100 How many smear positive PTB patients 
died? 
 
101 How many smear positive PTB patients 
defaulted (no follow-up for more than 2 
months)? 
 
102 How many smear positive PTB patients 
were smear positive at the end of treatment 
(treatment failures)? 
 
103 How many smear positive PTB patients 
were identified as MDR-TB patients? 
 
104 How many smear positive PTB patients 
were identified as XDR-TB patients? 
 
 
TB Infection Control plan review 
1. Review the infection control plan to determine whether the plan includes a policy 
regarding: 
A The availability and functioning of an infection control team 
 
□ Yes □ No 
B Screening patients for TB disease 
 
□ Yes □ No 
C Cough etiquette and respiratory hygiene 
 
□ Yes □ No 
D  Identifying patients under investigation or treatment for TB 
 
□ Yes □ No 
E Placing TB suspects and cases in a separate waiting area 
 
□ Yes □ No 
F  Triaging TB suspects and placing them at the front of the 
queue 
 
□ Yes □ No 
G  Access of TB suspects to TB diagnostic services 
 
□ Yes □ No 
H Use of personal respiratory protective equipment 
 
□ Yes □ No 
I Laboratory turnaround time for sputum smears 
 
□ Yes □ No 
J Communication of sputum smear results with facility staff 
 
□ Yes □ No 
K Access/referral of confirmed TB cases to TB treatment/TB 
treatment facilities 
 
□ Yes □ No 
L Maintaining a TB suspect register and a TB case register 
(according to national guidelines) 
 
□ Yes □ No 
M Ensuring adherence and completion of treatment of TB cases 
 
□ Yes □ No 
N Using, monitoring and maintaining environmental control 
measures 
 
□ Yes □ No 
O Staff education on TB, TB control and the TB infection control 
plan 
 
□ Yes □ No 
P Educating staff on risks of TB infection, including specific 
 
□ Yes □ No 
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risks for HIV-infected staff 
Q Provision of confidential TB services to health care workers 
and staff 
 
□ Yes □ No 
R Provision of confidential HIV services to health care workers 
and staff 
 
□ Yes □ No 
S Monitoring the infection control plan 
 
□ Yes □ No 
2. Who are the members of the infection control team (name, 
designation, responsibilities)? 
   
A ______________________________  ___________________________  ______________________________ 
B ______________________________  ___________________________  ______________________________ 
C ______________________________  ___________________________  ______________________________ 
D ______________________________  ___________________________  ______________________________ 
E ______________________________  ___________________________  ______________________________ 
F ______________________________  ___________________________  ______________________________ 
G ______________________________  ___________________________  ______________________________ 
H ______________________________  ___________________________  ______________________________ 
I ______________________________  ___________________________  ______________________________ 
J ______________________________  ___________________________  ______________________________ 
K ______________________________  ___________________________  ______________________________ 
L ______________________________  ___________________________  ______________________________      
3. How often does the team meet? ___________________________________________________ 
4. Does the team have a budget?   □ Yes □ No 
 
If YES, what is the budget? _____________________ per year 
   
5. Elaborate on the different policies addressed in the infection 
control plan: 
   
A TB screening: _______________________________________________________________________ 
B Cough etiquette: ____________________________________________________________________       
C Triaging of TB suspects:  ___________________________________________________________       
D TB diagnosis: ________________________________________________________________________ 
   
E TB treatment: _______________________________________________________________________       
F Environmental controls: ___________________________________________________________       
G Personal respiratory protective equipment:  _____________________________________ 
   
H Staff education:  _____________________________________________________________________       
I TB and HIV services for staff: ______________________________________________________       






KNOWLEDGE OF TB INFECTION CONTROL, TB AND LTBI 
ATTITUDES, CARE-SEEKING BEHAVIOUR, STIGMA 
 
1 Date of interview |__|__|/|__|__|/|__|__| 
Day/Month/Year 
2 Interviewer initials |__|__| 
3 Start time of interview |__|__|:|__|__| 
A. DEMOGRAPHIC DETAILS 
4 Participant number 1 4 0 2 |__|__|__| 
5 Date of birth |__|__|/|__|__|/|__|__| 
Day/Month/Year 
6 Age  |__|__|Years 
7 Gender |__| 
1 = Male, 2 = Female 
8 Profession |__| 
1 = Doctor, 2 = Dentist, 3 = General Nurse, 4 = 
TB nurse, 5 = Midwife, 6 = Laboratory worker, 7 
= Pharmacist, 8 = Nutritionist,  
9 = Environmental health officer, 10 = Public 
health officer, 11 = Administrative staff 
9 Currently working unit |__| 
1 = Outpatient department, 2 = TB clinic, 3 = 
Inpatient department, 4 = Laboratory, 5 = 
Administrative office, 6 = Other (please 
state)________________________ 
10 Educational status |__| 
1 = Diploma, 2 = First degree, 3 = Second degree 
or above  
In this health facility:   
11 Service months/years  |__|__|Months 
|__|__|Years 
12 Experience working in TB clinic  |__| 
1 = Yes, 0 = No 




In previous health facility:  




15 Experience working in any TB 
clinic  
|__| 
1 = Yes, 0 = No 
16 Months/years of experience in 
any TB clinic 
|__|__|Months 
|__|__|Years 
17 Has any formal TB training held 
by the NTP? 
If no, go to Q.20 
|__| 
1 = Yes, 0 = No 
18 If yes, when was the last training |__|__|Months ago 
|__|__|Years ago 
19 Has any informal TB training held 




If no, go to Q.23 
1 = Yes, 0 = No 
20 If yes, please state what the 
training was 
 
21 when was the last training |__|__|Months ago 
|__|__|Years ago 
B. TB INFECTION CONTROL KNOWLEDGE 
22 Every primary health centre 
should establish an IC committee 
for TB infection control  
|__| 
1 = Yes, 0 = No 
23 Every primary health centre 
should establish a guidelines for 
TB infection control 
|__| 
1 = Yes, 0 = No 
24 The windows of a room (such as 
waiting room, exam room, 
sputum collection room) should 
be left open whenever a patient 
suspected or confirmed to have 
TB is in the room 
|__| 
1 = Yes, 0 = No 
25 Patients suspected or confirmed 
to have TB should not be kept 
separately from the rest of the 
patients while in the health 
facility 
|__| 
1 = Yes, 0 = No 
26 HCWs should try to minimize the 
time a TB patient spends in health 
facility 
|__| 
1 = Yes, 0 = No 
27 Surgical masks can protect the 
HCWs from TB 
|__| 
1 = Yes, 0 = No 
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28 Respirator can protect the HCWs 
from TB 
|__| 
1 = Yes, 0 = No 
29 TB patients have to be educated 
to cover their mouth with a 
handkerchief or scarf 
|__| 
1 = Yes, 0 = No 
30 Fans can be used to reduce TB 
transmission in a TB ward 
|__| 
1 = Yes, 0 = No 
31 Regular screening of HCWs for TB 
is one of the TB infection control 
measures 
|__| 
1 = Yes, 0 = No 
32 Patients suspected or confirmed 
to have TB are coughing should 
get priority to be seen by a 
nurse/doctor first 
|__| 
1 = Yes, 0 = No 
C. TB KNOWLEDGE 
33 What is the germ which causes 
tuberculosis? 
|__| 
1 = Virus, 2 = Bacteria, 3 = Other (please state) 
_______________________________________ 
34 How is TB transmitted? 
(please read through the answer 
and ask participant to say only 
one correct answer) 
|__| 
1 = Spread through the air, 2 = Through 
handshakes, 3 = Through sharing dishes, 4 = 
Through eating from the same plate, 5 = 
Through touching items in public places, 6 = 
Other (please state) __________________ 
35 What is the most common 
symptom of pulmonary TB? 
(please read through the answer 
and ask participant to say only 
one correct answer) 
|__| 
1 = Coughing up blood or sputum, 2 = Pain in 
the chest, 3 = Cough that lasts 2 weeks or 
longer, 4 = Weakness or fatigue, 5 = Weight loss, 
6 = No appetite, 7 = Fever, 8 = Sweating at night, 
9 = other (please state) 
_______________________________________ 
36 Which is the most effective tool in 
the diagnosis of pulmonary TB in 
primary health centre? 
(please read through the answer 
and ask participant to say only 
one correct answer) 
|__| 
1 = Sputum smear, 2 = Chest X Ray, 3 = Culture, 
4 = Mantoux, 5 = IGRA, 6 = Other (please 
explain) ____________________________________________ 
37 Which is the most effective tool in 
the diagnosis of pulmonary TB in 
general? 
|__| 
1 = Sputum smear, 2 = Chest X Ray, 3 = Culture, 
4 = Mantoux, 5 = IGRA, 6 = Other (please 
explain) ___________________________________ 
38 Is it possible to cure TB? |__| 
1 = Yes, 0 = No 
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39 How long (in months) is a 
complete treatment for 
pulmonary TB under the primary 
scheme? 
|__|__| Months 
D. LTBI KNOWLEDGE 
40 What is the main symptom that 
indicates LTBI? 
(please read through the answer 
and ask participant to say only 
one correct answer) 
|__| 
1 = Cough >2 weeks, 2 = Cough with blood, 3 = 
Fever, 4 = Night Sweats, 5 = Weight loss, 6 = No 
symptom,  7 = Other (Please state) 
_________________, 8 = Do not know 
41 Can LTBI be spread from person 
to person? 
|__| 
1 = Yes, 0 = No, 2 = Do not know 
42 Do all people with the latent TB 
infection develop TB disease? 
|__| 
1 = Yes, 0 = No 
43 LTBI can be treated with? 
(please read through the answer 
and ask participant to say only 
one correct answer) 
|__| 
1 = No treatment, 2 = Prescribed TB medicine, 3 
= Prescribed LTBI medicine, 4 = General 
antibiotics, 5 = Herbal medicine, 6 = Bed rest, 7 
= other (please state) ______________, 8 = Do not 
know 
44 What is the benefit of treating 
LTBI? 
|__| 
1 = To prevent active TB disease, 2 = Other 
answer (please state) ________________, 3 = Do not 
know 
45 How long does the treatment of 
LTBI last? 
|__|__| Months 
46 Do you think BCG vaccine 
completely protects people from 
TB for their whole life?  
|__| 
1 = Yes, 0 = No, 2 = Do not know 
E. TB HISTORY, ATTITUDES, AND CARE SEEKING BEHAVIOUR 
47 Have you ever had been 
diagnosed with tuberculosis? 
If no, go to Q.53 
|__| 
1 = Yes, 0 = No 
48 If yes, type of TB |__| 
1 = Pulmonary, 0 = Extra Pulmonary 
49 How were you diagnosed? |__| sputum smear only 
|__| sputum culture only 
|__| chest x-ray only 
|__| all above  




|__| other (please state)_______________________ 




51 Did you finish your treatment?  
(cured or completed) 
|__| 
1 = Yes, 0 = No 
52 What was your reaction at that 





|__| embarrassment  
|__| sadness or hopelessness 
|__| other (please state) ____________________ 
53 Who did you talk to about your 
illness when you had TB (check 
all that are mentioned) 
|__| doctor or other health care worker in the 
same clinic 
|__| doctor or other health care worker in the 
other clinic 
|__| spouse 
|__| parent  
|__| other family member 
|__| close friend 
|__| no one 
|__| other (please state) ____________________ 
54 Have you ever had direct contact 
with family or friends who have 
been diagnosed with TB prior to 
your TB treatment?  
 
Go to Q.60 
|__| 
1 = Yes, 0 = No 
55 Do you think you can get TB? (ask 
the respondent to please explain 
his/her answer) 
|__| 
1 = Yes, 0 = No 
Reason: _____________________________________ 
____________________________________________ 
56 What would be your reaction if 
you were found out that you have 





|__| embarrassment  
|__| sadness or hopelessness 
|__| other (please state) ____________________ 
57 Who would you talk to about your |__| doctor or other health care worker in the 
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illness if you had TB? (check all 
that are mentioned) 
same clinic 
|__| doctor or other health care worker in the 
other clinic 
|__| spouse 
|__| parent  
|__| other family member 
|__| close friend 
|__| no one 
|__| other (please state) ____________________ 
58 What would you do if you thought 
you had symptoms of TB?  
(check all that apply)  
|__| go for examination in this clinic 
|__| go to other health facility for examination 
|__| go to pharmacy 
|__| go to traditional healer 
|__| pursue other self-treatment options (herbs, 
etc.) 
|__| other (please state) ____________________ 
59 If you had symptoms of TB, at 
what point would you go to the 
health facility? (please read 
through the answer and ask 
participant to say only one 
answer) 
|__| when treatment on my own does not work 
|__| when symptoms that look like TB signs last 
for 3- weeks  
|__| as soon as I realize that my symptoms might 
be related to TB 
60 Have you ever had direct contact 
with family or friends who have 
been diagnosed with TB  
|__| 
1 = Yes, 0 = No 
61 If there is a screening programme 
for TB disease, would you 
participate in this programme?  
(please state the reason)  
|__| 
1 = Yes, 0 = No 
Reason _____________________________________ 
F. TB STIGMA 
62 Do you know one of your 
colleagues who have/had TB 
|__| 
1 = Yes, 0 = No 
63 Which statement is closest to 
your feeling about colleagues 
with TB disease 
(please read through the answer 
and ask participant to say only 
one answer) 
|__| I feel compassion and desire to help 
|__| I feel compassion but I tend to stay away 
from these colleagues 
|__| it is their problem and I cannot get TB 
|__| I fear them because they may infect me 
|__| I have no particular feeling 




64 In your workplace, how is a staff 
who has TB usually 
regarded/treated?  
|__| most staff reject him/her 
|__| most staff are friendly, but they generally 
try to avoid him or her 
|__| other staff mostly supports and helps him or 
her 
|__| other (please explain) _____________________ 
G. LTBI STATUS AND WILLINGNESS FOR SCREENING AND TREATMENT 
65 Have you had a previous 
tuberculin skin test or interferon 
gamma release assays?  
If no, go to Q.70 
|__| 
1 = Yes, 0 = No 
66 If yes, what was the result? |__| 
1 = Positive, 2 = Negative, 3 = Indeterminate 
67 Where?  
68 When? |__|__|Months ago 
|__|__|Years ago 
69 Have you received any LTBI 
treatment?  
If no, go to Q.71 
|__| 
1 = Yes, 0 = No 
70 Where?  
71 When? |__|__|Months ago 
|__|__|Years ago 
72 Did you finish your treatment?  
(completed) 
|__| 
1 = Yes, 0 = No 
73 If there is a screening programme 
for latent TB infection, would you 
participate in this programme? 
(please state the reason) 
|__| 
1 = Yes, 0 = No 
Reason: ____________________________________ 
74 If you are diagnosed by LTBI and 
offered LTBI treatment, would 
you take the treatment? 
(please state the reason) 
|__| 
1 = Yes, 0 = No 
Reason: ____________________________________ 
 






A.2.2  Chapter five: Latent tuberculosis infection in health care workers in a 
teaching hospital in Bandung, Indonesia 
FORM 1. TUBERCULIN SKIN TEST RESULT 
Participant number 1 4 0 3 |__|__|__| 
If never tested or negative: 
 
1 Date of TST testing |__|__|/|__|__|/|__|__| 
Day/Month/Year 
2 Time of TST testing |__|__|:|__|__| 
3 Testing by |__|__|__| (Nurse Initials) 
4 Date of TST reading |__|__|/|__|__|/|__|__| 
Day/Month/Year 
5 Time of TST reading |__|__|:|__|__| 
6 First Read by |__|__|__|(Nurse Initials) 
7 TST Result (diameter)  |__|__| mm 
8 Second Read by |__|__|__|(Nurse Initials) 
9 TST Result (diameter) |__|__| mm 
10 TST Result conclusion |__|  
1 = Positive, 2 = Negative 
If positive prior TST, check and fill evidence of TST result: 
 
11 Date of TST testing |__|__|/|__|__|/|__|__| 
Day/Month/Year 
12 Date of TST reading |__|__|/|__|__|/|__|__| 
Day/Month/Year 
13 TST Result (diameter)  |__|__| mm 
14 TST Result conclusion |__|  
1 = Positive, 2 = Negative 
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FORM 2. ACTIVE TB SCREENING 
Participant number 1 4 0 2 |__|__|__| 
A. SYMPTOM SCREENING 
1 Dry cough 
 
|__| 1 = Yes, 0 = No 
Duration: |__|__| days or   |__|__| weeks 
2 Productive cough    |__| 1 = Yes, 0 = No 
Duration: |__|__| days or   |__|__| weeks 
3 Cough at night |__| 1 = Yes, 0 = No 
Duration: |__|__| days or   |__|__| weeks 
4 Pain in the chest |__| 1 = Yes, 0 = No 
Duration: |__|__| days or   |__|__| weeks 
5 Coughing up blood or sputum |__| 1 = Yes, 0 = No 
Duration: |__|__| days or   |__|__| weeks 
6 Night sweats |__| 1 = Yes, 0 = No 
Duration: |__|__| days or   |__|__| weeks 
7 Weakness or fatigue  |__| 1 = Yes, 0 = No 
Duration: |__|__| days or   |__|__| weeks 
8 Weight loss |__| 1 = Yes, 0 = No 
Duration: |__|__| days or   |__|__| weeks 
9 No appetite |__| 1 = Yes, 0 = No 
Duration: |__|__| days or   |__|__| weeks 
10 Fever |__| 1 = Yes, 0 = No 
Duration: |__|__| days or   |__|__| weeks 
11 Visible Mass in Neck  
 
|__| 1 = Yes, 0 = No 
Duration: |__|__| days or   |__|__| weeks 
12 Symptomatic:  
If Yes, ask for providing sputum 
and chest x ray 
|__| 
1 = Yes  
0 = No 
B. BODY MASS INDEX 
13 Height |__|__|__| cm 





C. SPUTUM EXAMINATION 
15 Date |__|__|/|__|__|/|__|__| 
Day/Month/Year 
16 First sputum result |__| 
0 = Negative, 1 = Positive 1, 2 = Positive 2, 3 = 
Positive 3, 4 = Scanty, 9 = not done 
17 Second sputum result |__| 
0 = Negative, 1 = Positive 1, 2 = Positive 2, 3 = 
Positive 3, 4 = Scanty, 9 = not done 
18 Third sputum result |__| 
0 = Negative, 1 = Positive 1, 2 = Positive 2, 3 = 
Positive 3, 4 = Scanty, 9 = not done 
19 Sputum culture result |__| 
0 = Negative, 1 = Positive 1, 2 = Indeterminate, 3 
= not done 
 
D. CHEST X-RAY  
20 Date |__|__|/|__|__|/|__|__| 
Day/Month/Year 
21 Result |__| 
0 = Normal, 1 = Abnormality TB related, 2 = 
Abnormality not TB related  
 
A. FINDINGS 
22 TB Disease 
 
|__| 






DEMOGRAPHIC DETAILS AND RISK FACTORS ASSOCIATED WITH LTBI 
1 Date of interview |__|__|/|__|__|/|__|__| 
Day/Month/Year 
2 Interviewer initials |__|__| 
3 Start time of interview |__|__|:|__|__| 
H. DEMOGRAPHIC DETAILS 
4 Participant number 1403|__|__|__| 
5 Date of birth |__|__|/|__|__|/|__|__| 
Day/Month/Year 
6 Age  |__|__|Years 
7 Gender |__| 
1 = Male, 2 = Female 
8 Ethnicity |__| 
1 = Sundanese, 2 = Other (please state) 
___________________________________________ 
9 Educational status |__| 
1 = High school, 2 = Diploma or below, 3 = First 
degree, 4 =  Second degree or above  
I. OCCUPATIONAL EXPOSURE PROFILE 
10 Profession |__| 
1 = Doctor/Dentist, 2 = Nurse, 3 = Midwife, 4 = 
Laboratory worker, 5 = Pharmacist, 6 = 
Nutritionist, 7 = Radiographer, 8 = other (please 
state) _________________________ 
11 Currently working unit |__| 
1 = TB/MDR clinic, 2 = Isolation ward, 3 = 
Outpatient department, 4 = Inpatient 
department, 5= Intensive care unit, 6 = 
Emergency room, 7 = Laboratory, 8 = Radiology 
department, 9 = Administrative office, 10 = 
Other (please state)__________________________ 
In this health facility:   
12 Service months/years  |__|__|Months 
|__|__|Years 





1 = Yes, 0 = No 
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15 Have you ever had any direct 
contact with TB patient or 
participation in sputum collection 
or examination? 
|__| 
1 = Yes, 0 = No 
16 If yes, state the location  |__| 
1 = TB/MDR clinic, 2 = Isolation ward, 3 = 
Outpatient department, 4 = Inpatient 
department, 5= Intensive care unit, 6 = 
Emergency room, 7 = Laboratory, 8 = Radiology 
department, 9 = Administrative office, 10 = 
Other (please state)__________________________ 
17 When?  |__|__|Months ago 
|__|__|Years ago 
18 Have you ever had direct contact 
with a colleague who has been 
diagnosed with TB? 
|__| 
1 = Yes, 0 = No 
19 When?  |__|__|Months ago 
|__|__|Years ago 
In previous or other health facility:  
20 Service months/years  |__|__|Months 
|__|__|Years 




1 = Yes, 0 = No 
22 Months/years of experience in 




23 Have you ever had any direct 
contact with TB patient or 
participation in sputum collection 
or examination? 
|__| 
1 = Yes, 0 = No 
24 If yes, state the location  |__| 
1 = TB/MDR clinic, 2 = Isolation ward, 3 = 
Outpatient department, 4 = Inpatient 
department, 5= Intensive care unit, 6 = 
Emergency room, 7 = Laboratory, 8 = Radiology 
department, 9 = Administrative office, 10 = 
Other (please state)__________________________ 




26 Have you ever had direct contact 
with a colleague who has been 
diagnosed with TB? 
|__| 
1 = Yes, 0 = No 
27 When?  |__|__|Months ago 
|__|__|Years ago 
J. TB EXPOSURE IN COMMUNITY  
28 Have you ever had direct contact 
with one of your family who have 
been diagnosed with TB? 
|__| 
1 = Yes, 0 = No 
29 Who is he/she? |__| 
1 = spouse, 2 = parent, 3 = child, 4 = other 
(please state) _____________________________ 




31 Have you ever had direct contact 
with a friend who has been 
diagnosed with TB? 
|__| 
1 = Yes, 0 = No 
32 Who is he/she? |__| 
1 = close friend, 2 = work colleague, 3 = other 
(please state) _____________________________ 




K. MEDICAL HISTORY 
34 BCG vaccination |__| 
1 = Vaccinated, 2 = Not vaccinated, 3 = Do not 
know 
35 Do you have a BCG scar? (can I 
please see it?) 
|__| 
1 = Yes, 0 = No, 2 = Do not know 
36 Have you ever been tested with 
HIV? 
|__| 
1 = Yes, 0 = No, 2 = Do not know 
37 If yes, what was the result? |__| 
1 = Positive, 0 = Negative, 2 = Do not know 
38 Do you have any other 
immunocompromised condition? 





1 = Diabetes, 2 = Systemic Lupus 
Erythematosus, 3 = Renal failure, 4 = Transplant 
anti-rejection therapy, 5 = TNFα inhibitor 
therapy, 6 = Other immune-suppressive 
condition or therapy (steroid), 7 = None 
 





40 Do you smoke cigarettes? 
(read the options to the 
participant) 
|__| 
1 = Yes current, 2 = Ex-Smoker, 0 = Never 
41 If current or ex-smoker Age started: |__|years 
Packs/day: |__| 
42 If ex-smoker Age stopped: |__|years 
43 Do you consume alcohol? |__| 
1 = Yes, 0 = No 
L. TB HISTORY 
44 Have you ever had been 
diagnosed with tuberculosis? 
If no, go to Q.40 
|__| 
1 = Yes, 0 = No 
45 What type of TB? |__|  
1 = Pulmonary 
2 = Extra Pulmonary (state location): 
______________ 
46 If yes, how were you diagnosed? |__|  
1 = sputum smear only 
2 = sputum culture only 
3 = chest x-ray only 
4 = all above  
5 = both sputum smear and chest x ray 
6 = biopsy 
7 = other (please state)_______________________ 




48 Did you finish your treatment?  
(cured or completed) 
|__| 
1 = Yes, 0 = No 
M. LTBI STATUS 
49 Have you had a previous 
tuberculin skin test or interferon 
gamma release assays?  
If no, go to Q.49 
|__| 
1 = Yes, 0 = No 
50 If yes, what was the result? |__| 
1 = Positive, 0 = Negative, 2 = Indeterminate 
 
51 Where? |__| 
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1 = This hospital, 2 = Other hospital, 3 = Private 
lab, 4 = Clinic, 5 = Primary Health Centre, 6 = 
Other (Please state) 
______________________________________ 
52 When? |__|__|Months ago 
|__|__|Years ago 
53 Is there any evidence for previous 
TST  
|__| 
1 = Yes, 0 = No 
54 Have you received any LTBI 
treatment?  
If no, go to Q.49 
|__| 
1 = Yes, 0 = No 
55 Where? |__| 
1 = This hospital, 2 = Other hospital, 3 = Private 
lab, 4 = Clinic, 5 = Primary Health Centre, 6 = 
Other (Please state) 
______________________________________ 
56 When? |__|__|Months ago 
|__|__|Years ago 
N. TB TRAINING 
57 Has any formal TB training held 
by the NTP? 
If no, go to Q.51 
|__| 
1 = Yes, 0 = No 
58 If yes, when was the last training |__|__|Months ago 
|__|__|Years ago 
59 Has any informal TB training held 




1 = Yes, 0 = No 












KNOWLEDGE OF TB INFECTION CONTROL, TB, AND LTBI 
TB ATTITUDES, CARE SEEKING BEHAVIOUR, AND STIGMA 
 
Participant number 1403|__||__| |__| 
 
A. TB INFECTION CONTROL KNOWLEDGE 
1 Every hospital should establish an IC committee for TB 
infection control  
|__| 
1 = Yes, 0 = No 
2 Every hospital should establish an IC guidelines for TB 
infection control 
|__| 
1 = Yes, 0 = No 
3 The windows of a room (such as waiting room, exam 
room, sputum collection room) should be left open 
whenever a patient suspected or confirmed to have TB is 
in the room 
|__| 
1 = Yes, 0 = No 
4 Patients suspected or confirmed to have TB should be 
kept separately from the rest of the patients while in the 
health facility 
|__| 
1 = Yes, 0 = No 
5 HCWs should try to minimise the time a TB patient spends 
in health facility 
|__| 
1 = Yes, 0 = No 
6 Surgical masks can protect the HCWs from TB |__| 
1 = Yes, 0 = No 
7 Respirator can protect the HCWs from TB |__| 
1 = Yes, 0 = No 
8 TB patients have to be educated to cover their mouth with 
a handkerchief or scarf 
|__| 
1 = Yes, 0 = No 
9 Fans can be used to reduce TB transmission in a TB ward |__| 
1 = Yes, 0 = No 
10 Regular screening of HCWs for TB is one of the TB 
infection control measures 
|__| 
1 = Yes, 0 = No 
11 Patients suspected or confirmed to have TB are coughing 
should get priority to be seen by a nurse/doctor first 
|__| 
1 = Yes, 0 = No 
B. TB KNOWLEDGE 
12 What is the germ which 
causes tuberculosis? 
|__| 




13 How is TB transmitted? 
(please read through the 
answer and ask participant to 
say only one correct answer) 
|__| 
1 = Through handshakes, 2 = Through touching 
items in public places, 3 = Through sharing dishes, 
4 = Through eating from the same plate, 5 = Spread 
through the air, 6 = Other (please state) ___________ 
14 What is the most common 
symptom of pulmonary TB? 
(please read through the 
answer and ask participant to 
say only one correct answer) 
|__| 
1 = Coughing up blood or sputum, 2 = Pain in the 
chest, 3 = Cough that lasts 2 weeks or longer, 4 = 
Weakness or fatigue, 5 = Weight loss, 6 = No 
appetite, 7 = Fever, 8 = Sweating at night, 9 = other 
(please state) _______________________________________ 
15 Which is the most effective 
tool in the diagnosis of 
pulmonary TB in this 
hospital? 
(please read through the 
answer and ask participant to 
say only one correct answer) 
 
|__| 
1 = Sputum smear, 2 = Chest X Ray, 3 = Culture, 4 = 
Mantoux, 5 = IGRA, 6 = Other (please explain) ______ 
____________________________________________ 
16 Which is the most effective 
tool in the diagnosis of 
pulmonary TB in general? 
(please read through the 
answer and ask participant to 
say only one correct answer) 
|__| 
1 = Sputum smear, 2 = Chest X Ray, 3 = Culture, 4 = 
Mantoux, 5 = IGRA, 6 = Other (please explain) ______ 
 
17 Is it possible to cure TB? |__| 
1 = Yes, 0 = No 
18 How long (in months) is a 
complete treatment for 
pulmonary TB under the 
primary scheme? 
|__|__| Months 
C. LTBI KNOWLEDGE 
19 What is the main symptom 
that indicates LTBI? 
(please read through the 
answer and ask participant to 
say only one correct answer) 
 
|__| 
1 = Cough >2 weeks, 2 = Cough with blood, 3 = 
Fever, 4 = Night Sweats, 5 = Weight loss, 6 = No 
symptom,  7 = Other (Please state) _________________, 
8 = Do not know 
20 Can LTBI be spread from 
person to person? 
|__| 
1 = Yes, 0 = No, 2 = Do not know 
21 Do all people with the latent 




1 = Yes, 0 = No 
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22 LTBI can be treated with? 
(please read through the 
answer and ask participant to 
say only one correct answer) 
|__| 
1 = No treatment, 2 = Prescribed TB medicine, 3 = 
Prescribed LTBI medicine, 4 = General antibiotics, 5 
= Herbal medicine, 6 = Bed rest, 7 = other (please 
state) ______________, 8 = Do not know 
23 What is the benefit of treating 
LTBI? 
|__| 
1 = To prevent active TB disease, 2 = Other answer 
(please state) ________________, 3 = Do not know 
24 How long does the treatment 
of LTBI last? 
|__|__| Months 
25 Do you think BCG vaccine 
completely protects people 
from TB for their whole life?  
 
|__| 
1 = Yes, 0 = No, 2 = Do not know 
D. TB ATTITUDES AND CARE SEEKING BEHAVIOUR 
HCWs with prior TB disease, if no go to Q. 33 
26 When you diagnosed with TB, 
what was your reaction at that 







|__| other (please state) ____________________ 
27 Who did you talk to about 
your illness when you had TB 
(check all that are mentioned) 
|__| doctor or other health care worker in the same 
clinic 
|__| doctor or other health care worker in the other 
clinic 
|__| spouse 
|__| parent  
|__| other family member 
|__| close friend 
|__| no one 
|__| other (please state) ____________________ 
28 What did you do when you 
had symptoms of TB?  
(check all that apply)  
|__| went for examination in this clinic 
|__| went to other health facility for examination 
|__| went to pharmacy 
|__| went to traditional healer 
|__| other self-treatment options (herbs, etc.) 




29 When you had symptoms of 
TB, at what point did you go 
to the health facility? (please 
read through the answer and 
ask participant to say only one 
answer) 
|__|  
1 = when treatment on my own does not work 
2 = when symptoms that look like TB signs last for 
3- weeks  
3 = as soon as I realise that my symptoms might be 
related to TB 
 
30 Do you know one of your 
colleagues who has/had TB 
|__| 
1 = Yes, 0 = No 
31 Which statement is closest to 
your feeling about colleagues 
with TB disease 
(please read through the 
answer and ask participant to 
say only one answer) 
|__|  
1 = I feel compassion and desire to help 
2 = I feel compassion but I tend to stay away from 
these colleagues 
3 = it is their problem and I cannot get TB 
4 = I fear them because they may infect me 
5 = I have no particular feeling 
6 =  Other (please explain) _____________________ 
32 In your workplace, how is a 
staff who has TB usually 
regarded/treated?  
(please read through the 
answer and ask participant to 




1 = most staff reject him/her 
2 = most staff are friendly, but they generally try to 
avoid him or her 
3 = other staff mostly supports and helps him or 
her 
4 = other (please explain) _____________________ 
HCWs with no TB disease 
33 Do you think you can get TB?  |__| 
1 = Yes, 0 = No 
 
34 Ask the respondent to please 
explain his/her answer 
Reason: _____________________________________ 
____________________________________________ 
35 What would be your reaction 
if you were found out that you 











36 Who would you talk to about 
your illness if you had TB? 
(check all that are mentioned) 
|__| doctor or other health care worker in the same 
clinic 
|__| doctor or other health care worker in the other 
clinic 
|__| spouse 
|__| parent  
|__| another family member 
|__| close friend 
|__| no one 
|__| other (please state) _______________________ 
____________________________________________ 
37 What would you do if you 
thought you had symptoms of 
TB?  
(check all that apply)  
|__| go for examination in this clinic 
|__| go to other health facility for examination 
|__| go to pharmacy 
|__| go to traditional healer 
|__| pursue other self-treatment options (herbs, 
etc.) 
|__| other (please state) ____________________ 
38 If you had symptoms of TB, at 
what point would you go to 
the health facility? (please 
read through the answer and 
ask participant to say only one 
answer) 
|__|  
1 = when treatment on my own does not work 
2 = when symptoms that look like TB signs last for 
3- weeks  
3 = as soon as I realise that my symptoms might be 
related to TB 
39 Do you know one of your 
colleagues who has/had TB 
|__| 
1 = Yes, 0 = No 
40 Which statement is closest to 
your feeling about colleagues 
with TB disease 
(please read through the 
answer and ask participant to 
say only one answer) 
|__|  
1 = I feel compassion and desire to help 
2 = I feel compassion but I tend to stay away from 
these colleagues 
3 = it is their problem and I cannot get TB 
4 = I fear them because they may infect me 
5 = I have no particular feeling 
6 =  Other (please explain) _____________________ 
41 In your workplace, how is a 





1 = most staff reject him/her 
2 = most staff are friendly, but they generally try to 





3 = other staff mostly supports and helps him or 
her 
4 = other (please explain) _____________________ 
E. WILLINGNESS FOR SCREENING AND TREATMENT 
42 If there is a screening 
programme for TB disease, 
would you participate in this 
programme?  
(please state the reason)  
|__| 
1 = Yes, 0 = No 
 
43 Please state the reason Reason _____________________________________ 
44 If there is a screening 
programme for latent TB 
infection, would you 
participate in this 
programme? 
|__| 
1 = Yes, 0 = No 
 
45 Please state the reason Reason _____________________________________ 
46 If you are diagnosed by LTBI 
and offered LTBI treatment, 
would you take the 
treatment? 
|__| 
1 = Yes, 0 = No 
 






A.2.3  Chapter six: Infection control and latent tuberculosis infection in 
Indonesian health care workers 
1. DATA COLLECTION FORM AT BASELINE 
1 Date of interview |__|__|/|__|__|/|__|__| 
Day/Month/Year 
2 Interviewer initials |__|__| 
3 Start time of interview |__|__|:|__|__| 
DEMOGRAPHIC DETAILS 
4 Participant number  
5 Date of birth |__|__|/|__|__|/|__|__| 
Day/Month/Year 
6 Age  |__|__|Years 
7 Gender |__| 
1 = Male, 2 = Female 
8 Student type |__| 
1 = Medical, 2 = Nursing 




10 Where do you stay |__| 
1 = Family housing, 2 = Student housing, 
3 = Other ________________________ 
11 Ethnicity |__| 
1 = Sundanese, 2 = Javanese, 3 =  Batak, 4 = 
Betawi, 5 = Madurese, 6 = Minangkabau, 7 = 
Malay, 8 = Acehnese, 9 = Balinese, 10 = 
Chinese, 11 = Indian, 12 = Other (please state) 
______________________ 
MEDICAL HISTORY 
13 BCG vaccination |__| 
1 = Vaccinated, 2 = Not vaccinated, 3 = Do not 
know 
14 Do you have a BCG scar? (can I 
please see it?) 
|__| 
1 = Yes, 2 = No, 3 = Do not know 
15 Have you ever been diagnosed with 
HIV? 
|__| 





16 Do you have any other 
immunocompromised condition? 
(read the options to the participant) 
  
|__| 
1 = Diabetes, 2 = Systemic Lupus 
Erythematosus, 3 = Renal failure, 4 = 
Transplant anti-rejection therapy, 5 = TNFα 
inhibitor therapy, 6 = Other immune-
suppressive condition or therapy (steroid), 7 
= None 
17 Do you smoke cigarettes? 
(read the options to the participant) 
|__| 
1 = Yes current , 2 = Ex-Smoker, 3 = Never 
18 If current or ex-smoker Age started: |__|years 
Packs/day: |__| 
19 If ex-smoker Age stopped: |__|years 
20 Do you consume alcohol? |__| 
1 = Yes, 2 = No 
TB EXPOSURE 
21 Have you ever been involved in 
other training/project in 
hospital/clinic prior to study 
enrolment? 
|__| 
1 = Yes, 2 = No 
22 If yes, any direct contact with TB 
patient or participation in sputum 
collection or examination? 
|__| 
1 = Yes, 2 = No 
23 If yes, state the location  |__| 
1 = DOTS clinic, 2 = Isolation ward, 3 = 
Laboratory, 4 = Pulmonary ward, 5 = Other 
(please state) __________ 
24 When?  |__|__|Months ago 
|__|__|Years ago 
25 Have you ever had direct contact 
with family or friends who have 
been diagnosed with TB? 
|__| 
1 = Yes, 2 = No 




ACTIVE TB SCREENING 
27 Dry cough 
 
|__| 1 = Yes, 2 = No 
Duration: |__|__| days or   |__|__| weeks 
28 Productive cough    |__| 1 = Yes, 2 = No 
Duration: |__|__| days or   |__|__| weeks 
29 Cough at night |__| 1 = Yes, 2 = No 
Duration: |__|__| days or   |__|__| weeks 
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30 Pain in the chest |__| 1 = Yes, 2 = No 
Duration: |__|__| days or   |__|__| weeks 
31 Coughing up blood or sputum |__| 1 = Yes, 2 = No 
Duration: |__|__| days or   |__|__| weeks 
32 Night sweats |__| 1 = Yes, 2 = No 
Duration: |__|__| days or   |__|__| weeks 
33 Weakness or fatigue  |__| 1 = Yes, 2 = No 
Duration: |__|__| days or   |__|__| weeks 
34 Weight loss |__| 1 = Yes, 2 = No 
Duration: |__|__| days or   |__|__| weeks 
35 No appetite |__| 1 = Yes, 2 = No 
Duration: |__|__| days or   |__|__| weeks 
36 Fever |__| 1 = Yes, 2 = No 
Duration: |__|__| days or   |__|__| weeks 
37 Visible Mass in Neck  
 
|__| 1 = Yes, 2 = No 
Duration: |__|__| days or   |__|__| weeks 
38 End time of interview |__|__|:|__|__| 
BODY MASS INDEX 
39 Height |__|__|__| cm 
40 Weight |__|__|__|. |__|__| kg 
IGRA TEST 
41 Date of blood drawing for IGRA |__|__|/|__|__|/|__|__| 
Day/Month/Year 
42 IGRA test result qualitative |__| 
1 = Positive, 2 = Negative, 3 = Intermediate 
TUBERCULIN SKIN TEST 
43 Date of TST administered |__|__|/|__|__|/|__|__| 
Day/Month/Year 
44 Date of TST read |__|__|/|__|__|/|__|__| 
Day/Month/Year 
45 TST Result (diameter) |__|__| mm 
46 TST Result  |__|  




2. DATA COLLECTION FORM AT FOLLOW UP 
1 Date of interview |__|__|/|__|__|/|__|__| 
Day/Month/Year 
2 Interviewer initials |__|__| 
3 Start time of interview |__|__|:|__|__| 
DEMOGRAPHIC DETAILS 
4 Participant number  
PERSONAL PROTECTION 
5 Do you use N95/FFP2 
respirators during your work in 
health care facilities 
|__| 
1 = Yes, always, 2 = Yes, during specific duties 
only, 3 = No 
6 Do you use any other mask 
respirators during your work in 
health care 
|__| 
1 = Yes, always, 2 = Yes, during specific duties 
only, 3 = No 
COMMUNITY EXPOSURE 
7 Have you ever had direct contact 
with family or friends who have 
been diagnosed with TB in the 
last year since we last 
interviewed you? 
|__| 
1 = Yes, 2 = No 
8 If yes, when |__|__|Months ago 
OCCUPATIONAL EXPOSURE 
9 Any direct contact with 
pulmonary TB patient/s in the 
last year? 
|__| 
1 = Yes, 2 = No 
10 Participation in bronchoscopy 
procedures or sputum collection 
|__| 
1 = Yes, 2 = No 
11 Total time spent working in 
health care 
See student log book 
|__|__|Days 
12 Total time spent caring directly 
for pulmonary TB patient/s 
See student log book 
|__|__|Days 
13 Total time spent on isolation 
wards 
See student log book 
|__|__|Days 
14 Total time spent working on 
pulmonary wards 
See student log book 
|__|__|Days 
15 Total time spent working in 
DOTS clinic 






ACTIVE TB SCREENING 
16 Dry cough 
 
|__| 1 = Yes, 2 = No 
Duration: |__|__| days or   |__|__| weeks 
17 Productive cough    |__| 1 = Yes, 2 = No 
Duration: |__|__| days or   |__|__| weeks 
18 Cough at night |__| 1 = Yes, 2 = No 
Duration: |__|__| days or   |__|__| weeks 
19 Pain in the chest |__| 1 = Yes, 2 = No 
Duration: |__|__| days or   |__|__| weeks 
20 Coughing up blood or sputum |__| 1 = Yes, 2 = No 
Duration: |__|__| days or   |__|__| weeks 
21 Night sweats |__| 1 = Yes, 2 = No 
Duration: |__|__| days or   |__|__| weeks 
22 Weakness or fatigue  |__| 1 = Yes, 2 = No 
Duration: |__|__| days or   |__|__| weeks 
23 Weight loss |__| 1 = Yes, 2 = No 
Duration: |__|__| days or   |__|__| weeks 
24 No appetite |__| 1 = Yes, 2 = No 
Duration: |__|__| days or   |__|__| weeks 
25 Fever |__| 1 = Yes, 2 = No 
Duration: |__|__| days or   |__|__| weeks 
26 Visible Mass in Neck  
 
|__| 1 = Yes, 2 = No 
Duration: |__|__| days or   |__|__| weeks 
27 End time of interview |__|__|:|__|__| 
BODY MASS INDEX 
28 Height |__|__|__| cm 
29 Weight |__|__|__|. |__|__| kg 
IGRA TEST 
28 Date of blood drawing for IGRA |__|__|/|__|__|/|__|__| 
Day/Month/Year 
29 IGRA test result qualitative |__| 
1 = Positive, 2 = Negative, 3 = Indeterminate 
TUBERCULIN SKIN TEST 
30 Date of TST administered |__|__|/|__|__|/|__|__| 
Day/Month/Year 




32 TST Result (diameter) |__|__| mm 
33 TST Result  |__|  





Appendix 3. Extra tables and figures (Chapter three) 
Table A.3.1 Strategy used for search database to identify studies for systematic 
review 
1. MEDLINE Results 
1 exp Latent Tuberculosis/ or exp Tuberculin Test/ or exp Tuberculin/ or exp 
Interferon-gamma Release Tests/ or (latent tuberculosis or tuberculin or 
Interferon Gamma Release or IGRA or QuantiFERON or t spot).ti,ab,kw. 
10021 
2 exp Health Personnel/ or exp Students, Medical/ or exp Students, Nursing/ or exp 
Community Health Workers/ or (Physician* or Doctor* or Nurs*).ti,ab,kw. or 
((Health* or Medica*) and (worker* or personnel* or professional* or staff* or 
student*)).ti,ab,kw. 
781514 
3 exp Infectious Disease Transmission, Professional-to-Patient/ or exp Infectious 
Disease Transmission, Patient-to-Professional/ or exp Occupational Exposure/ or 
exp Occupational Diseases/ or (nosocomial or Occupational Exposure* or 
Occupational Disease*).ti,ab,kw. 
109106 
4 2 or 3 857556 
9 1 and 4 1231 
10 limit 9 to (humans and yr="2005 -Current") 757 
2. EMBASE 
1 exp Latent Tuberculosis/ or exp Tuberculin Test/ or exp Tuberculin/ or exp 
interferon gamma release assay/ or (latent tuberculosis or tuberculin or 
Interferon Gamma Release or IGRA or QuantiFERON or t spot).ti,ab,kw. 
34784 
2 exp health care personnel/ or exp medical student/ or exp nursing student/ or 
(Physician* or Doctor* or Nurs*).ti,ab,kw. or ((Health* or Medica*) and (worker* 
or personnel* or professional* or staff* or student*)).ti,ab,kw. 
1979172 
3 exp Occupational Exposure/ or exp Occupational Diseases/ or (nosocomial or 
Occupational Exposure* or Occupational Disease*).ti,ab,kw. 
233519 
4 2 or 3 2162720 
5 1 and 4 3462 
10 limit 9 to (humans and yr="2005 -Current") 2079 
3. Web of Science 
1 TOPIC: (latent tuberculosis) OR TOPIC: (tuberculin 
test) OR TOPIC: (tuberculin) OR TOPIC:(interferon gamma release 
assay) OR TITLE: (latent tuberculosis) OR TITLE: (tuberculin test) 
OR TITLE: (tuberculin) OR TITLE: (interferon gamma release 
assay) OR TITLE: (IGRA) OR TITLE: (QuantiFERON) OR TITLE: (t spot) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC 
Timespan=2005-2017 
8520 
2 TOPIC: (health care worker*) OR TOPIC: (health 
personnel*) OR TOPIC: (physician*) OR TOPIC: (doctor*) OR  




student*) OR TITLE:(health care worker) OR TITLE: (health 
personnel*) OR TITLE: (physician*) 
OR TITLE: (doctor*)  OR TITLE: (nurs*)OR TITLE: (medical 
student*) OR TITLE: (nursing student*) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC 
Timespan=2005-2017 
3 TOPIC: (Infectious Disease Transmission, Professional-to-
Patient) OR TOPIC: (Infectious Disease Transmission, Patient-to-
Professional) OR TOPIC: (Occupational Exposure) ORTOPIC: (Occupational 
Diseases) OR TOPIC: (nosocomial exposure) OR TITLE: (Infectious Disease 
Transmission, Professional-to-Patient) OR TITLE: (Infectious Disease 
Transmission, Patient-to-Professional) OR TITLE: (Occupational 
Exposure) OR TITLE: (Occupational Diseases) OR TITLE: (nosocomial exposure) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC 
Timespan=2005-2017 
29572 
4 #3 OR #2 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC 
Timespan=2005-2017 
381969 
5 #4 AND #2 









Table A.3.2 Study quality assessment 
Items Quality Description/Definition 
1. Selection of the 
participants  
Sampling strategy?  
 High Census sampling (total population) or random sampling 
 Medium - 
 Low Convenience sampling (participants were recruited because they were the easiest to recruit for the study, it can be 
participants who admitted to the occupational department, medical check up, routine screening, etc.)  
 Not clear Not reported/not stated clearly 
2. Measurement of 
the exposure 
 High For cross-sectional study: Questionnaire verified by medical record/data provided by health facility manager 
For cohort study: diary or log book or questionnaire verified by medical record/data provided by health facility manager 
 Medium For cross-sectional study: Questionnaire not verified by medical record/data provided by health facility manager 
For cohort study: Questionnaire not verified by medical record/data provided by health facility manager and any serial 
questionnaire for serial testing  
 Low No questionnaire provided and data only based on job type, location, other proxies 
 Not clear Not reported/not stated clearly 
3. Measurement of 
the outcome 
 High Used the standard methods for TST or commercial assays for IGRA and definition based on the protocol or manufacturer 
 Medium Used the standard methods for TST or commercial assays for IGRA BUT definition not based on the protocol or 
manufacturer 
 Low - 
 Not clear Not reported/not stated clearly 
4.1. Response rate 
(for prevalence) 
 High More than 80% 
 Medium 50-80% 







Items Quality Description/Definition 
  Not clear Not reported/not stated clearly 
4.2. Retention rate 
(for incidence) 
 High More than 90% 
 Medium 50-90% 
 Low Less than 50% 
 Not clear Not reported/not stated clearly 
5. Results   High For cross-sectional study: reported prevalence with 95% CI and adjusted POR with 95% CI 
For cohort study: reported incidence with 95% CI and adjusted IRR/OR/RR/HR with 95% CI 
 Medium For cross-sectional study: reported prevalence with 95% CI and not adjusted (crude) POR with 95% CI 
For cohort study: reported incidence with 95% CI and not adjusted (crude) IRR/OR/RR/HR with 95% CI 
 Low - 
 Not clear Not reported/not stated clearly 
SUMMARY  High 
quality 
- Sampling strategy: census or random sampling 
AND 
- Participation rate: response rate >80% for prevalence or retention rate >90% for incidence 
 Medium 
quality 
- Sampling strategy: census or random sampling 
AND 




- Sampling strategy: convenience sampling or not clear 
AND/OR 







Table A.3.3 Quality assessment of cross-sectional studies 
Author Year Type of 
test 
1.  Selection of 
the participants 
2. Measurement of 
the exposure 
3. Measurement 






Agaya 2015 TST  High Medium High Medium High Medium 
Babayigit 2014 TST & IGRA Not clear Medium High Not clear Medium Low 
Bandyopadhyay 2010 IGRA  Not clear Not clear High Not clear Medium Low 
Belo 2017 TST High Medium High Medium High Medium 
Bozkanat 2016 TST & IGRA Not clear Medium High Not clear Medium Low 
Caglayan 2011 TST & IGRA Not clear Medium High Not clear Medium Low 
Christopher 2010 TST High High High High High High 
Da Costa 2006 TST Not clear Not clear High Not clear Medium Low 
Dagnew 2012 TST & IGRA Low Medium High High High Low 
de Oliveira 2007 TST High Medium High Not clear Medium Low 
de Souza 2014 TST & IGRA Not clear Medium High Not clear High Low 
Drobniewski 2007 IGRA High Medium High High High High 
El-Sokkary 2015 TST & IGRA High Medium High High Medium High 
Encinales 2010 TST Not clear Not clear High Not clear Medium Low 
Franco 2006 TST High Medium High High Medium High 
Gupta 2015 IGRA Low Medium High Not clear Medium Low 
He 2010 TST High Medium High High High High 
He 2012 TST & IGRA High Medium High Medium High Medium 
Hefzy 2016 TST & IGRA Not clear Medium High Not clear Medium Low 







Author Year Type of 
test 
1.  Selection of 
the participants 
2. Measurement of 
the exposure 
3. Measurement 






Kargi 2017 TST & IGRA Not clear Medium High Not clear Medium Low 
Khawcharoenporn 2009 TST High Medium High Medium High Medium 
Kwacharoenporn 2016 TST & IGRA Low High High High Medium Low 
Lien 2009 TST & IGRA High Medium High High High High 
Liu 2015 IGRA Not clear Not clear High Not clear Medium Low 
Lou 2015 TST High Medium High High High High 
Maciel 2007 TST High Medium High High Medium High 
Mirtskulava 2008 TST & IGRA Not clear Medium High Not clear High Low 
Mostafavi 2016 TST & IGRA High Medium High High Medium High 
Munisamy 2017 TST High Medium High High Medium High 
Nasehi 2017 TST High Medium High High High High 
Nikokar 2010 TST Not clear Medium High Not clear Medium Low 
Nikolova 2013 IGRA Not clear Not clear High Not clear Medium Low 
Nonghanphithak 2016 IGRA Not clear Medium High Not clear High Low 
Ozdemir 2006 TST Not clear Not clear High Low Medium Low 
Ozdemir 2007 TST & IGRA High Medium High Medium High Medium 
Ozsoy 2010 TST Not clear Not clear High Not clear Medium Low 
Powell 2011 TST High Medium High Medium High Medium 
Rafiza 2011 TST & IGRA High Medium High High High High 
Ratnatunga 2015 TST & IGRA High Medium High Medium Medium Medium 







Author Year Type of 
test 
1.  Selection of 
the participants 
2. Measurement of 
the exposure 
3. Measurement 






Rogerio 2013 TST High Medium High High Medium High 
Rogerio 2015 TST High Medium High High High High 
Rutanga 2015 TST High Medium High Medium High Medium 
Salmanzadeh 2016 TST & IGRA Not clear Medium High Not clear Medium Low 
Sawhney 2015 TST Not clear Not clear High Not clear Medium Low 
Severo 2011 TST High Medium High High Medium High 
Sharifi-Mood 2006 TST Not clear Not clear High Not clear Not clear Low 
Siddiqi 2012 IGRA Not clear Not clear High Not clear Medium Low 
Taheri 2013 TST Not clear High High Not clear Medium Low 
Talebi-Taher 2011 TST & IGRA Not clear Medium High Not clear Medium Low 
Thuong 2016 IGRA Not clear Medium High Not clear High Low 
Topic 2009 TST & IGRA Low Not clear High Not clear Medium Low 
van Rie 2013 TST & IGRA Not clear Medium High Not clear High Low 
Wei 2013 TST & IGRA Low Medium High Not clear High Low 
Yalcin 2005 TST High Not clear High Medium Medium Medium 
Zhang 2013 IGRA High High High High High High 
Zhou 2014 TST High Medium High Medium High Medium 
Zhu 2014 IGRA Not clear Not clear High Not clear Medium Low 







Table A.3.4 Quality assessment of cohort studies 


































Adams 2015 TST 
& 
IGRA 
High Medium High Medium Medium Medium High Medium Medium 
Borroto 2011 TST High Medium High High Medium High Medium High Medium 
Calixto-Aguilar  2016 TST High Medium High Medium High Medium Medium Medium High 
Christopher 2011 TST High High High Reported in 
other paper 
Medium Reported in 
other paper 
High Reported in 
other paper 
Medium 
Chung-Delgado 2012 TST High High High Medium  High High High Medium High 
Corbett 2007 TST High High High High High Medium High High High 
da Costa 2009 TST Not clear Medium High Not clear  Not clear Not clear High Low Low 
de Miranda 2012 TST High High High High Low Medium Medium High Low 
Emadi-Koochak 2009 TST Not clear Low High Not clear Medium Not clear Medium Low Low 
Escombe 2010 IGRA High High High Not clear  Medium Medium Medium Low Medium 
Gonzalez 2011 TST Not clear Low High NA Medium Low Low NA Low 
Gutierrez 2012 TST High Medium High Medium Medium Medium Medium Medium Medium 
He 2015 TST 
& 
IGRA 
High Medium High High Medium High High High Medium 
Hohmuth 2006 TST High Not clear High High Low Medium Medium High Low 
Kiertiburanakul 2012 TST High Not clear High Not clear  Medium High Medium Low Medium 
Li-fan 2013 TST 
& 
IGRA 
High Medium High High No data on 
incidence 
High No data on 
incidence 
High NA 









































McCarthy 2015 TST 
& 
IGRA 
High High High Reported in 
other paper 
Medium Reported in 
other paper 
High Reported in 
other paper 
Medium 
Moreira 2010 TST High High High High High Medium Medium High High 
Pai 2006 TST 
& 
IGRA 
High Not clear High Reported in 
other paper 
Medium Reported in 
other paper 
Medium Reported in 
other paper 
Medium 
Perez-Lu 2013 TST Low Medium High High High Medium High Low Low 
Rabahi 2007 TST High Medium High Not clear  Medium Medium Medium Low Medium 
Rafiza 2015 IGRA High Medium High Reported in 
other paper 
Medium Reported in 
other paper 
High Reported in 
other paper 
Medium 
Sawanyawisuth 2012 TST Low Low High Not clear  Low Not clear High Low Low 
Whitaker 2013 TST 
& 
IGRA 
Low Medium High Not clear  Medium High High Low Low 
Zwerling 2013 IGRA Not clear High High Not clear Not clear Medium High Low Low 







Table A.3.5 Characteristics of studies included  in the systematic review 






































All types of HCWs TST 898 P: Medium 










All types of HCWs 
TST & 
IGRA 













IGRA 50 P: Low 






Hospital All types of HCWs TST 209 P: Medium 
Borroto, 2011 Cuba 2007 7.8 
Cohort, 
prospective 
Hospital All types of HCWs TST 350 
P: High,  
I: Medium 
Bozkanat, 2016 Turkey 2008 29 
Cross-
sectional 
TB Hospital All types of HCWs 
TST & 
IGRA 
34 P: Low 
Caglayan, 2011 Turkey 2005 33 
Cross-
sectional 
TB Hospital All types of HCWs 
TST & 
IGRA 










Medical students TST 548 
P: Medium, 
I: High 
Christopher, 2010  India 2007 268 
Cross-
sectional 































Hospital Nursing students TST 436 













Medical students TST 547 
P:  Medium, 
I: High 






Hospital Nursing students TST 351 
P: High,  
I: High 





All types of HCWs TST 31 P: Low 






Hospital All types of HCWs TST Not clear P: -, I: Low 














107 P: Low 






Clinics All types of HCWs TST 251 
P: High,  
I: Low 





All types of HCWs TST 194 P: Low 






Health centers All types of HCWs 
TST & 
IGRA 
632 P: Low 
































































P: Low,  
I: Low 






TB hospital All types of HCWs TST 150 P: Low 






Hospital All types of HCWs IGRA 70 
P: Low,  
I: Medium 


















All types of HCWs 
and students 
TST 275 P: -, I: Low 
















All types of HCWs TST 183 
P: Medium, 
I: Medium 




with TB clinic 
All types of HCWs TST 2153 P: High 
He, 2012 China 2010 77 
Cross-
sectional 
Hospital All types of HCWs 
TST  & 
IGRA 







































P: High,  
I: Medium 












44 P: Low 







All types of HCSs: 
nursing, medical, 
pharmacy and lab 
technician students 
TST 559 
P: High,  
I: Low 





All types of HCWs TST 449 P: High 








All types of HCWs 
TST & 
IGRA 









Hospital Medical students TST 166 P: Medium 
Khawcharoenporn, 
2016 





All types of HCWs 
TST & 
IGRA 










Nurses, nursing and 
medical students 
TST 1438 
P: Low,  
I: Medium 










P: High,  
I: NA 






All types of HCWs 
TST & 
IGRA 











at the study 
year a 















All types of HCWs IGRA 115 P: Low 






Hospital Nurses TST 128 
P: Medium, 
I: Medium 
Lou, 2015 Uganda 2009 213 Cross-sectional Hospital 





TST 288 P: High 
Maciel, 2007 Brazil 
1999-
2002 
50 Cross-sectional Hospital 
Nursing and 
medical students 
TST 605 P: High 

















Georgia 2006 161 Cross-sectional 
Health care 
facilities which 
part of the NTP  
All types of HCWs 
TST & 
IGRA 
265 P: Low 











P: High,  
I: High 









177 P: High 
Munisamy, 2017 Malaysia 2014 92 Cross-sectional Hospital All types of HCWs TST 399 P: High 
Nasehi, 2017 Iran 2013 18 Cross-sectional 
Laboratory 
facility and Low 
risk HCWs 































Hospital All types of HCWs TST 185 P: Low 
Nikolova, 2013 Bulgaria 2009 45 
Cross-
sectional 











All types of HCWs IGRA 112 P: Low 
Ozdemir, 2006 Turkey 2005 33 
Cross-
sectional 
Hospital All types of HCWs TST 39 P: Low 





All types of HCWs 
TST & 
IGRA 
76 P: Medium 






Autopsy facility All types of HCWs TST 31 P: Low 












P: -,  
I: Medium 



















P: Low, I: 
Low 
Powell, 2011 Viet Nam 2009 159 
Cross-
sectional 
Hospital All types of HCWs TST 956 P: Medium 






Hospital All types of HCWs TST 437 
























Rafiza, 2011 Malaysia 
2008-
2009 
73 Cross-sectional Hospital 




953 P: High 







All types of 
HCWs 
IGRA 954 




Sri Lanka 2013 66 Cross-sectional Chest clinic 




36 P: Medium 


























43 Cross-sectional Primary care unit 
Community 
health workers 
TST 307 P: High 
Rutanga, 2015 Rwanda 2010 88 Cross-sectional 
Hospital, Health 
centres 
All types of 
HCWs 
TST 1023 P: Medium 
Salmanzadeh, 
2016 
Iran Not stated 14 Cross-sectional General Hospital Nurses  
TST & 
IGRA 










All types of 
HCWs 
TST 1025 P: -, I: Low 
Sawhney, 2015 India 
2011-
2013 
234 Cross-sectional General Hospital 
All types of 
HCWs 
TST 100 P: Low 
Severo, 2011 Brazil 
2009-
2010 












at the study 
year a 











Iran 2005 16 
Cross-
sectional 
Hospital All types of HCWs TST 100 P: Low 





All types of HCWs IGRA 31 P: Low 








Lab personnel & 
radiographers 











All types of HCWs 
TST & 
IGRA 
200 P: Low 







and TB centers 
All types of HCWs IGRA 109 P: Low 





All types of HCWs 
TST & 
IGRA 
54 P: Low 









199 P: Low 





All types of HCWs 
TST & 
IGRA 
210 P: Low 










P: Low,  
I: Low 






Not stated All types of HCWs TST 89 P: Medium 
Zhang, 2013 China 2012 74 
Cross-
sectional 




All types of HCWs IGRA 755 P: High 
Zhou, 2014 China 2011 76 
Cross-
sectional 












at the study 
year a 



















All types of HCWs IGRA 20 P: Low 










P: Low,  
P: Low 
a All figures were taken for the year of the study or the average if several years from WHO estimation for incidence of all forms of TB, in general population, in the 
country per 100,000 population per year. If the study years were not reported, we use year when the study published 
HCSs = health care students, HCWs = health care workers, I = Incidence, IGRA = interferon-gamma release assay, NTP = National Tuberculosis Programme, P = 







Table A.3.6 Prevalence of LTBI measured by TST 






TST positivity rate Proportion of BCG 







% 95% CI 
Adams, 2015, South Africa All types of HCWs 
10 mm in non HIV and 5 
mm in HIV infected 
147 123 83.7 76.9-88.8 98 
Agaya, 2015, Kenya All types of HCWs 10 mm 898 534 59.5 56.2-62.6 - 
Babayigit, 2014, Turkey All types of HCWs 15 mm 96 32 33.3 24.0-43.7 100 
Belo, 2017, Mozambique All types of HCWs 10 mm 209 72 34.4 28.0-41.3 72.7 
Borroto, 2011, Cuba All types of HCWs 10 mm 350 54 15.4 11.9-19.5 76.3 
Bozkanat, 2016, Turkey All types of HCWs 15 mm 34 20 58.8 40.7-75.4 94.1 
Caglayan, 2011, Turkey All types of HCWs 15 mm 78 57 73.1 61.8-82.5 - 
Calixto-Aguilar, 2016, Cuba Medical students 10 mm 548 37 6.7 47.9-91.9 - 
Christopher, 2010, India Nursing students 10 mm 436 219 50.2 45.4-55.0 76.9 
Chung-Delgado, 2012, Peru Medical students 10 mm 547 79 14.4 11.5-17.4 - 
Corbett, 2007, Zimbabwe Nursing students 10 mm 351 183 52.1 46.9-57.3 - 
Da Costa, 2006, Brazil All types of HCWs 10 mm 31 13 41.9 24.5-60.9 - 




10 mm 107 50 46.7 37.0-56.6 44.9 
de Miranda, 2012, Brazil All types of HCWs 10 mm 251 129 51.4 45.2-57.7 40.2 
de Oliveira, 2007, Brazil All types of HCWs 10 mm 194 75 38.7 31.8-45.9 - 













TST positivity rate Proportion of BCG 







% 95% CI 
de Souza, 2014, Brazil All types of HCWs 10 mm 632 252 39.9 36.0-43.8 - 
El-Sokkary, 2015, Egypt 
Nurses and Lab 
personnel 






10 mm 256 17 7 4.2-10.4 - 
Encinales, 2010, Colombia All types of HCWs 5 mm 150 77 51.3 43.0-59.6 90 
Franco, 2006, Brazil Nurses 10 mm 169 101 59.8 51.9-67.2 80 
Gutierrez, 2012, Cuba All types of HCWs 10 mm 183 93 50.8 43.4-58.2 - 
He, 2010, China All types of HCWs 10 mm 2153 1106 51.4 49.2-53.5 36.1 
He, 2012, China All types of HCWs 5 mm 924 637 69 65.8-71.9 34 
He, 2012, China All types of HCWs 10 mm 924 499 54 50.7-57.3 - 
He, 2015, China Village doctor 10 mm 875 171 19.5 17.1-22.3 89 
Hefzy, 2016, Egypt 
Physicians, nurse, 
and housekeeper 
10 mm 44 6 13.6 5.2-27.4 100 
Hohmuth, 2006, Peru All types of HCSs 10 mm 559 117 20.9 17.8-24.5 - 
Islam, 2014, Bangladesh All types of HCWs 10 mm 449 242 53.9 49.2-58.6 82 
Kargi, 2017, Turkey All types of HCWs 10 mm 100 42 42 32.2-52.3 42 
Khawcharoenporn, 2009, 
Thailand 


















TST positivity rate Proportion of BCG 
















All types of HCWs 13 mm 260 114 43.8 37.7-50.1 78 
Li-fan, 2013, China All types of HCWs 10 mm 96 53 55.2 45.3-64.8 - 
Li-fan, 2013, China All types of HCWs 5 mm 96 70 72.9 63.3-80.8 - 
Lien, 2009, Viet Nam All types of HCWs 10 mm 288 176 61.1 55.2-66.8 95 
Lien, 2009, Viet Nam All types of HCWs 10 mm 288 191 66.3 60.5-71.8 95 
Lopes, 2008, Brazil Nurses 10 mm 128 89 69.5 60.7-77.2 - 
Lou, 2015, Uganda All types of HCSs 10 mm 288 130 45.1 39.3-51.1 71.2 
Maciel, 2007, Brazil 
Nursing and 
medical students 
10 mm 605 114 18.8 15.8-22.2 98.7 
Mirtskulava, 2008, 
Georgia 
All types of HCWs 10 mm 265 177 66.8 60.8-72.4 92 
Moreira, 2010, Brazil 
Community health 
workers 
10 mm 72 11 15.3 8.8-25.3 - 
Mostafavi, 2016, Iran Lab personnel 10 mm 177 25 14.1 9.4-20.1 89.8 
Munisamy, 2017, Malaysia All types of HCWs 15 mm 399 184 46.1 41.1-51.1 - 
Nasehi, 2017, Iran Lab personnel 10 mm 689 168 24.4 21.3-27.7 - 
Nasehi, 2017, Iran Low risk HCWs 10 mm 317 47 14.8 11.3-19.2 - 







Study (Author, Year, 
Country) 
Type of participants 
TST Cut-off/ 
induration size 
TST positivity rate Proportion of BCG 






% 95% CI 
Ozdemir, 2006, Turkey All types of HCWs 15 mm 39 28 71.8 55.1-84.9 100 
Ozdemir, 2007, Turkey All types of HCWs 15 mm 76 41 53.9 42.1-65.5 - 
Ozsoy, 2010, Turkey All types of HCWs 
15 mm with BCG 
scar and 10 mm 
with no BCG scar 
31 26 83.9 66.3-94.5 93.5 
Perez-Lu, 2013, Peru All types of HCSs 10 mm 4842 49 1 0.6-1.3 70.9 
Powell, 2011, Viet nam All types of HCWs 10 mm 956 380 39.7 36.6-42.9 31 
Rabahi, 2007, Brazil All types of HCWs 10 mm 437 211 48.3 43.6-53.0 - 
Rafiza, 2011, Malaysia All types of HCWs 10 mm 95 56 58.9 48.4-68.9 99.7 
Rafiza, 2011, Malaysia All types of HCWs 15 mm 95 16 16.8 9.9-25.9 99.7 
Ratnatunga, 2015, Sri 
Lanka 
All types of HCWs 10 mm 36 17 47.2 30.4-64.5 - 
Rodrigues, 2009, Brazil 
Community health 
workers 
10 mm 30 8 26.7 12.3-45.9 93.3 
Rogerio, 2013, Brazil 
Medical and Nursing 
students 
10 mm 225 54 24 18.6-30.1 97.8 
Rogerio, 2015, Brazil 
Community health 
workers 
10 mm 307 116 37.3 31.0-42.0 89.2 
Rogerio, 2015, Brazil 
Community health 
workers 
5 mm 307 180 57.8 52.0-63.0 - 
Rutanga, 2015, Rwanda All types of HCWs 10 mm 1023 635 62.1 59.0-65.1 - 
Salmanzadeh, 2016, 
Iran 
Nurses  Not stated 87 31 35.6 25.6-46.6 - 













TST positivity rate Proportion of BCG 






% 95% CI 
Severo, 2011, Brazil Nurses  10 mm 55 26 47.3 33.7-61.2 98.2 
Sharifi-Mood, 2006, Iran All types of HCWs Not stated 100 55 55 44.7-64.9 - 
Taheri, 2013, Iran 
Lab personnel & 
radiographers 
10 mm 89 7 7.9 5.52-19.7 100 
Talebi-Taher, 2011, Iran All types of HCWs 10 mm 200 105 52.5 45.3-59.6 100 
Topic, 2009, Croatia All types of HCWs 10 mm 54 34 62.9 48.7-75.7 100 
Topic, 2009, Croatia All types of HCWs 5 mm 54 45 83.3 70.7-92.1 100 
Topic, 2009, Croatia All types of HCWs 15 mm 54 19 35.2  22.7-49.4 100 
van Rie, 2013, South 
Africa 
HCWs  10 mm 120 68 56.7 47.3-65.7 - 
van Rie, 2013, South 
Africa 
Medical students 10 mm 79 21 26.6 17.3-27.7 - 
Wei, 2013, China All types of HCWs 10 mm 85 83 97.6 91.7-99.7 94.3 
Whitaker, 2013, Georgia 
All types of HCWs 
and medical 
students 
10 mm 308 193 62.7 57.1-67.9 - 
Yalcin, 2005, Turkey All types of HCWs 10 mm 89 21 23.6 15.2-33.8 - 
Zhou, 2014, China All types of HCWs 10 mm 529 232 43.8 39.6-48.2 66.7 








Table A.3.7 Prevalence of LTBI in HCWs measured by IGRA 




IGRA positivity rate Proportion of 
BCG scar or 






% 95% CI 
Adams, 2015, South Africa All types of HCWs QFT-GIT 335 231 68.9 63.7-73.9 92 
Adams, 2015, South Africa All types of HCWs T-SPOT.TB 317 198 62.5 56.9-67.8 - 
Babayigit, 2014, Turkey All types of HCWs QFT-Gold 96 19 19.8 12.4-29.2 100 
Bandyopadhyay, 2010, India 
Nursing and medical 
students 
QFT-Gold 50 0 0 - - 
Bozkanat, 2016, Turkey All types of HCWs QFT-Gold 34 7 20.6 8.7-37.9 94.1 
Caglayan, 2011, Turkey All types of HCWs QFT-Gold 78 34 43.6 32.4-55.3 - 
Dagnew, 2012, Ethiopia 
Medical and 
paramedical students 
QFT-Gold 107 47 43.9 34.3-53.9 44.9 
de Souza, 2014, Brazil All types of HCWs QFT-Gold 632 252 27.2 23.8-30.9 86.4 
Drobniewski, 2007, Russia All type of HCWs  QFT-Gold 262 107 40.8 35.0-46.9  81.3 
Drobniewski, 2007, Russia Medical students QFT-Gold 238 24 10.1 6.7-14.4 87.8 
El-Sokkary, 2015, Egypt 
Nurses and Lab 
personnel 
QFT-Gold 132 38 28.8 21.2-37.3 92.4 
Escombe, 2010, Peru All types of HCWs QFT-GIT 70 39 56 43.3-67.6 - 
Gupta, 2015, India All types of HCWs T-SPOT 40 18 45 29.3-61.5 - 
He, 2012, China All types of HCWs QFT-Gold 999 679 68 64.9-70.9 34 
He, 2015, China Village doctor QFT-GIT 866 398 45.9 42.6-49.3 36.4 
Hefzy, 2016, Egypt 
Physicians, nurses, 
and housekeeper 







Study (Author, Year, Country) Type of participants IGRA used IGRA positivity rate 
Proportion of 
BCG scar or 
history of BCG 
vaccination (%) 
Kargi, 2017, Turkey All types of HCWs QFT-Gold 100 23 23 15.2-32.5 42 
Khawcharoenporn, 2016, Thailand All types of HCWs QFT-Gold 260 52 20 15.3-25.4 78 
Li-fan, 2013, China All types of HCWs T-SPOT.TB 101 29 28.7 19.9-37.5 98 
Lien, 2009, Viet Nam All types of HCWs QFT-Gold 300 142 47.3 41.6-53.2 95 
Liu, 2015, China All types of HCWs QFT-Gold 115 48 41.7 32.6-51.3 - 
Mirtskulava, 2008, Georgia All types of HCWs QFT-Gold 265 159 60 53.8-65.9 92 
Mostafavi, 2016, Iran Lab personnel QFT-Gold 177 33 18.6 13.2-25.2 89.8 
Nikolova, 2013, Bulgaria All types of HCWs QFT-Gold 21 10 47.6 25.7-70.2 100 
Nonghanphithak, 2016, Thailand All types of HCWs QFT-Gold 112 21 18.8 11.5-25.9 65.2 
Ozdemir, 2007, Turkey All types of HCWs QFT-Gold 76 65 85.5 75.6-92.5 - 
Rafiza, 2011, Malaysia All types of HCWs QFT-Gold 953 101 10.6 8.6-12.6 99.7 
Ratnatunga, 2015, Sri Lanka All types of HCWs T-SPOT 38 6 15.8 6.0-31.2 - 
Salmanzadeh, 2016, Iran Nurses  QFT-Gold 87 27 31 21.5-41.9 - 
Siddiqi, 2012, Philippines All types of HCWs QFT-Gold 31 15 48.4 30.2-66.9 - 
Talebi-Taher, 2011, Iran All types of HCWs QFT-Gold 200 17 8.5 5.0-13.2 100 
Thuong, 2016, Vietnam All types of HCWs QFT-Gold 109 41 37.6 28.5-47.4 49.5 
Topic, 2009, Croatia All types of HCWs QFT-Gold 54 17 31.5 19.5-45.6 100 
van Rie, 2013, South Africa All types of HCWs QFT-Gold 120 83 69.2  60.0-72.3 - 







Study (Author, Year, Country) 
Type of 
participants 
IGRA used IGRA positivity rate 
Proportion of 
BCG scar or 
history of BCG 
vaccination (%) 
Wei, 2013, China All types of HCWs QFT-Gold 210 161 76.7 70.4-82.2 94.3 
Whitaker, 2013, Georgia 
All types of HCWs 
and medical students 
QFT-GIT 319 146 45.8 40.2-51.4 89 
Zhang, 2013, China All types of HCWs T-SPOT 755 254 33.6 30.2-37.0 100 
Zhu, 2014, China All types of HCWs T-SPOT 20 6 30 11.9-54.3 - 
Zwerling, 2013, India 
Nursing and medical 
students 
QFT-GIT 226 64 28.3 22.5-34.7 75.6 
BCG = Bacille Calmette-Guerin, CI = confidence interval, HCWs = health care workers, IGRA = interferon-gamma release assay, QFT = Quantiferon, QFT-GIT = 







Table A.3.8 Prevalence of LTBI measured by TST and by IGRA (Stratified by type of participants and TB incidence per 100,000) 
Study description 
Prevalence of LTBI - all studies Prevalence of LTBI - high and medium quality studies 





















Prevalence of LTBI measured by tuberculin skin test 
Health care workers 
> 300 4 51-66 59 41-77 3 47-72 59 36-82 
200-299 3 37-62 48 24-72 1 - 54 44-49 
100-199 4 43-66 54 39-69 2 46-60 46 44-49 
25-99 29 46-62 53 46-61 18 44-59 48 40-56 
0-24 13 15-53 36 26-47 5 15-51 32 19-46 
Physicians 
> 300 0 - - - 0 - - - 
200-299 1 - 58 39-74 1 - 58 39-74 
100-199 1 - 67 54-77 0 - - - 
25-99 4 40-56 49 11-87 3 33-63 49 2-95 
0-24 5 41-48 40 29-52 2 30-45 31 22-40 
Nurses 
> 300 1 - 35 25-47 1 - 35 25-47 
200-299 2 59-73 65 59-70 1 - 52 45-65 
100-199 1 - 68 57-77 0 - - - 
25-99 9 49-67 60 53-66 5 60-70 63 56-70 








Prevalence of LTBI - all studies Prevalence of LTBI - high and medium quality studies 





















Prevalence of LTBI measured by tuberculin skin test 
Allied health professionals 
> 300 2 38-47 37 29-44 1 - 34 26-42 
200-299 2 61-64 64 59-69 1 - 59 47-70 
100-199 1 - 66 47-80 0 - - - 
25-99 8 31-64 50 39-62 8 29-64 46 30-61 
0-24 8 22-44 31 21-41 5 14-40 25 14-36 
General services 
> 300 0 - - - 0 - - - 
200-299 1 - 53 45-61 1 - 53 45-61 
100-199 0 - - - 0 - - - 
25-99 3 40-54 50 40-60 2 52-55 55 50-60 
0-24 3 33-53 39 10-69 2 24-43 23 17-28 
Health care students 
> 300 2 33-46 46 42-51 1 - 52 47-57 
200-299 5 47-65 56 46-67 3 48-62 56 41-72 
100-199 4 5-16 11 2-19 3 11-18 14 6-22 
25-99 2 20-23 20 17-23 2 20-23 20 17-23 








Prevalence of LTBI - all studies Prevalence of LTBI - high and medium quality studies 





















Prevalence of LTBI measured by interferon-gamma release assay 
Health care workers 
> 300 3 59-69 66 58-74 1 - 69 64-74 
200-299 1 - 45 31-60 0 - - - 
100-199 6 24-54 40 25-55 1 - 47 42-53 
25-99 16 28-46 41 29-54 8 25-51 41 22-60 
0-24 7 14-26 20 13-26 2 21-26 22 118-27 
Physicians 
> 300 0 - - - 0 - - - 
200-299 0 - - - 0 - - - 
100-199 4 42-58 45  18-71 1 - 58  46-69 
25-99 6 27-44 40  23-56 5 34-46 45  29-61 
0-24 3 12-22 15  1-29 0 - - - 
Nurses 
> 300 0 - - - 0 - - - 
200-299 0 - - - 0 - - - 
100-199 5 39-46 41  22-60 1 - 46  36-56 
25-99 8 23-41 37  16-57 5 32-33 35  12-58 








Prevalence of LTBI - all studies Prevalence of LTBI - high and medium quality studies 





















Prevalence of LTBI measured by interferon-gamma release assay 
Allied health professionals 
> 300 1 - 67  48-81 0 - - - 
200-299 1 - 62  36-82 0 - - - 
100-199 5 23-38 33  15-52 1 - 58  49-68 
25-99 9 25-35 32  17-47 6 12-55 34  11-56 
0-24 5 15-19 16 12-21 2 20-23 19  14-25 
General services 
> 300 0 - - - 0 - - - 
200-299 0 - - - 0 - - - 
100-199 0 - - - 0 - - - 
25-99 1 - 74  66-80 1 - 74  66-80 
0-24 1 - 14  6-31 0 - - - 
Health care students 
> 300 1 - 15  9-25 0 - - - 
200-299 2 32-40 33  28-38 0 - - - 
100-199 0 - - - 0 - - - 
25-99 1 - 10  7-15 1 - 10  7-15 







Table A.3.9 Risk factors associated with prevalence of LTBI measured by TST and IGRA 




Occupational Non Occupational 
Risk factors 
assessed 
Significant risk factors in 
multivariate analysis; 
Adjusted OR (95% CI)  




OR (95% CI)  
Risk Factors for Positive TST 
Agaya, 2015 All types of 
HCWs 
898 Active TB contact, 
Facility type, 
Duration worked in 
health care, Job type, 
Job location 
Active TB contact (ref no): 
yes; 1.8 (1.3-2.4) 
Duration worked in health 
care (ref <2 y): >10 y; 2.3 
(1.3-4.0) 
 
Sex, HIV status, Number 
of persons per room in 
household 
Male sex; 1.8 (1.3-2.4) 











Not significant Age, Sex, Perceived health 
status, 
Immunosuppression, 
People living at same 
house (> 6), Contact with 




yes; 5.82 (1.84-18.39) 
Borroto All types of 
HCWs 
350 Occupation at risk, 
Contact with TB 
patient 
Contact with TB patient; 
Prevalence risk ratio 1.72 
(1.1-2.8)a  











Occupational Non Occupational 
Risk factors 
assessed 
Significant risk factors in 
multivariate analysis; 
Adjusted OR (95% CI)  
Risk factors assessed Significant risk 
factors in 
multivariate analysis; 
Adjusted OR (95% CI)  
Christopher, 2010 Nursing 
students 
436 Worked in health 
care prior to current 
training programme, 
time (years) spent in 
health care work 
after entry, Worked 
together with a TB 
patients (previously 
or during current 
training, 
Conversational 
distance contact with 
a pulmonary TB 
patient, Number of 
days spent working 
in medium or high 
risk ward, Patient-
days caring for active 
TB 
Time (years) spent in 
health care work after 
entry; 1.19 (1.10-1.28) 
Age (years), Age at entry 
(years) (Age-years in 
health care), Sex, Body 
mass index, Highest 
education achieved, 
Current nursing course, 
Average household 
monthly income, BCG scar, 
Past history of TST, 






547 Not determined Not determined Sex, Age, Year of 
university entry, Previous 
TB, Smoking, Alcohol 
consumption, BMI 
Year of university 
entry: 2009-2010; 0.47 
(0.29-0.77) 
Previous TB: yes; 12.47 
(2.02-77.03) 
Dagnew, 2012 Medical, 
Paramedical 
students, 
107 Department, Year of 
study 
Not significant Age, Place of birth, 
Religion, Khat 
consumption, BCG scar, 
BMI  
Age; 1.6 (1.11-2.20) 












Occupational Non Occupational 
Risk factors 
assessed 
Significant risk factors in 
multivariate analysis; 
Adjusted OR (95% CI)  




OR (95% CI)  
de Oliveira, 2007 All types of 
HCWs 
194 Not determined Not determined Gender, Age, Drinker, 
Smoker 
Smoker: Yes; RR 1.72 
(1.20-2.45) a 
de Souza, 2014 All types of 
HCWs, 
632 Professional category, 
Work only at primary 
health care, Years 
served in health care 
profession at primary 
health care 
Years served in health care 
profession at primary 
health care (ref < 5): > 5; 
1.66 (1.12-2.47) 
Gender, Age, Presence of 
BCG scar, Contact with a 
household member with 
TB, Alcohol abuse, Prior 
TST, Smoker, Comorbidity 
Age group (ref 19-30 
y): 36-40 y; 41-45 y; 
2.11 (1.13-3.93), 46-
64 y; 2.02 (1.14-3.58) 
Presence of BCG scar: 
yes; 1.78 (1.09-2.90) 
He, 2010 All types of 
HCWs 
2153 Position, Job location, 
Duration of 
employment (years), 
Inpatient ward, Size of 
clinic (no. of staff), 
Level 
Job location (ref 
administrative/logistic): TB 
outpatient clinic; 1.9 (1.4-
2.6), Supervision and 
monitoring; 1.6 (1.2-2.3), X-
ray department; 1.8 (1.1-
2.9) 
Duration of employment 
(ref < 1 y): 5-9 y; 2.3 (1.6-
3.1), > 10 y; 3.0 (2.2-4.1) 
Inpatient ward: yes; 2.3 
(1.9-2.9) 
Gender and smoking, Age 
group, BCG scar, Income, 
Education,  
Age (ref 18-29 y): 30-
39 y; 1.6 (1.2-2.1), 
40-49 y; 1.8 (1.3-2.5), 
> 50 y; 2.6 (1.7-4.0) 












Occupational Non Occupational 
Risk factors assessed Significant risk factors 
in multivariate analysis; 
Adjusted OR (95% CI)  
Risk factors assessed Significant risk 
factors in 
multivariate 
analysis; Adjusted OR 
(95% CI)  
He, 2012 All types of 
HCWs 
924 Hospital, Job category, 
Years in health care, 
Cared for TB patient in 
last year, Average daily 
time in patient last 
year, Ever had co-
worker with TB, Aware 




Years in health care (ref < 
1):  > 15; 3.43 (2.08-5.66) 
Cared for TB patient in 
last year: yes; 1.72 (1.06-
2.78) 
Age, Sex, Education, Self-
report having BCG, 
Household contact with 
TB, Smoking status, 
Density of household 
Male sex; 1.84 (1.25-
2.70) 
Household contact 
with TB: yes; 1.92 
(1.01-3.65) 
He, 2015 Village doctor 875 Working duration, 
Minutes spend on 
diagnosing one patient, 
Whether referred 
suspected TB patient in 
recent three years, 
Density of clinical areas 
(m2 per staff)  
Not significant Gender, Age, Education, 
BCG scar, Smoking 
status, Average yearly 
income, Density of 
household 
Male gender: NS 
BCG scar: yes; 1.45 
(1.03-2.04) 
Smoking status: yes; 
1.67 (1.17-2.44) 
Kargi, 2017 All types of 
HCWs 
100 Occupation, Duration of 
work 
Not determined Age, gender, BCG 
positivity 





166 History of TB exposure Not significant BCG scar, Age, Sex BCG scar: yes; 
associated with an 
initial TST 1.97 (1.05-
3.66), associated with 












Occupational Non Occupational 
Risk factors assessed Significant risk factors in 
multivariate analysis; 
Adjusted OR (95% CI)  
Risk factors assessed Significant risk factors 
in multivariate 
analysis; Adjusted OR 









1438 Type of Health care 
personnel 
Not significant Age, Gender, Positive 
BCG scar, Year of TST 
Age; NS 
Male gender; 1.82 (1.33-
2.49) 
Positive BCG scar; 1.46 
(1.12-1.91) 
Year of TST; 0.76 (0.69-
0.84) 
Li-fan, 2013 All types of 
HCWs 
96 Job category, Years 
served in the health 
care profession, 
Exposure to sputum 
smear positive TB 
patient 
Not significant Age, gender, BCG 
vaccine scar 
Not significant 
Lopes, 2008 Nurses 128 Length of professional 
activity, Last 
professional contact 
with pulmonary TB 
patients 
Length of professional 
activity (ref < 5 y): > 5 y; 6.3 
(1.5-26.3) 
Last professional contact 
with pulmonary TB patients 
(ref < 2 y): > 2 y; 11.3 (1.2-
106.3)  
Not determined Not determined 
Lou, 2015 All types of 
HCSs 
288 Contact with a case of 
TB 
Contact with a case of TB: 
yes; 1.86 (P value 0.022) 
Age, Sex, Course, 
Student 
categorization, History 
of smoking, History of 
alcohol intake, HIV 
status, BCG 
vaccination scar, 
Knowledge of TB 
transmission 
Male sex; 2.23 (P value 
0.004) 
Course (ref bachelor's 
degrees in Medicine and 
Surgery): Dental 












Occupational Non Occupational 
Risk factors assessed Significant risk factors in 
multivariate analysis; 
Adjusted OR (95% CI)  




OR (95% CI)  
Mirtskulava, 
2008 
All types of 
HCWs 
265 Occupation, Length of 
employment as a HCW, 
Has routine direct 
contact with TB 
patients 
Length of employment as a 
HCW (ref < 5 y): > 5 y; 5.09 
(2.77-9.33) 
Age, Gender, Education 
level, Positive history of 
BCG 
Not significant 
Mostafavi, 2016 Lab personnel 177 Job group, History of 
work (year), Contact 
with TB patients 
Not significant Sex, Age, Education level, 
BCG vaccination 
Not significant 
Munisamy, 2017 All types of 
HCWs 
399 Occupation category, 
Time worked in 
current position, Total 
time working in health 
care, Current 
workplace 
Occupation category (ref 
management): health 
professional; 2.07 (1.34-
3.55), allied health staff; 2.03 
(1.02-2.78), support staff; 
2.21 (1.19-3.89) 
Time worked in current 
position (ref < 5 y): 5-9 y; 
1.77 (1.04-4.67), > 10 y: 1.59 
(1.12-3.93) 
Current workplace (ref non-
clinical areas): outpatient 
areas; 1.51 (1.07-4.46), 
inpatient wards 1.67 (1.10-
4.32), intensive care 
unit/operation theater 1.36 
(1.09-3.94) a  
Age, Ethnicity, Gender, 
Marital status, Chronic 
disease, Diabetes 
mellitus, Hypertension, 
Ischemic heart disease, 
Dyslipidemia, Lung 
disease 
Chronic disease: any 
(one or more); 1.19 
(1.03-2.14) 
Diabetes mellitus: 











Occupational Non Occupational 
Risk factors assessed Significant risk factors in 
multivariate analysis; 
Adjusted OR (95% CI)  




OR (95% CI)  
Nasehi, 2017 Lab personnel 
and low risk 
HCWs 
1006 Group, Length of 
employment, Contact with 
TB patients 
Group (ref low risk HCWs): 
TB lab staff; 2.06 (1.35-3.17) 
Sex, Age, Education 
level, History of 
smoking, Chronic 
disease 






Chronic disease: yes; 
1.82 (1.13-2.95) 
Powell, 2011 All types of 
HCWs 
956 Department assignment, 
Work setting, Job 
assignment 
Not significant Age, Sex Age (ref 20-28 y): 
29-40 y; 1.9 (1.3-
2.9), 41-45 y: 2.2 
(1.5-3.3), > 45 y; 2.1 
(1.3-3.1) 
Male sex; 1.5 (1.1-
2.1) 
Rogerio, 2015 Community 
health workers 
307 Working in a primary care 
unit that had 
implemented a TB control 
programme, Media 
duration of employment, 
Working in facility with 
high risk of TB, Frequency 
of using personal 
protective equipment, 
Easy access to personal 
protective equipment, 
Received any training on 
TB, How good training for 
the clinical practice, 
Frequency on TB 
information  
Working in a primary care 
unit that had implemented a 
TB control programme: yes; 
1.9 (1.1-3.4) 
Sex, Age, Education 
level, District 





vaccination, History of 
household contact with 
TB, Previous TST result 
History of household 
contact with TB: yes; 
1.7 (1.1-3.0) 













Occupational Non Occupational 
Risk factors assessed Significant risk factors in 
multivariate analysis; 







OR (95% CI)  
Rutanga, 2015 All types of 
HCWs 
1023 Facility type, Years 
worked in health care, 
Department 
assignment, Work 
setting, Job assignment 
Years worked in health care: 
each additional year; 1.01 
(1.01-1.06) 
Age, Gender, HIV 
status 
Not significant 
Severo, 2011 Nurses  55 Occupation, Duration of 
employment, 
Workplace 
Not significant Gender, Skin color, 
Age, BCG scar, 
Smoker,  
Not significant 









TB knowledge score 
(ref > 8): < 8; 0.29 
(0.09-0.98) 
van Rie, 2013 
(HCWs) 










308 Contact with TB 
patients, Years in 
healthcare, Occupation 
Occupation (ref admin): 
Nurse; 2.77 (1.01-7.55) 
Gender, Age, BCG 
vaccine history 












Occupational Non Occupational 
Risk factors assessed Significant risk factors in 
multivariate analysis; 







OR (95% CI)  
Zhou, 2014 All types of 
HCWs 
529 Duration of healthcare 
profession, Type of 
hospital, Department of 
hospital work, Had ever 
worked in TB clinic or 
ward, Had ever worked 
in HIV clinic or ward, 
Contact with blood or 
other body fluid in 
work, Work hours 
everyday, Consistent 
mask use in 
professional work, Kind 
of mask used in medical 
work, Wash hands, 
Attending regular 
physical examination 
every time, Attending 
infection control 
training, Intimate 
contact with TB 
patients, Knowledge of 
TB prevention and 
control, Policy of TB 
treatment and care 
  
Duration of healthcare 
profession (ref < 5 y): 6-10 y; 
1.89 (1.10-3.25), > 10 y; 1.80 
(1.20-2.68) 
Type of hospital (ref general 
hospital): infectious disease 
hospital; 2.40 (1.59-3.62) 
Had ever worked in HIV clinic 
or ward: yes; 1.87 (1.08-3.26) 





area, Live status, 
Average per-capita 




exercise (times per 
week), Self-reported 












Occupational Non Occupational 
Risk factors assessed Significant risk factors in 
multivariate analysis; 







OR (95% CI)  
Risk Factors for Positive IGRA 
Babayigit, 2014 All types of 
HCWs  
96 Health care facility, 
Working duration 
Health care facility (ref 
university hospital): TB 
control dispensary; 22.05 
(1.35-358.85) 
Working duration (months); 
1.017 (1.002-1.033) a 
Age Not determined 
Dagnew, 2012 Medical and 
paramedical 
students 
107 Department, Year of 
study 








de Souza, 2014 All types of 
HCWs 
632 Professional category, 
Work only at primary 
health care, Years 
served in health care 
profession at primary 
health care 
Years served in health care 
profession at primary health 
care (ref < 5): > 5; 1.70 (1.07-
2.71) 
Gender, Age, Presence 
of BCG scar, Contact 
with a household 
member with TB, 





Presence of BCG 




Medical students 238 Not stated clearly Not significant Not stated clearly Not significant 
Drobniewski, 
2007  
All type of HCWs 262 Work in a TB clinic, 
More than 5 years in 
medical practice 
Work in a TB clinic; 1.9 (1.1-
3.5) 





Nurses and Lab 
personnel, 
132 Profession, Duration of 
work 
Profession (p= 0.01) Duration 
of work (P=0.032) 
Age, Sex, BCG 
vaccination, HCV, 
Smoking, Family 
history of TB, Diabetes 
mellitus 














Occupational Non Occupational 
Risk factors assessed Significant risk factors in 
multivariate analysis; 







OR (95% CI)  
He, 2012 All types of 
HCWs 
999 Hospital, Job category, 
Years in health care, 
Cared for TB patient in 
last year, Average daily 
time in patient last 
year, Ever had co-
worker with TB, Aware 




Years in health care (ref < 1): 
> 15; 1.94 (1.13-3.32) 
Average daily time in patient 
last year (ref 0): > 4 hours; 
1.87 (1.21-2.89) 
Ever had co-worker with TB: 
yes; 1.86 (1.01-3.42) 
Age, Sex, Education, 
Self-report having 
BCG, Household 
contact with TB, 
Smoking status, 
Density of household 
Age (ref 18-29): 30-
39 y; NS, 40-49 y; 
1.93 (1.15-3.24), > 
50 y; 3.21 (1.77-
5.82) 
Self-report having 
BCG: yes; 0.61 (0.42-
0.88) 
He, 2015 Village doctor 866 Working duration, 
Minutes spend on 
diagnosing one patient, 
Whether referred 
suspected TB patient in 
recent three years, 
Density of clinical areas 
(m2 per staff)  
Working duration (ref < 15 
y):  >25 y; 1.64 (1.12-2.39) 
Gender, Age, 
Education, BCG scar, 
Smoking status, 
Average yearly 
income, Density of 
household 
Male gender; 2.69 
(2.02-3.58) 
Education (ref 
college or above): 
below college; 1.42 
(1.01-1.97) 
Kargi, 2017 All types of 
HCWs 
100 Occupation, Duration of 
work 
Not significant Age, gender, BCG 
positivity 
Not determined 
Li-fan, 2013 All types of 
HCWs 
101 Job category, Years 
served in the health 
care profession, 
Exposure to sputum 
smear positive TB 
patient 
Exposure to sputum smear 
positive TB patients: yes; 5.76 
(1.38-24.00) 













Occupational Non Occupational 
Risk factors assessed Significant risk factors in 
multivariate analysis; 







OR (95% CI)  
Lien, 2009 All types of 
HCWs 
300 Hospital, Job, Working 
years, Mask use 
Hospital: TB; 1.94 (1.04-3.64) Age, Sex, BMI, 
Education 
BMI (ref 18.5-25.0): > 
25; 4.18 (1.14-15.36) 
Education (ref 
university and 
higher): high school 






All types of 
HCWs 
265 Occupation, Length of 
employment as a HCW, 
Has routine direct 
contact with TB 
patients 
Length of employment as a 




Positive history of 
BCG 
Age (ref < 30 y): > 30 
y; 2.91 (1.32-6.43) 
Mostafavi, 2016 Lab personnel 177 Job group, History of 
work (year), Contact 
with TB patients 






All types of 
HCWs 
112 Occupation, Work 
location, Employment 
length in years, Hours 
worked per day, Known 
TB exposure in the 
hospital, Type of 
exposure, Frequency of 




Nurse; 2.78 (1.19-6.49) 
Employment length in years 
(ref < 10 y): > 10 y: 8.78 (1.26-
62.29) 
Known TB exposure in the 
hospital: yes; 13.32 (1.61-
110.04) 
Gender, Age, BMI, 
BCG vaccination, 
Education 
Age (ref < 30 y): > 30 
y; 18.880 (1.52-
234.36) 
Ozdemir, 2007 All types of 
HCWs 
76 Working duration Not significant Gender, Age, BCG 












Occupational Non Occupational 
Risk factors assessed Significant risk factors in 
multivariate analysis; 
Adjusted OR (95% CI)  




OR (95% CI)  
Rafiza, 2011 All types of 
HCWs 
953 Duration of 
employment, Risk 
group, Job category, 
Workplace, Clinical 
base 
Job category (ref others): 
Nurse; 4.65 (1.10-19.65) 
Age, Sex, Marital status, 
Race, Level of education, 
Income group, Body 
mass index, Lived in 
same house with 
friend/family with 
active TB, Co-morbid 
condition, Previous 
active TB, Had received 
TB treatment, Substance 
abuse 
Age group (ref < 24 
y):  > 35 y; 9.49 
(2.22-40.50) 
Male sex; 3.70 (1.36-
10.02) 
Lived in same house 
with friend/family 
with active TB: yes; 
8.69 (3.00-25.18) 
Thuong, 2016 All types of 
HCWs 




BMI (ref 18.5-24.9): 





van Rie, 2013 
(Medical 
students) 
All types of 
HCWs 
79 Not determined Not determined Age, Gender, Non-
occupational TB contact, 
TB knowledge score 
Not significant 




120 Job category Not significant Age, Gender, HIV status, 
Non-occupational TB 













Occupational Non Occupational 
Risk factors 
assessed 
Significant risk factors in 
multivariate analysis; Adjusted 







OR (95% CI)  
Wei, 2013 All types of 
HCWs 
210 Nurse, Length of 
work 
Nurse: yes; 2.43 (1.08-5.44) Age, BCG vaccination Age (ref < 30 y): > 30 
y; 6.15 (1.88-20.15) 




319 Contact with TB 
patients, Years in 
healthcare, 
Occupation 
Contact with TB patients (ref 
rare): frequent; 3.04 (1.79-5.14) 
Gender, Age, BCG 
vaccine history 
Age in years; 1.05 
(1.01-1.09) 
Zhang, 2013 All types of 
HCWs 
755 Working years, Job, 
Workplace, 
Laboratory staff 
Working years (ref < 2 y): 11-20 
y; 3.57 (1.46-8.71), > 20 y; 3.41 
(1.28-9.11) 
Job (ref admin staff): technician 
staff; 2.02 (1.12-3.64), laboratory 
staff; 2.76 (1.36-5.60) 
Age, Gender, 
Education, The 
history of household 
TB contact 
The history of 
household TB 
contact: yes; 2.47 
(1.15-5.33) 
Zwerling, 2013 Nursing and 
medical 
students 
226 Number days spent 
working on medical 
wards 
Not significant Not determined Not determined 
BCG= Bacille Calmette-Guerin, BMI = body mass index, CI = confidence interval, HCSs = health care students, HCWs = health care workers, HIV = human 
immunodeficiency virus, IGRA = interferon-gamma release assay, NS = not significant, OR = odds ratio, TB = tuberculosis, TST = tuberculin skin test 







Table A.3.10 Incidence of LTBI in HCWs as measured by TST conversion 
Study (Author, Year, 
Country) 























(%, 95% CI)b % 95% CI 
Adams, 2015, South 
Africa 
All types of HCWs One year B 147 34 34 13 38.2 22-56 38.2 (22-56) 
Borroto, 2011, Cuba All types of HCWs One year A 350 296 220 3 1.4 0.3-3.9 1.4 (0.3-3.9) 
Calixto-Aguilar, 2016, 
Cuba 
Medical students Maximum 
two years 
A 548 511 548 61 11.1 8.6-14.1 5.6 (4.3-7.1) 
Christopher, 2011, 
India 
Nursing students One year B 436 217 179 14 7.8 4.3-12.8 7.8 (4.3-12.8) 
Chung-Delgado, 2012, 
Peru 
Medical students One year B 547 468 505 24 4.7 3.1-6.9 4.7 (3.1-6.9) 
Corbett, 2007, 
Zimbabwe 
Nursing students 6-12-18 
months 
B 351 159 148 30 20.3 14.1-
27.7 
- 
de Miranda, 2012, 
Brazil 
All types of HCWs One year B 251 122 39 2 5.1 0.6-17.3 5.1 (0.6-17.3) 
Emadi-Koochak, 2009, 
Brazil 
Medical students and 
pharmacy students 
Three years B 256 239 212 24 11.3 7.4-16.4 3.8 (2.4-5.6) 
Gonzalez, 2011, 
Argentina 




A 1549 544 275 23 8.3 5.4-12.3 4.2 (2.7-6.2) 
He, 2015, China Village doctor One year A 618 465 465 53 11.4 8.6-14.6 11.4 (8.6-14.6) 
C 618 465 465 45 9.7 7.1-12.7 9.7 (7.1-12.7) 




assistance, nursing and 
medical students 







CI = confidence interval, HCWs = health care workers, QFT-GIT = QuantiFERON-TB Gold In-Tube, TST = tuberculin skin test 
aTST conversion definition: A: A newly positive TST (induration >10 mm) after a documented negative-baseline TST (induration of <10 mm) at any time after a 
negative two-step baseline, or more than 1 year after a negative single TST, B: Baseline TST <10 mm and a follow up TST >10 mm and a 10 mm increase over the 
baseline, C: Baseline TST <10 mm and a follow up TST >10 mm and a 6 mm increase over the baseline 




Study (Author, Year, 
Country) 























(%, 95% CI)b % 95% CI 
Lopes, 2008, Brazil Nurses, Nursing aids One year A 128 49 32 7 21.9 9.3-39.9 21.9 (9.3-39.9) 
McCarthy, 2015, South 
Africa 





A 196 107 93 25 26.7 18.2-
37.1 
- 
Moreira, 2010, Brazil Community Health 
Agents 
One year B 72 61 61 15 24.5 14.5-
37.3 
24.5 (14.5-37.3) 
Pai, 2006, India Nursing and medical 
students 
1,5 year B 353 168 147 6 4.1 1.5-8.7 2.7 (1.0-5.8) 
C 353 168 147 14 9.5 5.3-15.5 6.3 (3.5-10.4) 
Perez-Lu, 2013, Peru All types of HCSs One year A 4842 Not clear Not clear Not clear 
  
- 
Rabahi, 2007, Brazil All types of HCWs One year B 437 257 131 28 21.3 14.7-
29.4 
21.3 (14.7-29.4) 
Two years B - 103 90 12 13.3 7.1-22.1 - 
Three years B - 78 40 3 7.5 1.5-20.4 - 
Sawanyawisuth, 2012, 
Thailand 





















































(%, 95% CI)b % 95% CI 
Adams, 2015, 
South Africa 




A 332 113 113 25 22.1 14.9-30.9 22.1 (14.9-30.9) 
B 332 113 113 20 17.7 11.2-26.0 17.7 (11.2-26.0) 
C 332 113 113 16 14.2 8.3-21.9 14.2 (8.3-21.9) 





A 292 115 115 25 21.7 14.6-30.4 21.7 (14.6-30.4) 
B 292 115 115 23 20 13.1-28.5 20 (13.1-28.5) 
Escombe, 
2010, Peru 











A 613 361 361 69 19.1 15.2-23.6 19.1 (15.2-23.6) 
B 613 361 361 68 18.8 14.9-23.2 18.8 (14.9-23.2) 
C 613 361 361 63 17.5 13.7-21.8 17.5 (13.7-21.8) 


















QFT-GIT 1,5 year A 353 208 147 17 11.6 6.9-17.9 7.7 (4.5-12.0) 
D 353 208 147 11 7.5 3.8-13.0 4.9 (2.5-8.7) 
Rafiza, 2012, 
Malaysia  

































































A 270 162 441c 63 14.3 11.1-17.9 - 
CI = confidence interval, HCWs = health care workers, IGRA = interferon-gamma release assay, QFT-GIT = QuantiFERON-TB Gold In-Tube 
aQFT-GIT conversion definition: 
A: baseline TB antigen-Nil <0.35 IU/ml and follow up TB antigen-Nil ≥0.35 IU/ml 
B: baseline TB antigen-Nil <0.35IU/ml and follow up TB antigen-Nil ≥0.35IU/ml, plus a 30% increase over the baseline 
C: baseline TB antigen-Nil <0.35IU/ml and follow up TB antigen-Nil ≥0.35IU/ml, plus an absolute increase of 0.35IU/ml over the baseline 
D: baseline TB antigen-Nil<0.35IU/ml and follow up TB antigen-Nil ≥0.70IU/ml 
T-SPOT.TB conversion definition: 
A: baseline TSPOT.TB negative and follow-up positive using the ⩾6 spot increment  
B: baseline T-SPOT.TB negative and follow-up positive using the ⩾8 spot increment  
bAll incidence were converted to an annual incidence or equivalent to an annual incidence 









Table A.3.12 IGRA reversion rates (annual) 
Study (Author, Year, 
Country) 









IGRA reversion rate 
% 95% CI 
Adams, 2015, South Africa All types of HCWs QFT-GIT One year 219 15 6.8 3.9-11.0 
Escombe, 2010, Peru All types of HCWs QFT-GIT One year 20 1 5 1.3-24.9 
He, 2015, China Village doctors QFT-GIT One year 252 53 21.0 16.2-26.6 
Pai, 2006, India 
Nursing and medical 
students 
QFT-GIT 1,5 year 38 9 23.7 11.4-40.2 
Rafiza, 2012, Malaysia All types of HCWs QFT-GIT One year 64 19 29.7 18.9-42.4 







Table A.3.13 Risk factors associated with LTBI incidence measured TST and IGRA conversion 




Occupational Non Occupational 











OR (95% CI)  
Risk Factors for TST Conversion 
Adams, 2015 All types of 
HCWs 
34 Employment sector, Formal 
health qualification, 
Occupational tasks, Facility 








Smoking history, BCG 
vaccination, HIV 
positive status, TB 
symptom screen 
positive, Interval 
Referral for TB/HIV, 
History of TB 
Treatment (ever TB) 
Not significant 
Chung-Delgado, 2012 Medical 
students 
505 Not determined Not determined Sex, Age, Year of 
university entry, 
Previous TB, Smoking, 
Alcohol consumption, 
BMI 
Year of university 
entry: 2009-2010; 
2.53 (1.11-5.76) 
Christopher, 2011 Nursing 
students 
179 Nursing course currently 
enrolled, Total time spent in 
health care, Direct contact with 
sputum positive TB patients, 
Days spent caring for 
pulmonary TB patients, Ever 
performed or assisted in 
sputum collection, Days spent 
working on isolation wards, 
Days spent working on 
pulmonary medicine wards 
Days spent caring 
for pulmonary TB 
patients; 1.12 (1.04-
1.20) 
Ever performed or 
assisted in sputum 
collection; 4.57 
(1.11-18.86) 
Age, BCG vaccination, 
BMI, Highest level of 
education completed, 
Average household 
monthly income, QFT 
positive, Continuous 
IGRA result 












Occupational Non Occupational 
Risk factors assessed Significant risk 
factors in 
multivariate analysis; 
Adjusted OR (95% CI)  
Risk factors assessed Significant risk 
factors in 
multivariate analysis; 
Adjusted OR (95% CI)  
Corbett, 2007 Nursing 
students 
148 Not determined Not determined Age, Sex, Crowding in 




with TB patient during 
study, Having parents 
who were HCWs, HIV 




da Costa, 2009 All types of 
HCWs 
Not clear Occupation, Work 
location, Ward with 
respiratory isolation 
room, Exposure to 
pulmonary TB case in 
hospital 
Exposure to pulmonary 
TB case in hospital: yes; 
0.31 (0.13-0.73) 
Sex, BCG scar Not significant 
He, 2015 Village 
doctor 
465 Working duration, 
Minutes spend on 
diagnosing one patient, 
Whether referred 
suspected TB patient in 
recent three years, 
Density of clinical areas 
(m2 per staff)  
Working duration (ref 
< 15 y): 15-25 y; 0.46 
(0.22-0.96) 
Gender, Age, Education, 
BCG scar, Smoking 
status, Average yearly 













Occupational Non Occupational 
Risk factors assessed Significant risk factors 
in multivariate 
analysis; Adjusted OR 
(95% CI)  
Risk factors assessed Significant risk factors 
in multivariate 
analysis; Adjusted OR 
(95% CI)  




93 Occupation, TB 
exposure, TB 
knowledge score, TB 
infection control 
training, TB infection 




Not significant Sex, HIV status, Age Not significant 
Perez-Lu, 2013 All types of 
HCSs 
Not clear TB contact history, 
Careers, Internship 
year 
Careers (ref admin, 






Internship year; 1.94 
(1.64-2.30) 
Age, Sex, BMI,  Age (ref under 18 y): 18 
y: 2.97 (2.29-3.84), 
between 18-21 y; 3.92 
(3.09-4.96), 21 y or 
more; 4.00 (3.16-5.06) 
Sawanyawisuth, 2012 All types of 
HCWs 
1025 Job Job (ref office staff): 
nurses; 2.3 (1.3-4.1), 
nurse assistants; 2.3 







Gender, BCG scar Male gender; 3.0 (1.9-
4.6) 











Occupational Non Occupational 
Risk factors assessed Significant risk factors 
in multivariate 
analysis; Adjusted OR 
(95% CI)  
Risk factors assessed Significant risk factors 
in multivariate 
analysis; Adjusted OR 
(95% CI)  
Risk factors associated with LTBI incidence measured IGRA conversion 
Adams, 2015 All types of 
HCWs 





Employment in health 
care 
Using QFT-GIT: Engaged 





individuals in local 
authority employment 
working for the 
provincial health 
department (OR 14.19, 
95% CI 1.28–157.75), 
and having a positive 
TST at baseline (OR 




Smoking history, BCG 
vaccination, HIV 
positive status, TB 
symptom screen 
positive, Interval 
Referral for TB/HIV, 
History of TB Treatment 
(ever TB) 
Not significant 
He, 2015 Village 
doctors 
361 Working duration, 
Minutes spend on 
diagnosing one 
patient, Whether 
referred suspected TB 
patient in recent three 
years, Density of 
clinical areas (m2 per 
staff)  
Minutes spend on 
diagnosing one patient 
(ref < 15 minutes): > 15 
minutes; 2.62 (1.39-
4.97)  
Gender, Age, Education, 
BCG scar, Smoking 
status, Average yearly 













Occupational Non Occupational 
Risk factors assessed Significant risk factors 
in multivariate 
analysis; Adjusted OR 
(95% CI)  
Risk factors assessed Significant risk factors 
in multivariate 
analysis; Adjusted OR 
(95% CI)  




97 Occupation, TB 
exposure, TB 
knowledge score, TB 
infection control 
training, TB infection 




Occupation (ref medical 
student): HCW; 7.7 (1.6-
36.9) 
Sex, HIV status, Age Not significant 
Rafiza, 2012 All types of 
HCWs 
704 Duration of 
employment, Job 
category, Workplace 
Workplace (ref other): 
emergency department; 
RR 2.18 (1.07-4.43) 
Sex, Age Not significant 




77 Contact with TB 
patients, Years in 
healthcare, Occupation 
Not significant Gender, Age, BCG 
vaccine history 
Increasing age per year; 
1.07 (1.01-1.13) 
Zwerling, 2013 Nursing and 
medical 
students 
270 Occupational exposure Not significant Not determined Not determined 
BCG= Bacille Calmette-Guerin, BMI = body mass index, CI = confidence interval, HCSs = health care students, HCWs = health care workers, HIV = human 
immunodeficiency virus, IGRA = interferon-gamma release assay, NS = not significant, OR = odds ratio, QFT-GIT = QuantiFERON-TB Gold In-Tube, RR = relative risk, 
TB = tuberculosis, TST = tuberculin skin test 









Table A.3.14 Summary of non-English studies where an English abstract was available 
First Author Year Journal Language 
(Country) 











HCWs 19 TST positivity rate 36.8% 
QFT-GIT positivity rate 47.4% 





Cohort TST HCWs 201 Prevalence of LTBI 31.8% 
(64/201) 




Cross-sectional TST  Hospital 
cleaning staff 
106 The prevalence of LTBI 74.5% 






HCWs 74 No data 




Cross-sectional TST  HCWs 60 TST was found over 10 mm in all 
subjects 
TST was found over 15 mm in 
65% of the subjects 




















Figure A.3.1 Forest plot for the prevalence of latent tuberculosis infection in health 






Figure A.3.2 Forest plot for the prevalence of latent tuberculosis infection in health 
care workers and health care students in studies using both tuberculin skin test 




Figure A.3.3 Forest plot for the prevalence of latent tuberculosis infection in health 









Figure A.3.4 Forest plot for the prevalence of latent tuberculosis infection in health 
care students in studies using tuberculin skin test (TST) comparing Joshi’s review 








Figure A.3.5 Forest plot for the incidence of latent tuberculosis infection in health 









Figure A.3.6 Forest plot for the incidence of latent tuberculosis infection in health 
care workers and health care students studies using both tuberculin skin test (TST) 





Appendix 4. Lessons learnt from the data collection and PhD process 
1. Before the data collection, conducting trainings on study protocols and 
standard operational procedures (SOPs) for research assistants were very 






2. During data collection, supervision from the candidate with assistance from 
supervisors and co-investigators would help research assistants to find 
solutions for common problems. Some of the most common problems: 
 
- Difficulty in finding the schedule and place for recruiting study participants 
during their busy time working in health care facilities. Solution: getting 
help from TB nurse in each PHC, head of department/coordinator in each 
department/unit for a study in hospital, and student coordinator in each 





*Photos of participants shown in this appendix were taken on their consent 
 
- We collected a substantial amount of data, including questionnaires, clinical 
examination data, anthropometric measurements, tuberculin skin test, and 
blood samples for interferon-gamma release assay, with a high possibility 
of missing a variable. Solution: we made a form with checklist boxes to 
ensure the completeness of the data and assigned a coordinator to check 







*Photos of participants shown in this appendix were taken on their consent 
 
- Blood collection and tuberculin skin test were the most difficult 
components of the study as some participants refused it mostly because of 
fear of needles. Solution: we provided information on the benefit and risk 
of discomfort or harm of receiving the test, assigned experienced and 
trained study nurses and provided a snack and small gift for appreciation 
to study participants. The provision of the snack to participants is a 







*Photos of participants shown in this appendix were taken on their consent 
 
- Handling, labelling, and mapping samples were very important. Solution: 
we worked together with the laboratory personnel to revise the SOP for 







3. We, however still found some other problems during the data collection. 
Having frequent progress meeting and discussion time and learning as a team 
made it easier to solve the problem faster. Providing feedback and giving 
appreciation for research assistants helped the team perform better. We 
believe that a happy team who work with dedication, care and good humour is 
necessary for conducting a good study. 
  
 
4. The Bandung TB research group has an established working relationship with 
Bandung Municipal Health Office through other previous studies conducted in 
Bandung. Conducting a study under this collaboration will help researchers to 
translate the knowledge and help the PHCs and Bandung Municipal Health 
Office to formulate an effective program that can influence better practices of 







5. The candidate with the support of supervisors was able to attend the 
systematic review course held by McGill University Montreal, Canada and 
worked with supervisors and learned from other colleagues in preparing and 






6. Finally, having a great bunch of supervisors helped the candidate to learn and 
grow during the PhD process.  
  
 
 
